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While difficulty walking can cause a severe limitation for many cases of Parkinson's disease 
due to a symptom termed 'freezing of gait', many patients retain the ability to ride a bike.
Snijders AH, Bloem BR. Cycling for freezing of gait. New England Journal of Medicine, 
2010;362:E46
Photo: Ineke riding her bike
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Part 1 
General Introduction
Alice: "When I get home I shall write a book about this place... If I ever 
do get home"
12
13
Chapter 1
General introduction and outline of the thesis
“Begin at the beginning," the King said, very gravely, "and go on till you 
come to the end: then stop.”
14
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General Introduction
Neurodegenerative Diseases
Neurodegenerative diseases are conditions affecting the cells of the central nervous 
system which result in the loss of cells, primarily neurons, in the brain and spinal cord. 
They are characterised by chronic, progressive degeneration of cells, in the motor, 
sensory, or cognitive systems of the brain 1, 2. Depending on the brain area and extent of 
damage, this can bring about changes in memory, cognition, abstract thinking, skilled 
movement, behaviour, emotion, capacity for independent living and other disabilities 1, 3. 
Most neurodegenerative diseases are chronic in nature and lead to the slow deterioration 
of cells over a period of many years. There are hundreds of different neurodegenerative 
diseases, the two most common of which are Alzheimer’s disease and Parkinson’s disease. 
Taken together, Alzheimer’s disease and Parkinson’s disease affect over 40 million people 
worldwide. Disturbingly, this estimate is expected to double over the next two decades as a 
result of increasing age in the world population and the fact that most neurodegenerative 
diseases affect people over the age of 55 years 4-8. Due to their chronic nature and the 
requirement for long-term health care, these diseases place a huge economic burden on 
society 4, 6, 7. Furthermore, gaps in healthcare provision mean that family members and 
friends often take on the burden of caring for their loved ones creating an additional 
social burden 9-11.
Among the neurodegenerative diseases, many share similar clinical features, a fact that 
is perhaps not unexpected given the partial overlap in underlying neurodegenerative 
processes and extent of the associated pathology. Hence, neurodegenerative diseases are 
often categorised according to their shared clinical features leading to classifications such 
as ‘Dementia disorders’, ‘Movement disorders’, or ‘demyelinating disorders’ 12. Even within 
these categories, there are frequent multiple diseases sharing similar clinical features 
make it difficult for clinicians to distinguish one disease from another. Dementia disorders, 
for example, all share features of altered memory and/or cognition, behaviour, emotion, 
and an inability to follow simple instructions that interfere with daily functioning 13-15. 
Similarly, movement disorders involve altered voluntary and involuntary movements, 
often associated with a tremor, loss of balance or muscle weakness 16, 17. Furthermore, 
many of the key features that can distinguish one disease from another appear at much 
later stages of disease, making an accurate diagnosis at early stages of disease challenging 
for clinicians. What’s more, there is sometimes an overlap in clinical features between the 
classification groups 12. For example, Dementia with Lewy bodies presents with Parkinson’s 
disease-like movement difficulties, termed parkinsonisms, together with memory loss, 
behavioural disturbances, hallucinations, confusion, sleep disorder associated with 
dreaming, and trouble interpreting visual information 18, 19. Similarly, dementia can 
develop during the course of Parkinson’s disease, but the dementia often occurs 10 to 
15 years after parkinsonisms appears rather than at the same time. Finally, two diseases 
can co-occur so that, for example, one patient may have both Parkinson’s disease and 
Alzheimer’s type dementia 19. Accordingly, many patients will be left facing an uncertain 
diagnosis.
16
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On the surface it might seem inconsequential to give separate labels to diseases with such 
similar clinical features. However, there are actually many reasons why a precise diagnosis 
might be important. One of the most critical reasons for wanting an accurate diagnosis 
is to ensure that optimal medical treatment is provided. Unfortunately there are very 
few medicines currently available for the treatment of symptoms of neurodegenerative 
diseases, and none that can cure them. Crucially, the use of a particular medication for 
one disease may be inadvisable for another disease due to known side-effects, which 
are occasionally fatal. For example, neuroleptics may be used in patients with Alzheimer 
disease, but should be avoided in patients with dementia with Lewy bodies. Other 
judicious reasons for aspiring to a precise diagnosis include: assignment of patients to 
appropriate patient groups for facilitating the determination of treatment effects in 
those groups when testing trial medications; prediction of disease outcome, including 
alertness to specific and sometimes life-threatening complications (e.g. development of 
nocturnal stridor in patients with multiple system atrophy); and to facilitate examination 
of the pathological and neuroanatomical features of individual diseases. At other times, 
an accurate diagnosis of disease is desirable simply because it is of comfort to patients to 
put a name to their disease. 
Differential Diagnosis of Neurodegenerative Diseases
This brings me to the main question underlying this thesis: “How can we improve the 
differential diagnosis of neurodegenerative diseases?” That is, how can we better 
distinguish one neurodegenerative disease from another? In trying to answer this 
question, a lot of prior research has focussed on searching for suitable biological markers, 
or ‘biomarkers’. A biomarker is essentially any biological indicator used to identify the 
presence of a disease 20. The most common biomarkers used in current medicine involve 
blood tests that measure abnormal levels of proteins or other substances in the blood. 
For example, high levels of the troponin proteins and the enzyme, creatine kinase can be 
used as blood biomarkers for diagnosis of cardiac injury following a myocardial infarction 
(heart attack)21. However, biomarkers are not just found in blood. Measurement of proteins 
can also be performed in other biological fluids such as urine, synovial fluid of the joints, 
pleural fluids surrounding the lungs, or cerebrospinal fluid (CSF) which surrounds the brain 
and spinal cord 22-25. Furthermore, biomarkers can be derived from imaging techniques 
such as computer tomography or magnetic resonance imaging (to look at changes in 
brain volume and neuronal loss), from positron emission tomography with 18F-2-deoxy-
2-fluoro-D-glucose or Pittsburgh compound B, which can be used in positron emission 
tomography  (to provide information about cerebral amyloid beta accumulation) 26, 27, or 
from dopamine transporter  single-photon emission computed tomography (to visualise 
dopaminergic  degeneration in Parkinson’s disease and multiple system atrophy) 28.
In terms of biomarkers for neurodegenerative diseases, if we could accurately measure 
brain-specific proteins in biological fluids we might expect that any clear differences 
observed between healthy and disease subjects would be an indication of pathological 
changes in the brains of the diseased subjects 29. Although blood-based biomarkers are 
highly desirable for disease diagnosis because they are relatively easy to obtain, cause 
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General Introduction
minimal discomfort for the patient and are cost- and time-efficient, blood as a source of 
brain-specific biomarkers has drawbacks. Blood contains huge numbers of proteins owing 
to the fact that there is extensive exchange of proteins and other substances between 
the blood and all organs of the body during blood circulation, not just the brain and 
spinal cord. Furthermore, the exchange of proteins between the central nervous system 
and periphery is highly regulated by the blood-brain and blood-CSF barriers meaning 
that brain-specific proteins are present in the blood at very low concentrations making 
it extremely difficult to detect changes in brain-specific proteins in the blood. This is why 
the focus of current research has moved towards examining the potential of cerebrospinal 
fluid (CSF) biomarkers in the differential diagnosis of disease.
Why focus on cerebrospinal fluid biomarkers?
CSF surrounds the brain and spinal cord and represents the primary component of the 
brain extracellular matrix that exchanges a broad array of biological products with the 
central nervous system. Thus the CSF matrix contains a complex mixture of proteins 
and other biological substances that can reflect dynamic changes occurring in the 
physiological and pathological state of the brain 30, 31. Furthermore, it can be accessed 
fairly readily using lumbar puncture (Figure 1). Of relevance to biomarker research, many 
of these proteins are brain specific and the exchange of proteins between the brain and 
the CSF and the CSF and blood is tightly controlled by the blood-brain and blood-CSF 
barriers (Figure 2). Hence, levels of these proteins in CSF largely reflect physiology that 
is specific to the central nervous system. Thus aberrant concentrations of brain-specific 
proteins in CSF are likely to reflect underlying disease pathology 32-34. 
18
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Figure 1. Lumbar puncture. During a lumbar puncture (or spinal tap), a needle is carefully 
inserted into the lower (lumbar) part of the spine and a small sample of CSF is removed 
for testing. Reprinted with permission from Ref 35 © (2006) American Medical Association.
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Fig. 2. Barriers of the brain. Barriers of the brain are present at three main sites: the brain 
endothelium forming the blood–brain barrier (BBB) (1), the arachnoid barrier cell layer (2) 
forming the middle layer of the meninges, and the blood-CSF barrier (3) located at choroid 
plexus epithelium, which secretes cerebrospinal fluid (CSF). At each site, the physical barrier 
is caused by tight junctions that reduce the permeability of the paracellular (intercellular 
cleft) pathway. Printed, with permission, from Refs 35, 36 © 1990 (Kluwer Academics).
20
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Since the cerebrospinal fluid contains many thousands of different components, of 
which there are thousands of different proteins, it may seem a daunting task to identify 
just a few proteins that might be of interest for measurement as potential biomarkers. 
Many clues are already available from studies which have examined altered proteins in 
familial diseases, that is, those in which a genetic alteration leads to disease 37. While most 
neurodegenerative diseases are sporadic (occur randomly), a minority have an underlying 
genetic component. Determining which proteins are encoded by these genes, and thus 
altered in familial disease, also provides a starting point for similar investigations in 
sporadic form(s) of disease 37, 38. For example, the α-synuclein (α-Syn) gene is frequently 
mutated in familial forms of Parkinson’s disease leading to loss of function of the protein 
α-Syn 38-40. This discovery led to other studies investigating the structure and function of 
α-Syn, and the assessment of CSF α-Syn levels in sporadic forms of disease compared 
with controls 41, 42. These studies have shown that α-Syn is also altered in sporadic forms of 
disease. However, levels of α-Syn in CSF have not yet adequately been shown to distinguish 
Parkinson’s disease from healthy subjects or from other neurodegenerative diseases 43-45.
Other methods being used to identify proteins of interest for biomarker research include: 
genome-wide association studies – a broader study identifying gene mutations involved 
in neurodegenerative disease; proteomics – examination of proteins; and metabolomics 
– the study of metabolites. These methods have identified a large and diverse range of 
proteins that are altered, or likely to be altered, in neurodegenerative diseases. Indeed 
many of the proteins analysed during the research performed for this thesis have been 
identified by earlier studies investigating the underlying molecular mechanisms of these 
diseases using various methods.
Molecular mechanisms of disease and biomarker identification
Protein misfolding and aggregation
One of the most comprehensively investigated mechanisms of pathology in 
neurodegenerative diseases is that of protein misfolding and aggregation. These 
investigations originated with Alois Alzheimer who, in 1906, was the first person to describe 
primary neuropathological features in the brain of a woman with slowly progressing 
dementia 46. He identified deposits of the protein amyloid beta (Aβ) and degenerating 
neurons with bundles of fibrils (neurofibrillary tangles) scattered in the brain and his 
reports ultimately gave rise to the name ‘Alzheimer’s dementia’. This led to subsequent 
investigations of the levels of Aβ, tau and phosphorylated tau in the CSF of Alzheimer’s 
patients compared with controls. These studies have consistently shown altered levels 
of these proteins in patients with Alzheimer’s disease compared with healthy subjects. 
Alzheimer’s disease patients have much lower levels of CSF Aβ and higher levels of 
total and phosphorylated tau than healthy controls 47. Since these markers show clear 
differences between Alzheimer’s patients and healthy controls, they are increasingly 
being used as an adjunct to clinical diagnosis 48, 49. 
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Not only Alzheimer’s disease but many other neurodegenerative disease such as 
amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s disease and multiple system 
atrophy can be characterised by hallmark pathological features visible at post-mortem 
(after death) examination of the brain 50-53. Most of these features include degeneration of 
specific brain regions and deposits of abnormal proteins that are thought to be specific 
to individual diseases. Some of the best-described of these brain changes include: the 
presence of α-syn containing Lewy bodies 54, 55 and loss of dopamine-producing neurons 
in the striatum 56 of Parkinson’s disease; α-syn containing  glial inclusion bodies in multiple 
system atrophy 52, 53; deposits of TDP-43 in amyotrophic lateral sclerosis and frontotemporal 
dementia 57-59, and aggregates of the protein huntingtin in Huntington’s disease 60, 61. In 
other neurodegenerative diseases, such as the demyelinating disease multiple sclerosis, 
changes in the white matter of the brain and spinal cord can be seen using special imaging 
techniques such as magnetic resonance imaging and computer tomography rather than 
being characterised by abnormal protein deposits. However, more recently, the discovery 
of aggregated fibronectin in demyelinated lesions in the white matter of brains from 
multiple sclerosis patients 62 suggesting that protein aggregates may also play a role in, or 
arise from, the pathogenesis of demyelinating diseases.
Most proteins associated with neurodegeneration are natively unfolded 63 and initiation 
of protein misfolding in particular cells likely facilitates the aggregation and accumulation 
of the specific protein 64. Although the underlying mechanisms of protein misfolding have 
not been fully elucidated, another common feature of many neurodegenerative diseases, 
‘oxidative stress’, is thought to facilitate the aggregation and accumulation of proteins 
through post-translational, covalent modifications of the proteins. 
Oxidative stress
The brain is a highly aerobic organ, consuming more oxygen per weight than any other 
organ in the body and leading to the generation of reactive oxygen species and reactive 
nitrogen species, which can have damaging effects on cells 65. Oxidative stress arises due 
to an imbalance between production of reactive oxygen species and/or dysfunction of 
antioxidant protection systems  and is a common feature of neurodegenerative diseases 
66 including Alzheimer’s disease 67-69, Parkinson’s disease 42, 70, Huntington’s disease 71 and 
multiple sclerosis 72, 73. Oxidative stress can be identified by measures of lipid and DNA 
peroxidation and protein carbonyl moieties, which are increased in neurodegenerative 
disease states compared with healthy controls 67, 74, 75. Moreover, the proteins that are 
oxidised appear to be specific to individual diseases. In Alzheimer’s disease, specifically 
oxidised proteins include glutamine synthetase, α-enolase, amyloid-β, and the prolyl 
peptidyl isomerase, Pin1 68, 69, 76, 77 whereas α-synuclein and DJ-1 are prone to oxidation in 
Parkinson’s disease 78, 79 and β-actin, glial fibrillary acid protein and neurofilaments are the 
target of protein carbonylation in multiple sclerosis 72, 80.  Since carbonylation can easily be 
detected in experimental designs, measurement of carbonylated proteins is a common 
measurement of oxidative stress 74, 75.
22
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Neurotransmitter dysfunction
In addition to oxidative stress, dysfunction in neurotransmitter transmission is a common 
element of neurodegeneration. The loss of dopaminergic transmission arising from death 
of dopaminergic neurons of the substantia nigra is well-recognised in Parkinson’s disease 
and is known to cause some of the more characteristic motor dysfunctions such as resting 
tremor and bradykinesia 56, 81. Similarly, alterations in cholinergic transmission, namely 
loss of cholinergic neurons and decreased acetylcholinesterase activity, are thought to 
underlie many of the cognitive and behavioural symptoms of Alzheimer’s disease and 
dementia in Parkinson’s disease since acetylcholine is a neurotransmitter essential for 
processing memory and learning 2, 82-84. Indeed, many of the medications available to treat 
these symptoms are targeted at counteracting the loss of acetylcholinesterase activity 2, 84. 
More recent investigations have highlighted the likelihood that dysfunction of other 
neurotransmitters, particularly glutamate, but also epinephrine, norepinephrine and 
serotonin, and their metabolites are involved in the non-motor deficits of movement 
disorders and many of the behavioural deficits observed in dementia disorders 70, 85-88. 
Glutamate is the predominant excitatory neurotransmitter in the human central nervous 
system and is normally kept at relatively low concentrations in the extracellular spaces 
of the brain 89. However, in Alzheimer’s disease in particular, chronic low-level chronic 
stimulation of glutamate receptors has been associated with glutamate excitotoxicity 
leading to overstimulation of neuronal signalling and eventual neuronal death 90, 91. 
Disturbances in glutamate transmission are not confined to Alzheimer’s disease but are 
implicated in several other neurodegenerative diseases including Parkinson’s disease, 
amyotrophic lateral sclerosis and multiple sclerosis 89.
Where our quest begins…
Taken together, the investigation of protein misfolding and aggregation, oxidative stress, 
and neurotransmitter alterations have identified a plethora of potential biomarkers of 
individual neurodegenerative diseases. This raises the question “Where do we start?” 
Alzheimer’s disease is the most common and most studied of all neurodegenerative 
diseases. Furthermore, several biomarkers have already been established to aid in the 
diagnosis of Alzheimer’s disease. Thus it makes sense to begin by attempting to build on 
the available knowledge. Hence our investigation began with how we can improve the 
diagnosis of Alzheimer’s disease and improve the differential diagnosis of the various forms 
of dementia using a combination of the so-called ‘signature biomarkers’ of Alzheimer’s 
disease (Aβ-42, total tau and Phosphorylated tau) combined with more recently identified 
proteins showing promise as biomarkers. We then continued our journey by exploring 
possible CSF biomarkers for the differential diagnosis of the second most common 
neurodegenerative disorder, Parkinson’s disease, from analogous diseases. Sporadic forms 
of Alzheimer’s disease and Parkinson’s disease are most commonly associated with aging 
and predominantly affect people over the age of 55. Since neurodegenerative diseases 
are not confined to elderly patients, we also began an initial exploration into the use of 
CSF biomarkers for the differential diagnosis of the most common neurodegenerative 
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disease among younger adults, multiple sclerosis. The rationale for the choice of target 
proteins and literature supporting those choices, are outlined in the individual chapters.
In summary, neurodegenerative diseases affect vast numbers of people every year. 
Despite decades of intensive research, precise diagnosis of many individual diseases 
continues to challenge clinicians. Distinguishing one neurodegenerative disease from 
another can be rather difficult when using clinical symptoms alone, certainly in early 
disease stages when the clinical picture is often still incomplete. Moreover, in the early 
phases of disease, many neurodegenerative diseases share common symptoms, the rate 
of disease progression is not yet apparent, and the response to medical treatment is often 
not yet fully clear. Therefore, additional tools to help clinicians in the differential diagnosis 
of neurodegenerative diseases are needed. The current challenge for researchers is to 
identify potential biomarkers enabling earlier, faster and more accurate diagnosis of 
specific neurodegenerative diseases.
Aims of the thesis
The primary aim of this thesis was to determine the diagnostic utility of recently identified 
potential CSF biomarkers, and combinations of these biomarkers, as diagnostic tools in 
the differential diagnosis of dementias, movement disorders, and demyelinating diseases.
Outline of the thesis
Part one | General introduction
Chapter one, this introduction, acquaints the reader with the neurodegenerative diseases, 
their molecular and pathological features, the importance of differential diagnosis of 
disease, and the usefulness of CSF biomarkers in differential diagnosis. Finally, the aims 
and outline of the thesis are provided.
Part two | CSF biomarkers in the differential diagnosis of dementia disorders
Chapter two probes the diagnostic value of combining measures of MHPG with the 
traditional biomarkers for Alzheimer’s disease (Aβ, p-tau and t-tau) for improving the 
differential diagnosis of dementia with Lewy bodies from other forms of dementia such as 
Alzheimer’s disease, vascular dementia and fronto-temporal dementia
Chapter three outlines the development of an enzyme-linked immunoassay for the 
specific measurement of oxidised Pin1 in brain tissue. This assay can be used to measure 
levels of oxidised Pin1 in brain tissue and was used to compare levels of oxidised Pin1 in 
the brain tissue of Alzheimer’s disease compared with that of control tissue.
24
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Part three | CSF biomarkers in the differential diagnosis of movement 
disorders
Chapter four explores levels of the CSF proteins neurofilament light chain, fms-like 
tyrosine kinase ligand (FLT3L), and total tau in the differential diagnosis of Parkinson’s 
disease from multiple system atrophy and compares levels of these proteins in non-
neurological controls.
Chapter five examines the diagnostic utility of the Parkinson’s disease-linked proteins, 
DJ-1, as a biomarker for differentiating Parkinson’s disease from multiple system atrophy 
and for comparison with controls. 
Chapter six investigates the levels of neurotransmitter metabolites in the cerebrospinal 
fluid of patients with vascular parkinsonism compared with Parkinson’s disease patients 
and illuminates possible reasons why patients with vascular parkinsonism might respond 
more poorly to levodopa medications than those with Parkinson’s disease.
Part four | CSF biomarkers in the differential diagnosis of demyelinating 
disorders
Chapter seven outlines the development and optimisation of enzyme-linked 
immunoassays for the measurement of glutamine synthetase and myelin basic protein in 
cerebrospinal fluid as possible disease biomarkers. In addition this chapter highlights the 
sometimes difficult task of detecting proteins and how obstacles might be overcome by 
using modifications of standard assays.
Chapter eight studies changes in levels of glutamine synthetase in the cerebrospinal 
fluid of patients with demyelinating disorders (multiple sclerosis, neuromyelitis optica, 
optic neuritis) compared with controls. The potential use of glutamine synthetase as a 
biomarker is discussed.
Part five | General Discussion and Summary
Chapter nine provides a general discussion of the findings and conclusions made from 
the findings outlined in the thesis, and identifies future perspectives for the studied 
biomarkers.
Chapter ten summarises the research findings and their relevance.
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Photo series - Part 2: A key feature of Alzheimer's disease is progressive loss of memory, 
with most recent memories being lost first.
31
“It's a poor sort of memory that only works backwards" says the White 
Queen to Alice. 
Part 2 
The use of CSF biomarkers
for the differential diagnosis of dementia
32
33
"I can't go back to yesterday - because I was a different person then."
Chapter 2
Addition of MHPG to Alzheimer’s disease biomarkers improves 
differentiation of dementia with Lewy bodies from Alzheimer’s 
disease but not other dementias 
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Abstract
Background: Overlapping clinical features make it difficult to distinguish dementia 
with Lewy bodies (DLB) from Alzheimer’s disease (AD) and other dementia types. In 
this study we aimed to determine whether the combination of cerebrospinal fluid (CSF) 
biomarkers, amyloid-β42 (Aβ42), total tau protein (t-tau) and phosphorylated tau (p-tau), in 
combination with 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), could be useful in 
discriminating DLB from vascular dementia (VaD) and frontotemporal dementia (FTD), as 
we previously demonstrated for differentiation of DLB from AD.
Methods: We retrospectively analysed concentrations of MHPG, Aβ42, t-tau, and p-tau 
in CSF in patients with DLB, AD, VaD, and FTD. Using previously developed multivariate 
logistic regression models we assessed the diagnostic value of these CSF parameters.
Results: The currently used combinations of Aβ42, t-tau, and p-tau yielded a sensitivity of 
61.9% and a specificity of 91.7% for the discrimination between DLB and AD, but could not 
discriminate between DLB and VaD or FTD. The addition of MHPG to Aβ42, t-tau, and p-tau 
improves the discrimination of DLB from AD, yielding a sensitivity of 65.1% and specificity 
of 100%, but could not distinguish DLB from other forms of dementia.
Conclusions: Our results confirm, in a separate patient cohort, that the addition of 
MHPG to Aβ42, t-tau, and p-tau improves the discrimination of DLB from AD but not the 
differentiation of DLB from VaD or FTD.
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Introduction
The number of people living to older age is increasing globally 1. Advancing age is the 
single biggest risk factor for the development of dementia and thus the prevalence of 
dementia is also rapidly increasing and is fast becoming a major economic and health 
burden 2. Up to 9.4% of the European population aged ≥65 years are affected by dementia 
3 and this estimate is expected to double by the year 2040 4. After Alzheimer's disease 
(AD), dementia with Lewy bodies (DLB) and vascular dementia (VaD) are the second most 
common forms of dementia 5,6.
DLB patients often present with varying combinations of cognitive, behavioural, and 
physical symptoms that make differential diagnosis challenging 7. Not only is there a 
considerable overlap of clinical features among the dementias, but patients also often 
have a mixed pathology 8. Clinically, DLB is characterised by fluctuating cognition, 
visual hallucinations, and agitation 7. Such behavioural symptoms are often treated with 
neuroleptics, but these medications are contraindicated in DLB as neuroleptic sensitivity 
can lead to worsening of symptoms or even sudden death in some DLB patients 9,10. An 
earlier study indicated that behavioural disturbances in DLB patients could be improved 
using treatment with the cholinesterase inhibitor rivastigmine 11. However, more recent 
reviews indicate that there was variable or no positive response of cholinesterase 
inhibitors on cognitive function 12.
A timely diagnosis of DLB is necessary to ensure optimal management of a patient, 
but this is often difficult to accomplish within the patient's lifetime. Given that AD and 
DLB differ significantly in aspects such as memory, behaviour, and sleep patterns, an 
earlier diagnosis would aid in early recognition of disease-specific symptoms, clinical 
decision-making, adequate patient counselling, and targeted treatment strategies. Thus, 
biomarkers capable of affording more precise differentiation between DLB and other 
forms of dementia would be of tremendous clinical and diagnostic value.
In a previous study 13  we assessed which combination of cerebrospinal fluid (CSF) biomarkers 
could provide optimal differentiation of DLB from AD. We first assessed concentrations 
of Amyloid-β42  (Aβ42), total tau protein (t-tau) and phosphorylated tau (p-tau), the 
traditionally used biomarkers for AD, for their efficacy in differentiating between AD and 
DLB. In addition, we tested concentrations of 3-methoxy-4-hydroxyphenylethyleneglycol 
(MHPG), the primary metabolite of the neurotransmitter norepinephrine. We observed 
significantly reduced levels of MHPG in the CSF of DLB patients compared with AD patients 
and, when MHPG concentrations were used in combination with Aβ42, t-tau, and p-tau 
levels in CSF, we could discriminate DLB from AD with enhanced diagnostic accuracy 13.
Reduced MHPG concentration in the CSF of DLB patients is congruent with earlier 
observations of decreased concentrations of norepinephrine in the putamen and 
neocortex 14,15, and substantial degeneration of locus coeruleus noradrenergic neurons 
in the brains of patients with DLB 16, 17. Moreover, concentrations of MHPG are generally 
unchanged or only slightly reduced in VaD and FTD 18-20, whereas they are generally 
unchanged or increased in AD compared with controls 21,22. Thus significant reductions 
in CSF MHPG may represent a unique feature of DLB. Therefore, in the current study we 
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aimed to confirm, in a separate patient cohort, that the addition of MHPG to Aβ42, t-tau, 
and p-tau in CSF improves the discrimination of DLB from AD, and we expanded our earlier 
study to determine whether these CSF parameters could also be useful in discriminating 
DLB from VaD and FTD. 
Methods
Patients
CSF samples were collected according to standard protocols and all patients or their legal 
representative provided informed consent for lumbar puncture. We identified patients 
with a clinical diagnosis of DLB, AD, VaD, or FTD using up-to-date databases of patients 
who had been referred to either the movement disorders clinic of the Department of 
Neurology of the memory clinic of the Department of Geriatric Medicine at the Radboud 
University Medical Centre during the period May 1996 to December 2009. Patients for 
whom lumbar puncture was performed as part of the diagnostic work-up and for whom 
informed consent was obtained, were included in the study. From these groups we 
selected patients for whom relevant CSF parameters were available for inclusion in the 
current study (Figure 1), but we excluded those patient who were part of our earlier study 
13.
As part of the referral process, patient diagnosis was made based on a detailed medical 
history, comprehensive physical and neurologic examination, routine laboratory testing, 
and a brain magnetic resonance imaging (MRI) scan. Diagnoses were established by a 
multidisciplinary team consisting of a geriatrician, a neurologist, and a neuropsychologist. 
Clinical diagnosis was confirmed according to the consensus criteria for DLB 23, AD 24, VaD 
25, and FTD 26. In July 2012, a geriatrician and memory clinic specialist (JAHRC) reassessed 
the final clinical diagnosis by clinical chart review to improve diagnostic accuracy. Patients 
with FTD were also divided into subtypes according to newer clinical criteria for FTD 27-31 
by the same geriatrician in February 2013. 
CSF parameters
CSF samples were obtained by lumbar puncture and collected in polypropylene tubes and 
centrifuged for 5 minutes (860 g at room temperature). Samples were then transferred to 
clean polypropylene tubes and stored at -800C. All CSF measurements were performed by 
technicians trained in CSF analysis. These technicians were neither aware of the clinical 
diagnosis nor of the results of other individual tests at the time of CSF analysis. The CSF 
measures taken into consideration for this study were MHPG, Aβ42, t-tau, and p-tau. MHPG 
measurements were performed within 4 weeks of CSF collection in all but 8 cases. These 
final 8 cases were measured for the purpose of this study and been stored at -800C until 
the time of measurement. The method of analysis and the validation of MHPG have been 
described previously 32,33. The inter-assay coefficient of variation (CV) for MHPG was 4.8%.
Aβ42, t-tau, and p-tau were measured using commercially available kits (INNOTEST®; 
Innogenetics N.V., Ghent, Belgium). All assays were performed according to the 
manufacturer's instructions and the methodology did not change during the period in 
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which the analyses were performed. For the measurement of t-tau we included additional 
standards with concentrations of 1200pg/mL and 2400 pg/mL. Internal controls were 
included in all enzyme-linked immunosorbent assays (ELISAs) to control for inter-assay 
variation. Inter-assay CVs were 2.9% - 7.0% for Aβ42, 1.7- 6.0% for t-tau and <5.0% for p-tau. 
Measurements of Aβ42, t-tau, and p-tau were performed within 4 weeks of collection for 
all samples received during or after 2004 and were performed retrospectively for all CSF 
samples obtained prior to 2004. All patient information was decoded to maintain patient 
confidentiality.
Statistical analysis
Statistical analyses were carried out using GraphPad PRISM, version 5 (GraphPad, Inc., San 
Diego, CA), and SPSS software, version 16 (SPSS, Inc. Chicago, IL). Normally distributed 
data were analysed using Student's t-tests for comparison between two groups and one-
way analysis of variance (ANOVA) with Tukey's post hoc analyses to determine between-
group differences in the case of multiple groups. In the case of non-Gaussian-distributed 
CSF parameters, data were log-transformed prior to analysis or, alternatively, analysed 
using the Mann-Whitney U-test. Receiver operator curve (ROC) analysis was employed to 
evaluate the diagnostic value of CSF parameters and the previously developed models 13. 
ROC curve comparisons were performed using MedCalc version 12.2.1 (MedCalc Software, 
Belgium). 
Figure 1. Flowchart of patient selection from memory clinic databases for inclusion in this study. AD, 
Alzheimer's disease; DLB, dementia with Lewy bodies; VaD, vascular dementia; FTD, frontotemporal 
dementia; CSF, cerebrospinal fluid; n, number.
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Results
Patients
At the time of selection, 14 patients fulfilled the criteria for DLB, 15 for VaD, 26 for FTD, 
and 64 for AD. Patients' demographics and CSF parameters are presented in Table 1. Given 
the retrospective nature of this study, Mini-Mental State Examination (MMSE) findings 
and disease duration were not available for all patients, particularly for the DLB group. 
However, MMSE and disease duration were not correlated with any of the CSF parameters 
in any of the patient or control groups. The average age at time of lumbar puncture for 
the FTD patients was significantly lower (p < .001) than for all other patient groups, but no 
significant differences in age were apparent for the AD, DLB, or VaD groups.
CSF parameters
As depicted in Figure 2, CSF analyses showed reduced levels of Aβ42 for AD and DLB, 
increased levels of t-tau and p-tau for AD, and decreased levels of MHPG for DLB. 
Repeat analyses adjusting for age, gender, disease duration, and cognitive function 
did not markedly alter our results. We observed some unexpected heterogeneity in all 
CSF parameters for the AD patients. However, compared with our reference values, we 
observed an expected decrease in Aβ42, and increase in t-tau in our AD patients that was 
much greater than for all other groups, suggesting that these patients were correctly 
classified as AD. The percentages of patients with decreased CSF Aβ42, (≤ 500 ng/L) were 
as follows: AD, 70.3%; DLB, 50%; VaD. 15.4%; and FTD, 11.5%. CSF t-tau was increased (≥ 
350 ng/L) in AD patients (78.1%) and less frequently in VaD (46.2%), FTD (46.2%), and 
DLB (28.6%) patients. p-tau was increased (≥ 85 ng/L) in most AD patients (62.5%) and in 
smaller numbers of FTD (23.1%), VaD (15.4%), and DLB (7.1%) patients. Finally, MHPG was 
decreased (<38 nmol/L) in 50% of DLB patients compared with 19.2% of FTD patients, 
15.4% of VaD patients, and 14.1% of AD patients.
We also observed heterogeneity in the CSF parameters for our FTD patients, which we 
further investigated by analysing differences between different FTD subtypes: behavioural 
variant FTD (bvFTD, n =7); primary progressive aphasias of the semantic/agrammatic type 
(sdFTD, n=3) and nonfluent type (nfFTD, n=9); FTD with motor neuron disease (FTD-MND, 
n=2); and FTD with parkinsonism (n=3). Two patients were excluded from the subtype 
analysis as we had insufficient information to classify these 2 patients into subtypes. We 
found no significant differences in Aβ42, t-tau, and p-tau between FTD subtypes (refer 
to Table S1 in supplementary data). Interestingly, we observed that all FTD subgroups, 
except bvFTD, had MHPG levels similar to those of the DLB group.
Statistical analysis revealed that Aβ42, levels were significantly lower in the AD group than 
in the VaD (p  < .05) and FTD (p < .001) groups, but were similarly decreased in DLB patients. 
Aβ42, levels were also significantly lower in the DLB group than the FTD group (p <.05). 
Most of this difference in Aβ42, levels between FTD and AD was accounted for the nfFTD 
(p <.001) group and bvFTD group (p < .05) subtypes. t-tau levels were significantly higher 
for the AD group compared with the DLB and VaD groups (both p < .001), but no further 
between group differences were found. Levels of p-tau were increased significantly in 
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Table 1
Characteristics of the diagnostic groups
Demographic characteristics DLB AD VaD FTD p-value†
Number of patients
Age, years (SD)*
Gender, M/F (% male)
MMSE, average (s.d.)
Disease duration, months (s.d.)
CSF parameters‡
   MHPG nmol/L (s.d.)
    Aβ42, ng/L
    t-tau, ng/L
    p-tau, ng/L**
    t-tau/ Aβ42 ratio
14
72.4 (8.0)
10/4 (71%)
22 (5.0), n = 4
24 (24.0), n = 6
38.9 (12.6)
513 (154)
287 (159)
58 (17)
1.72 (1.51)
64
73.1 (8.3)
13/51 (20%)
20 (4.0), n = 61
15 (15.6), n = 61
50.0 (12.8) §
481 (145)
727 (484) ||
112 (53) ||
0.62 (0.39) ¶
15
76.5 (4.8)
10/5 (67%)
18 (3.7), n = 12
17 (15), n = 12
49.9 (15.2) ¶
568 (168)
380 (269)
54 (19)
0.77 (0.80)
26
61.6 (8.4)
17/9 (65%)
18 (7.3), n = 12
7.3 (14), n = 10
46.5 (10.9) ¶
683 (215) §
443 (303)
64 (31)
0.72 (0.62)
< 0.001
< 0.001
    0.463
    0.112
Abbreviations: DLB, dementia with Lewy bodies; AD, Alzheimer's disease; VaD, vascular dementia; FTD, frontotemporal dementia; SD, standard 
deviation; M, males; F, females; CSF, cerebrospinal fluid; MHPG, 3-methoxy-4-hydroxyphenylethyleneglycol.
   * At time of lumbar puncture; †p-vaues are presented for differences using one-way analysis of variance in the case of Gaussian-distributed data 
or Kruskal-Wallis in the case of non-Gaussian-distributed data (disease duration only). Gender distribution was analysed using the chi-square test.
    ‡Analysis of variance of transformed data was performed to test differences in MHPG, t-tau, and p-tau and the Kruskal-Wallis test was used to test 
differences in Aβ42 for each group compared with DLB (p <0.1 indicates a trend).
§p < 0.05; ||p< 0.01; ¶p< 0.001; **p-tau values missing for 1 AD patient, 2 DLB patients, and 1 VaD patient
Figure 2. Scatterplots of CSF analytes. CSF concentrations of Aβ42 (A), t-tau (B), p-tau (C), and MHPG 
(D) in each patient group.
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the AD group compared with all other groups (p <.001), but no significant differences in 
p-tau between the DLB, VaD, or FTD groups were observed. Finally, the DLB group had 
significantly lower MHPG levels compared with the AD group (p <.01) and also tended to 
be lower in the DLB group than in the VaD (p =.057) and FTD (p =.099) groups, but did not 
differ significantly between other groups.
In the AD group compared with all other groups (p <.001), but no significant differences 
in p-tau between the DLB, VaD, or FTD groups were observed. Finally, the DLB group had 
significantly lower MHPG levels compared with the AD group (p <.01) and also tended to 
be lower in the DLB group than in the VaD (p =.057) and FTD (p =.099) groups, but did not 
differ significantly between other groups. Among the DLB patients, Two subgroups with 
"high MHPG" and "low MHPG" were unexpectedly observed on the vertical scatterplot 
(Figure 2). Student's t-tests did not reveal any significant differences between these 2 
groups with respect to Aβ42, t-tau, and p-tau, or age, nor did the groups differ in gender 
distribution (5 males and 2 females in each subgroup). Due to insufficient data we were 
unable to determine whether these difference correlated with disease duration or 
cognitive function.
Diagnostic accuracy of CSF parameters
ROC analysis (Table 2) showed that the currently used combination of Aβ42, t-tau, 
and p-tau (using model 1 from the previous study: y = -5.098 + 0.005 X p-tau + 0.020 X 
t-tau - 0.002 X Aβ42) could differentiate between the DLB and AD groups with a sensitivity 
of 61.9% and specificity of 91.7% (AUC = 0.80). As anticipated from the results of our 
previous study 13, the addition of MHPG levels (using model 2 of the previous study: y 
= -13.965 + 0.072 X p-tau + 0.021 X t-tau + 0.143 X MHPG - 0.006 X Aβ42) to the current 
combination of Aβ42, t-tau, and p-tau resulted in improved diagnostic accuracy (p <.05), 
giving a sensitivity of 65.1% and specificity of 100% (AUC = 0.85). Additional models 
created using multivariate logistic regression were tested but our previously tested 
models afforded the highest diagnostic accuracy. This combination of did not significantly 
improve the discrimination of DLB from VaD or FTD. Interestingly, the combination used in 
model 2 also marginally improved the diagnostic value for the differentiation of AD from 
FTD (AUC model 1 = 0.73; AUC model 2 = 0.78), although sensitivity was slightly reduced 
from 77% to 73% and specificity rose from 60% to 82.5%. However, comparison of the ROC 
curves showed that this improvement was not significant (p =.10). To increase the power 
of the study, we combined our data with finding from our previous study 13 and repeated 
the analyses (refer to Tables S2 and S3 in supplementary data). These results show that 
MHPG was reduced significantly in DLB compared with AD (p <.001), VaD (p <.01), and 
FTD (p <.01), and is consistent with out current findings that the addition of MHPG to the 
traditional measures of Aβ42, t-tau, and p-tau improves the differentiation of DLB from AD, 
but not FTD or VaD. Although disease duration and MMSE differed significantly between 
groups in the combined analysis, there were no correlations between MMSE or disease 
duration and any of the CSF parameters. Furthermore, controlling for age, gender, MMSE, 
and disease duration did not alter the levels of significance.
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Discussion
The current results are in accordance with our earlier study 13 in which we found 
significantly lower levels of CSF MHPG in DLB compare with AD. In this extended study, 
we have shown that CSF MHPG levels are also reduced in DLB compared with VaD and 
bvFTD, and we confirmed that the addition of MHPG to Aβ42, t-tau, and p-tau improves the 
differentiation of DLB from AD. However, the addition of MHPG to these markers did not 
improve the differentiation of DLB from either VaD or FTD. Reduced MHPG concentrations 
in the CSF of DLB patients have been reported previously and are consistent with other 
studies that identified disturbances of noradrenergic function in patients with DLB 13,34. 
Substantial degeneration of locus coeruleus noradrenergic neurons and upregulation  of 
α2-adrenergic receptor (A2R) binding are frequently observed in the brains of both DLB 
and AD patients but not VaD or FTD patients 16,35. The upregulation of A2R, in particular, 
is associated with behavioural disturbances and a more extensive upregulation of A2R in 
DLB may account for the higher prevalence of behavioural problems in DLB compared 
with AD 35.
Degeneration of the noradrenergic neurons is reflected by reduced levels of 
norepinephrine in several brain areas of both AD and DLB patients but not in the lumbar 
CSF of AD patients 14,15. Although CSF norepinephrine is consistently reported as being 
reduced in DLB compared with controls, unchanged to markedly increased levels have 
been reported for AD patients 36-38. This may reflect a compensatory mechanism occurring 
in AD brains that may be influenced by other factors such as insulin or medications 37,38. On 
the whole, these finding support the notion that reduced CSF MHPG levels reflect more 
profound disturbances of the noradrenergic system in DLB compared with AD. However, 
MHPG alone does not adequately discriminate DLB from AD in this study. Interestingly, 
the DLB patients fell into two distinct group with regard to MHPG levels. The reason for 
this difference is unclear but was not dependent on age, gender, disease duration, or time 
between collection and CSF analyses.
Table 2
ROC analysis of CSF parameters DLB versus other dementias
CSF variables Number of patients* Cut-off† point Sensitivity (%) Specificity (%) AUC (95% CI) Youden Index‡ Likelihood ratio§
DLB vs AD
    Model 1||
    Model 2¶
DL vs VaD
    Model 1||
    Model 2¶ 
DLB vs FTD
    Model 1||
    Model 2¶
DLB n=12, AD n=64
DLB n=12, VaD n=14
DLB n=12, FTD n=26
>4.30
>5.68
>1.795
>2.336
>0.6545
> - 2.808
61.5
64.6
83.3
35.7
53.9
76.9
91.7
100
42.9
91.7
66.7
50
0.80 (0.69-0.91)
0.85 (0.76-0.95)
0.53 (0.30-0.82)
0.59 (0.37-0.82)
0.56 (0.38-0.76)
0.57 (0.38-0.77)
53.2
64.2
26.2
27.4
20.5
26.9
7.38
1.46
4.29
1.62
1.54
*Due to missing data points, not all CSF parameters were available for all patients. †Cut-off refers to the selected value of the individual biomarker or 
the combination where the two groups can be separated at the indicated sensitivity and specificity.
‡Youden index: sensitivity + specificity - 1.0. §Likelihood ratio: sensitivity / (1 - specificity).
Model 1: y = -5.098 + 0.005 X p-tau + 0.020 X t-tau - 0.002 X Aβ42.
Model 2: y = -13.965 + 0.072 X p-tau + 0.021 X t-tau + 0.143 X MHPG - 0.006 X Aβ42.
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Measurement of the brain-specific proteins Aβ42, t-tau, and p-tau have been analysed 
rigorously for diagnostic accuracy in distinguishing DLB from AD and the CSF levels of Aβ42, 
t-tau, and p-tau observed in our study are in agreement with those previously reported in 
the literature 39-41. The reduction of CSF Aβ42 in DLB patients has been observed previously 
and was shown to reduce the power of the traditional markers in differentiating AD 
from DLB 42. In contrast, a combination of CSF levels of Aβ42, t-tau, and p-tau shows good 
diagnostic value for discriminating AD patients from healthy controls and is currently being 
considered for routine diagnostic use to supplement clinical parameters 43. Nevertheless, 
these CSF parameters have been shown to be of limited use in differentiating AD from 
DLB and other forms of dementia. Indeed, we have again shown that CSF levels of Aβ42 
are significantly reduced in the DLB group and hamper the differentiation of DLB from AD, 
and the combination of Aβ42, t-tau, and p-tau provided only moderate discrimination of 
AD from DLB. 
As in our previous study, the addition of MHPG levels )model 2' improved the diagnostic 
accuracy compared with traditional markers alone in the discrimination of AD from DLB, 
albeit to a lesser extent than previously observed. The reduced discriminatory power 
in this study compared with our previous study 13 may have arise due to the limited 
number of DLB patients with available CSF data for analysis. Contrary to our hypothesis, 
the addition of MHPG to Aβ42, t-tau, and p-tau did not improve the differentiation of DLB 
from VaD or FTD, even after combining our data set with that of the previous study 13. 
Although degeneration of the noradrenergic system has been demonstrated repeatedly 
in DLB and AD, there has been little or no evidence of degeneration of the locus coeruleus 
noradrenergic neurons in patients with FTD or VaD 44,45. Thus, it was surprising that the 
addition of MHPG to the traditional markers did not confer any improvement in the 
discrimination of DLB from these dementias, particularly given that both MHPG and Aβ42 
levels were reduced in DLB compared with VaD and FTD.
However, when we looked more closely at MHPG levels in the FTD subgroups, we found 
that all but the bvFTD subgroups had MHPG levels indistinguishable from the DLB 
group. This seems to suggest that noradrenergic neurons may also be affect in FTD but 
dependent on FTD subtype. This is, however, rather speculative, because the low numbers 
of patients in each subgroup, particularly the FTD-MND subgroup (n=2), limited our ability 
to generalise these observations. Additional studies in larger cohorts will be needed to 
further elucidate these observations.
In the AD group, we had a much larger percentage (79%)  of female patients than for the 
other groups (29% - 50%). This may have arisen due to the fact that a greater number 
of males were included in the previous study (79%), and those patients were excluded 
from the current analysis, possibly leading to a female selection bias. The larger number of 
males and younger age for the FTD patients is reflective of greater predominance in males 
and an earlier age of onset of dementia as established by prior research 46,47.  Repeated 
analysis with adjustment for age and gender did not markedly alter our findings.
The majority of the patients in our study were classified as probable or possible and 2 
autopsy-confirmed cases of DLB were included in the study. We acknowledge that, 
because neuropathologic confirmation was not available for most cases, misclassification 
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Research in Context
1. Systematic review: We searched previous publications to iden-
tify articles describing noradrenergic changes in diferent forms 
of dementia. Several studies showed reduced brain levels of 
norephinephrine and its metabolite MHPG in DLB compared with 
other forms of dementia and we hypothesised that this difference 
in MHPG levles may be reflected in CSF and provide a tool for dis-
criminating DLB from other forms of dementia.
2. Interpretation: Our results demonstrated that CSF levels of 
MHPG are reduced in DLB compared with AD, VaD and FTD and 
that the addition of MHPG to traditional biomarkers (Aβ42, t-tau, 
and p-tau) leads to optimal discrimination of DLB from AD.
3. Future directions: Our findings warrant validation in a prospec-
tive study with long-term follow p or neuropathological confirma-
tion of the diagnosis. Future research is also required to identify 
additional biomarkers for the accurate discrimination of DLB from 
dementia disorders other than AD.
may have occurred and that some DLB, VaD, and FTD patient could have had comorbid 
AD. However, accuracy of the final diagnosis was optimised by extensive clinical and 
ancillary investigations at baseline and extensive follow-up. Furthermore, the t-tau/ Aβ42 
ratio was significantly lower in the DLB, VaD, and FTD patients compared with the AD 
patients, suggesting that these patient groups did not have comorbid AD 48-51. 
Correct diagnosis is crucial for ensuring the provision of timely and appropriate clinical 
management 5,7. Notably, neuroleptics contributed to worsening of physical and cognitive 
function and increased mortality in patients with DLB and neuroleptic sensitivity is thus 
considered to be a major feature of DLB 9-11. Despite relatively small numbers of patients 
with DLB, the results are consistent with the previous findings 13 and emphasise the 
potential for CSF biomarkers to enhance the differential diagnosis of DLB from AD. Thus, 
these finding warranted further investigation in larger, independent cohorts with a 
prospective design. 
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Table S1
Characteristics of the frontotemporal dementia subtypes
Demographic characteristics bvFTD nfFTD-PPA svFTD-PPA FTD-MND FTD + park
Number of patients
Age, years (SD)*
Gender, M/F
MMSE, average (SD)
Disease duration, months (SD)
CSF parameters†
    MHPG, nmol/L (SD)
    Aβ42
    t-tau, ng/L
    p-tau, ng/L
    t-tau/ Aβ42 ratio
7
60.0 (10.6)
6/1
18.8 (4.0), n=4
17 (27), n=3
56.0 (13.1)
738 (236)
401 (301)
65 (36)
0.56 (0.47)
9
63.2 (4.8)
5/4
18.6 (6.1), n=5
4 (2), n=5
44,7 (5.5)
735.9 (225)
436 (237)
64 (26)
0.65 (0.42)
3
63.8 (10.3)
1/2
10 (--), n=1
2 (--), n=1
38.3 (6.1)
529 (180)
795 (606)
95 (39)
1.71 (1.24)
2
56.0 (15.7)
1/1
26 (--), n=1
1 (--), n=1
34.0 (7.1)‡
619 (217)
279 (78)
37 (18)
0.46 (0.04)
3
61.7 (12.7)
3/0
2 (--), n=1
NA
48.3 (13.6)
666 (264)
326 (190)
41 (18)
0.52 (0.31)
Abbreviations: bvFTD, behavioural variant frontotemporal dementia; nonfluent type FTD; PPA, primary progressive aphasia; MND, motor neuron 
disease; SD, standard deviation; M, males; F, females; MMSE, Mini-Mental State Examination; NA, not available; CSF, cerebrospinal fluid; MHOG, 
3-methoxy-4-hydroxyphenylethyleneglycol.
*At time of lumbar puncture. 
†p-values for differences using one-way analysis of variance.  Gender distribution was analysed using chi-square test.
‡p<0.05.
Table S2
Characteristics of the combined diagnostic groups
Demographic characteristics DLB AD VaD FTD p-value
Number of patients
Age, years (SD)*
Gender, M/F
MMSE, average (SD)
Disease duration, months (SD)
CSF parameters‡
    MHPG, nmol/L (SD)
    Aβ42
    t-tau, ng/L
    p-tau, ng/L**
    t-tau/ Aβ42 ratio
36
72.1 (8.7)
44/14
23 (4.4), n=28
34 (25), n=27
38.3 (13.5)
528 (184)
246 (128)
52 (16)
0.54 (0.34)
109
72.5 (8.8)
47/62
20 (4.6), n=106
15 (16), n=61
50.0 (12.8)¶
474 (162)
706 (440)¶
109 (49)¶
1.669 (1.29)¶
15
76.5 (4.8)
10/5
18 (3.7), n=12
17 (15), n=12
49.9 (15.2)||
568 (168)
380 (269)
54 (19)
0.77 (0.80)
26
61.6 (8.4)
17/9
18 (7.3), n=13
7.3 (14), n=10
46.5 (10.9)||
683 (215)§
443 (303)||
64 (31)
0.72 (0.62)
<0.001
<0.001
<0.01
<0.01
Abbreviations: DLB, dementia with Lewy bodies; AD, Alzheimer's disease; VaD, vascular dementia; FTD, frontotemporal dementia. Refer to Table S1 
for other abbreviations.
‡At time of lumbar puncture.
†p-values are presented for differences using one-way analysis of variance in the case of Gaussian-distributed data or Kruskal-Wallis in the case of 
non-Gaussian-distributed data (disease duration only). Gender distribution was analysed using the chi-square test.
‡Analysis of variance of transformed data was performed to test differences in MHPG, t-tau, and p-tau, and the Kruskal-Wallis itest was used to test for 
differences in Aβ42 for each group compared with DLB.
§p<0.05; ||p<0.01; ¶p<0.001; **p-tau values were missing for 1 AD patient, 2 DLB patients, and 1 VaD patient.
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Table 3
ROC analysis of CSF parameters DLB versus other dementias in combined data
CSF variables Number of patients* Cut-off† point Sensitivity (%) Specificity 
(%)
AUC (95% CI) Youden index‡ Likelihood 
ratio§
DLB vs AD
    Model 1||
    Model 2¶
DLB vs VaD
    Model 1||
    Model 2¶
DLB vs FTD
    Model 1||
    Model 2¶
DLB n=31, AD n=107
DLB n=31, AD n=105
 
DLB n=31, VaD n=15
DLB n=31, VaD n=14
DLB n=31, FTD n=2
>2.102
>-0.0455
>0.6015
>-1.814
>0.1315
>-0.036
75.7
90.5
50.0
71.4
57.7
53.9
90.3
80.7
80.7
67.7
77.4
80.7
0.89 (0.84-0.95)
0.92 (0.88-0.97)
0.63 (0.45-0.81)
0.70 (0.56-0.83)
0.70 (0.56-0.83)
0.69 (0.55-0.83)
66.02
71.1
30.65
39.17
35.11
34.50
7.82
4.67
2.58
2.21
2.55
2.78
Abbreviations: AUC, area under the curve. Refer to Table S1 for other abbreviations.
*Due to missing data points, not all CSF parameters were available for all patients.
†Cut-off refers to the selected value of the individual biomarker or the combination where the 2 groups could be separated at the indicated sensitivity 
and specificity.
‡Youden index: sensitivity + specificity - 1.0.
§Likelihood ratio: sensitivity / (1 - specificity).
||Model 1: y = -5.098 + 0.005 X p-tau + 0.020 X t-tau - 0.002 X Aβ42
¶Model 2: y = -13.965 + 0.072 X p-tau + 0.021 X t-tau + 0.143 X MHPG - 0.006 X Aβ42
Biomarkers distinguish Alzheimer’s disease from dementia with Lewy bodies
49
50
51
Chapter 3
Elevated oxidised Pin1 /total Pin1 levels in early stage 
AD pathology 
"That's the effect of living backwards," the Queen said kindly: "it always 
makes one a little giddy at first--"
Megan K Herbert, Marcel M Verbeek, Benno Küsters, H Bea Kuiperij
Manuscript in preparation
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Abstract
Oxidative stress occurs in many neurodegenerative diseases including Alzheimer’s disease 
(AD) and evidence suggests that specific proteins are oxidised in individual diseases. In AD 
in particular, the peptidyl prolyl isomerise Pin1, has been shown to be sensitive to oxidative 
stress. Thus measures of oxidised proteins such as Pin1 in human biological samples could 
represent potential disease-specific biomarkers. Protein carbonylation is considered to be 
an important marker of oxidative stress. Based on this protein modification we developed 
a novel, enzyme-linked sandwich immunoassay for the quantification of oxidised Pin1 
(oxPin1) in human brain tissue samples. Our results show an increased ratio of oxPin1 to 
total Pin1 in the hippocampal tissue of patients with early AD pathology compared with 
controls. This is consistent with increased oxidative stress in the early stages of AD and 
suggests that the oxPin1/Pin1 ratio could indicate early stage pathology and warrants 
further investigation in other biological fluids. 
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Introduction
The brain uses more oxygen than any other organ of the body, making it prone to 
damage by reactive oxygen species (ROS) produced by its aerobic activity.  ROS are 
produced continuously and play an important role in biological processes such as signal 
transduction, immune responses and aging (Dickinson and Chang, 2011). An imbalance 
between endogenous pro-oxidants and antioxidant defences leads to unregulated 
production of ROS and subsequent oxidative stress (Axelsen et al., 2011) and is implicated 
in the progression of neurodegenerative brain diseases including Alzheimer’s disease 
(AD) (Barnham et al., 2004).
 AD is characterised by progressive memory loss and cognitive deterioration, and is the most 
common neurodegenerative disease.  Post-mortem histopathological examination of the 
brain reveals the presence of pathological hallmarks of AD, amyloid-beta (Aβ)- containing 
senile plaques (SPs) and neurofibrillary tangles (NFTs) composed of hyperphosphorylated 
tau protein (Braak and Braak, 1991; Mirra et al., 1991). Another common feature of AD 
brain is extensive oxidative stress, manifesting as lipid peroxidation, DNA hydroxylation 
and protein carbonylation (Barnham et al., 2004). Moreover, Aβ proteins in the presence 
of copper are directly capable of producing ROS, particularly H2O2, and likely contribute to 
oxidative stress in AD (Butterfield et al., 2001; Feaga et al., 2011).
There is increasing evidence that specific proteins are oxidised in individual 
neurodegenerative diseases (Butterfield et al., 2006; Sultana et al., 2010). In AD, proteins 
most vulnerable to oxidative stress include the peptidyl-prolyl isomerase, Pin1 (Sultana et 
al., 2006). This is of particular importance to AD, since Pin1 binds to phosphorylated tau 
(p-tau), amyloid precursor protein (APP) and glycogen synthase kinase-3β (GSK3β), all of 
which play a significant role in its pathogenesis. Pin1 binds specifically to proteins with 
phosphorylated serine (Ser) or threonine (Thr) residues preceding a proline residue. Upon 
binding, Pin1 catalyses the isomerisation of the protein at the proline residue, twisting 
it from cis to trans conformation (Lopez et al., 2003). Upon Pin1 binding at Thr231, tau is 
isomerised to trans conformation, facilitating its dephosphorylation by the trans-specific 
protein phosphatase 2A (PP2A) (Landrieu et al., 2011). Similarly, processing of APP via the 
non-amyloidogenic pathway is favoured when APP is in trans-conformation and binding 
of Pin1 to APP at Thr668 reduces production of Aβ42  (Davies et al., 2001). Pin1 is also 
responsible for inhibition of glycogen-synthase kinase 3β (GSK-3β), which is involved in 
the phosphorylation of both APP and tau (Ma et al., 2012; Martić et al., 2012). By binding to 
GSK-3β, Pin1 further reduces phosphorylation of both APP and tau thus further reducing 
amyloidogenic processing of APP and hyperphosphorylation of tau. When Pin1 is oxidised, 
its activity is restrained and can no longer bind to its substrates. Hence, the absence of 
Pin1 may correlate with enhanced amyloidogenic APP processing and increased Aβ42 
production together with hyper-phosphorylation of tau and subsequent formation of 
NFTs (Butterfield et al., 2006; Sultana et al., 2006). 
In this study, we aimed to develop a simple, effective means for measuring levels of 
oxidised Pin1 in human brain tissue and to determine the extent of Pin1 oxidation in AD 
compared with controls. For this purpose, we developed an ELISA for the measurement of 
oxidised Pin1 (oxPin1) in brain tissue and measured levels of oxPin1 at different stages of 
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Alzheimer’s disease pathology, compared with cognitively normal controls.
Materials and Methods
Tissue Samples
Frozen human hippocampal tissue samples from controls and patients with AD pathology 
were obtained from the Pathology department, collected using standard protocols, and 
informed consent had been obtained according to European guidelines. Additional 
hippocampal samples were obtained from the Netherlands Brain Bank (NBB, Netherlands 
Institute for Neuroscience Amsterdam), collected from donors for or from whom a written 
informed consent for a brain autopsy and the use of the material and clinical information 
for research purposes had been obtained by the NBB. Tissue samples were taken as quickly 
as possible after autopsy and rapidly frozen in liquid nitrogen. Post-mortem diagnosis 
and grading was performed and judged by a neuropathologist, according to the criteria 
established by Braak & Braak (all samples) and CERAD (for Radboud University Medical 
Centre patients only) (Braak and Braak, 1991; Braak and Braak, 1995; Mirra et al., 1991). 
Clinical diagnosis of AD was based on the clinical criteria of probable AD (McKhann et al., 
1984; Waldemar et al., 2007). Patient characteristics for all patients are described in Table 1.
Table 1
Patient demographics and protein levels
Advanced AD 
pathology
Early AD pathology Controls p-value1
Hippocampus
Age
Gender; M/F
Post-mortem delay (hours)
oxPin1 (pg/µg total protein)
Pin1 (ng/µg total protein)
oxPin1:Pin1
Total protein (µg/ml)
79.1 (8.2); n=9
4/5
4.6 (2.3)
6103 (1719)
54.1 (9.6)
0.113 (0.025)
13.6 (2.8)
81.9 (6.1); n=10
5/5
4.4 (0.8)
5810 (608)
41.2 (6.8)
0.143 (0.020)
13.4 (1.3)
79.6 (4.7); n=5
3/2
4.5 (1.0)
5328 (850)
45.2 (7.3)
0.118 (0.022)
14.9 (2.0)
ns
ns
ns
ns
p=0.008
p=0.018
ns
Values are presented as mean (standard deviation) except where otherwise indicated; 1 p-values obtained using ANOVA
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Protein extraction from brain tissue was performed by suspending serial cryosections 
of hippocampus or cortex (10 µm thickness) in cold 5M guanidine hydrochloride 
(GuHCl)/50 mM Tris-HCL, pH 8.0 containing a protease inhibitor cocktail (Complete Mini, 
EDTA free, Merck Millipore, Darmstadt, Germany) and vortexing until the tissue was fully 
lysed. Samples were centrifuged for 20 minutes (16,000 x g at 4°C) and the supernatant 
was stored at -80 °C in clean polypropylene tubes. Total protein concentrations were 
determined using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, 
Rockford, IL, USA).
Production and purification of recombinant Pin1 protein
Recombinant Pin1 protein was produced using a construct of Pin1 cDNA cloned in the 
pET-46 Ek expression vector (®Merck KGaA, Darmstadt, Germany) and OneShot® BL21 
(DE3) StarTM cells (Life Technologies,Carlsbad, CA,  USA ) by isopropyl β-D -thiogalactoside 
(ITPG) induction. His-tagged recombinant protein was purified under native conditions 
using a Nickel Nitrilotriacetic acid (Ni-NTA) chromatography column (Qiagen, Hilden, 
Germany) and elution with imidazole. The protein was cleared of imidazole using dialysis 
with phosphate buffered saline and subsequently concentrated using a 9 kDa cut-
off protein concentrator according to the manufacturer’s instructions (Thermo Fisher 
Scientific, Rockford, IL, USA). The final protein concentration was determined using the 
BCA protein assay kit.
Oxidation of recombinant Pin1 protein
Purified Pin1 protein (80.8 µL; 0.5 µg/mL; estimated purity ~95% based on SDS-PAGE gel 
analysis) was incubated with an oxidation solution containing 0.2mM Fe(II)SO4, 10mM 
H2O2 and 0.3mM EDTA in PBS (pH 7.4) in a final volume of 100 µL for 3h (Sultana et al., 
2006). One microliter of 40µM butylated hydroxytoluene in methanol was added to stop 
the reaction giving a final (theoretical) protein concentration of 0.4 µg/mL. The mixture 
was dialysed against PBS (pH 7.4) at 4⁰C using a mini slide-a-lyser cassette (2 kDa cut-off; 
Thermo Scientific, Rockford, IL, USA) for 2 hours and then overnight in fresh, cold PBS. 
Following dialysis, the sample was divided into aliquots and stored at -80⁰C.
SDS-PAGE analysis of Pin1
Recombinant Pin1 protein (1 µg) and an equal volume of oxidised recombinant Pin1 
protein were mixed with 4X reducing sample buffer (25% (w/v) glycerol, 2% (w/v) SDS, 
62.5 mM Tris–HCl, pH 6.8, 32 mM DTT and 0.005% (w/v) bromophenol blue) and PBS to 
a final volume of 16 μl. Samples were then heated to 95°C for 5 minutes, loaded on to 
SDS-PAGE gels with 4% acrylamide stacking gel and 12% acrylamide running gel, and 
electrophoresed at 200V. Gels were stained with Coomassie brilliant blue (R250, Serva) 
stain for 45 minutes. The Precision Plus Protein™ Standard (All Blue) molecular weight 
marker (10-250 kDa; Biorad Laboratories, Inc., California, USA) was used to approximate 
protein size. Protein bands were scanned using a BioRad Gel Doc 2000 apparatus and 
density measurements were used to calculate oxPin1 concentration in comparison to 
non-oxidised protein (Quantity One programme – BioRad v.4.2.1). 
Chapter 3
56
Direct ELISA for carbonylated proteins
A direct ELISA for the measurement of carbonyl content in the protein samples with minor 
modifications from the original protocol (Korolainen et al., 2010) was used to confirm 
protein carbonylation as a measure of protein oxidation. Protein samples derivatised 
with 2,4-dinitrophenyl hydrazine (5 µM DNPH ; 45 min) in 6M GuHCl, pH 2.4 (1:3 ratio) 
were absorbed onto an ELISA plate. The hydrazone adducts, 2,4-dinitrophenyl (DNP), 
were detected using a biotinylated antibody directed against DNP (Anti-Dinitrophenyl-
KLH, Rabbit IgG Fraction, Biotin-XX Conjugate; Molecular Probes ®, Oregon, USA)  and the 
extent of protein oxidation was assessed by comparison with an oxidized BSA standard. 
Oxidized and reduced BSA were prepared as previously described (Davies et al., 2001).
OxPin1 sandwich ELISA
OxPin1 levels in brain tissue were quantified using a novel homemade sandwich ELISA with 
oxidised recombinant Pin1 as standard. ELISA plates (F96 cert. MaxiSorp™ Immunoplate; 
Nunc, Roskilde, Denmark) were incubated overnight at 4°C with polyclonal rabbit anti-
DNP (2 µg/mL in 1M NaHCO3, pH 9.6; Life Technologies) and washed (5 X 300 μL, 0.05% 
Tween-20/phosphate buffered saline (PBST)) between all incubation steps. Plates were 
blocked with 0.1% BSA/PBS, pH 7.4 (250 μL). Samples, standards (oxPin1, stock = 0.2µg/
µL) and blank (PBS) were derivatised with 5 µM DNPH in 6M GuHCl, pH 2.4 (1:3 ratio), 
vortexed, incubated for 45 minutes in the dark, and subsequently diluted in sample 
diluent (1mM EDTA, 0.5% Triton X-100 in PBS). The highest standard (50 ng/mL) was serially 
diluted in sample diluent to obtain a 6-point standard curve. Standards, blank (PBS) and 
tissue samples (100 µL/well) were incubated for 2 hours at room temperature (RT) with 
agitation (650 rpm). An additional wash step (1:1 Ethanol:PBS) was used to ensure removal 
of unbound DNPH that could react with the detection antibody. Detection antibody (250 
ng/mL biotinylated polyclonal goat anti- Pin1; R&D Pin1 DuoSet, #DYC2294) was applied 
for 1 hour followed by 20 min incubation with 100 μL of streptavidin-HRP complex (1:200 
R&D DuoSet kit). The colour reaction was developed using TMB substrate (30 minutes at 
RT), stopped with 0.5 M H2SO4 (50µl) and read at 450nm (Tecan Sunrise ELISA plate reader 
and Magellan data analysis software). 
Total Pin1 sandwich ELISA
Pin1 levels in brain tissue (diluted 1:25) were measured using a commercially available 
ELISA kit (R&D DuoSet® IC for total Pin1; Abingdon, UK) according to the manufacturer’s 
instructions. 
Statistical Analysis
Between groups comparison was performed using Kruskal-Wallis tests for non-Gaussian 
distributed data (oxPin1) and one-way analysis of variance (ANOVA) or Student’s t-test for 
Gaussian-distributed data. Analysis of covariance (ANCOVA) was performed to control for 
covariant influences such as age, gender and post-mortem delay.
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Results
Confirmation of Pin1 oxidation
Several oxidation conditions were tested and we found that oxidation using 0.2mM Fe(II)
SO4, 10mM H2O2 and 0.3mM EDTA gave the optimal results with respect to oxidation level 
versus protein degradation. Still, SDS-PAGE gel analysis (Figure 1A) suggested that Pin1 
was partially degraded after oxidation. Using band density measurements we calculated 
the concentration of full-length oxidised Pin1 to be 0.2 μg/μL. The oxidised protein 
migrated more slowly through the gel than non-oxidised protein, indicating an increased 
size or altered charge likely resulting from addition of carbonyl side chains during the 
oxidation procedure. Oxidation of Pin1 was confirmed using a direct ELISA for detection 
of carbonyl side chains. Compared with untreated Pin1, reduced Pin1, reduced BSA, and 
PBS treated with DNPH, high OD450 values in the direct ELISA obtained for oxPin1 and 
oxidised BSA confirmed their oxidation status (Figure 1B). Furthermore, the OD450 value 
for reduced Pin1 did not differ significantly from untreated Pin1 suggesting that untreated 
Pin1 was not oxidised.
37
25
15
10
Marker Lane 1 Lane 2
Figure 1. Analysis of Pin1 oxidation. A) SDS-PAGE analysis (visualised with CBB staining) of Pin1 and 
oxidised Pin1. Recombinant Pin1 runs as a 17kDa product (Lane 1) whereas oxPin1 has a slightly 
higher molecular weight (Lane 2). B) Direct ELISA for carbonyl proteins. The high OD 450 values 
obtained from the direct ELISA for carbonyl proteins shows oxidation of oxidised BSA (oxBSA) and 
oxidised Pin1 (oxPin1) whereas the very low signals for reduced BSA (rBSA), non-oxidised Pin1 (Pin1) 
and the derivatised PBS blank (PBS) show that these samples contain minimal carbonyl side chains.
Bars show average OD values from 4 experiments with error bars showing standard error of themean.
A B
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Validation of the Sandwich ELISA for oxPin1
A typical standard curve for oxPin1 is shown in Figure 2. Linearity was observed up to 
50 ng/mL. The lower limit of detection was 2.7 ng/mL. Omission of capture antibody, 
detection antibody or antigen gave absorbance values resembling the blank confirming 
the absence of cross-reaction of either capture or detection antibodies with other proteins 
or each other. It also indicated that neither the biotinylated Pin1 antibody nor brain tissue 
samples bind non-specifically to the plate. 
Levels of total protein, Pin1 and oxPin1 in brain extracts
Grouped patient demographics and protein levels are reported in Table 1. Patients were 
divided into groups and analysed according to Braak stage pathology as follows: Controls 
(Braak 0-2), early AD pathology (Braak 3-4) and advanced AD pathology (Braak 5-6) (Hyman 
and Trojanowski, 1997).  Levels of Pin1 and oxPin1 reported in the main text are reported 
per µg of total protein. The clinical characteristics of individual patients are provided in 
supplementary Table S1. 
Figure 2. Standard line – oxPin1 sandwich ELISA. The graph shows average OD values for each 
oxPin1 standard taken from 7 consecutive experiments. Bars show standard error of the mean for 
each standard.
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Analysis of hippocampal tissue according to the degree of pathology, showed that Pin1 
tended to be correlated with post-mortem delay in controls (r=0.872, p=0.054) and was 
correlated with age in advanced AD (r=0.789, p=0.012). No other correlations between 
protein measurement and age, gender or post-mortem delay were observed. When using 
ANCOVA to control for both age and post-mortem delay, Pin1 levels were significantly 
higher in advanced AD pathology compared with both early pathology (p<0.01) and 
controls (p<0.05; Figure 3A). The oxPin1:Pin1 ratio was significantly higher in early 
pathology than controls (p<0.05) and advanced AD pathology (p=0.01; Figure 3C). 
Figure 3. Protein levels in hippocampal tissue. 
Levels of Pin1 per total protein (TP) (A) are 
increased in advanced AD pathology (Braak 
stage 5-6) compared with both controls and early 
AD pathology (Braak stage 3-4) whereas levels of 
oxidised Pin1 (B) are not different between the 
groups. The ratio of oxPin1 to Pin1 (C) is increased 
in early AD pathology compared with controls 
and advanced AD pathology. Significance levels 
are those obtained from ANCOVA analysis: * 
p<0.05, ** p<0.01.
Discussion
Pathologically, Alzheimer’s disease is characterised by the presence of abundant NFTs 
and amyloid-β containing SPs. Pin1 is a protein that functions in inhibiting the processes 
leading to the formation of these pathological lesions. Binding of Pin1 to p-tau facilitates 
its dephosphorylation and, in addition, Pin1 may reduce the phosphorylation of tau by 
inhibiting GSK-3β, a major tau kinase. Furthermore, binding of Pin1 to APP may reduce its 
amyloidogenic processing. Thus, reduced function of Pin1 may accelerate the production 
of Aβ and p-tau, and hence, SPs and NFTs. A possible mechanism of Pin1 dysfunction is its 
oxidation, as enhanced oxidative stress is another key feature of AD (Axelsen et al., 2011) 
and Pin1 is a protein that seems to be particularly vulnerable to oxidation, which may lead 
to its reduced function (Butterfield et al., 2006; Sultana et al., 2006).  
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We designed a novel sandwich ELISA for the purpose of measuring oxPin1 in biological 
samples and illustrated its use by assessing levels of oxPin1 in human hippocampal 
samples from AD patients and healthy controls. We successfully demonstrated that 
oxPin1 was measurable in human hippocampal samples using the developed ELISA. Our 
findings substantiate the need for further investigation of the role of Pin1 and oxPin1 in 
the pathophysiology of AD. 
Interestingly, we observed a ~40% increase in Pin1 levels in the hippocampus of patients 
with advanced AD pathology compared with controls and a ~19% decrease in early 
stage AD pathology compared with controls. The increase in Pin1 levels in the advanced 
pathology samples was surprising as we expected from previous research that Pin1 levels 
would be generally decreased in AD (Lu et al., 1999; Sultana et al., 2006). However, a more 
recent report using immunohistochemical methods showed redistribution and deposition 
of Pin1 into neuronal granules in the brains of patients with advanced AD pathology 
compared with controls (Dakson et al., 2011). Rather than a reduction of Pin1, per se, in 
these tissues the immunohistochemical investigations tended to suggest an abnormal 
accumulation of Pin1 that might support our finding of increased Pin1 in advanced AD 
pathology (Dakson et al., 2011). Since Pin1 is known to be localised in the nucleus we used 
a GuHCl protocol to extract proteins from the brain tissue. This procedure should enable 
extraction from all cell fractions including any Pin1 that might have been accumulated 
abnormally in granules. The previous study also found some correlation, although weak, 
between severity of Pin1 granules and NFTs in patients with Braak stages 5-6 (Dakson et al., 
2011) hinting that levels of Pin1 may be associated with pathological changes. Therefore, 
it may be interesting in future studies to investigate, using combined techniques, whether 
oxPin1 might be associated with Pin1 granules or NFTs. Finally, observation of increased 
levels of Pin1 in advanced stage AD may be a response of the brain to counteract the 
pathological accumulation of p-tau and Aβ proteins.
In the current study, differences in oxPin1 and Pin1 levels between the groups hinted 
that the ratio of oxPin1:Pin1 might be more informative than individual measurement 
of Pin1 or oxPin1 alone.  Indeed, when we analysed the ratio of oxPin1:Pin1 in human 
hippocampal samples we observed an increased ratio in the hippocampi of patients with 
early AD pathology (Braak stage 3-4) compared with controls (Braak stage 0-2; p= 0.032). 
This is consistent with the notion that Pin1 is not only oxidised in AD, but that this occurs 
early in the disease process. Somewhat unexpectedly, we did not observe an increase 
in the ratio of oxPin1:Pin1 in the patients with advanced AD pathology compared with 
controls which contradicts previous reports (Butterfield et al., 2006; Sultana et al., 2006). 
However, there are fundamental differences between the studies in that we classified 
our samples according to Braak staging as opposed to using clinical diagnoses as in 
these previous studies and this may provide an explanation for the differences observed 
between studies. 
We argue that classifying patients according to Braak stage was most appropriate for 
the current study since we were primarily interested in investigating the relationship 
between levels of oxPin1 and the pathological features of AD as defined by Braak staging. 
In support of this argument our finding that oxPin1:Pin1 is increased in the hippocampus 
of early AD pathology confirms suggestions that changes arising from oxidative stress 
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occur early in the pathophysiology of AD (Butterfield et al., 2006; Sultana et al., 2010). This 
is relevant in consideration of other research showing the involvement of Pin1 in both the 
direct regulation of tau phosphorylation and the indirect regulation via GSK3β and PP2A. 
Together, observations that Pin1 is oxidised early in AD, and likely leads to its dysfunction, 
helps to confirm that oxidation of Pin1 may lead to enhanced formation of NFTs as it can 
no longer bind to and dephosphorylate tau.
We acknowledge that relatively small numbers of hippocampal tissues limit our ability 
to generalise the findings, however, we believe that the main purpose of demonstrating 
the use of our developed ELISA for the measurement of oxPin1 in human hippocampal 
samples has been adequately achieved. What’s more, the design of our ELISA using an anti-
DNP antibody to capture all carbonylated proteins and specifically detect a target protein 
using a protein-specific detection antibody enables its adaptation for measurement of 
other potential disease-specific oxidised proteins such as glutamine synthetase in AD 
(Butterfield et al., 2006), and DJ-1 and alpha-synuclein in Parkinson’s disease (Andersen, 
2004; Choi et al., 2006; Glaser et al., 2005). Such studies may also reveal if protein oxidation 
is a global process in early stage AD pathology not restricted to Pin1.
In conclusion, we have developed a novel sandwich ELISA for the measurement of 
oxPin1 in human brain tissue and shown that the ratio of oxPin1:Pin1 is increased in 
the hippocampus of early stage Alzheimer pathology compared with both controls and 
advanced AD pathology. Further development of the assay design will enable multi-
functional use for the quantification of oxidised proteins in tissues and biological fluids that 
may be used in investigating the role of oxidised proteins in a range of neurodegenerative 
diseases, particularly in which disease-specific protein oxidation has been implicated.
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Supplementary information
Supplementary Table S1. Individual patient characteristics
Age Gender Braak 
stage
CERAD ApoE genotype
Late AD Pa-
thology
(Braak V-VI)
AD3
AD4
AD6
AD9
AD11
AD12
AD15
AD16
AD17
94
76
89
84
87
77
75
77
65
F
F
F
F
F
F
M
M
M
6
6
6
6
5
5
6
6
6
+++
+++
+++
+++
+++
+++
+++
+++
+++
3/3
3/4
3/4
3/4
3/3
4/4
4/4
3/4
3/4
Moderate
AD pathology
(Braak III-IV)
EAD1
EAD2
EAD3
EAD4
EAD5
EAD6
EAD7
EAD8
EAD9
EAD10
83
88
90
88
83
76
70
80
78
83
F
M
M
F
F
F
M
M
M
F 
3
3
4
4
3
3
4
4
3
4
Not Known
Not known
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Photo series - Part 3: Patients with Parkinson's disease often have difficulty initiating 
movement. These photos are intended to represent the delay in initiation of movement 
for simple tasks such as answering the telephone.
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"The hurrier I go, the behinder I get"
Part 3 
The use of CSF biomarkers for the 
differential diagnosis of movement disorders
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“Now, here, you see, it takes all the running you can do, to keep in the 
same place. If you want to get somewhere else, you must run at least 
twice as fast as that!" 
Chapter 4
Cerebrospinal fluid neurofilament light chain discriminates 
multiple system atrophy from Parkinson’s disease
Megan K Herbert, Marjolein B Aerts, Marijke Beenes, Niklas Norgren, Rianne AJ Esselink, 
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Abstract
Objective: The differentiation between multiple system atrophy (MSA) and Parkinson’s 
disease (PD) is difficult, particularly in early disease stages. Based on previous studies, 
we aimed to evaluate the diagnostic value of neurofilament light chain (NFL), fms-like 
tyrosine kinase ligand (FLT3L) and total tau protein (t-tau) in cerebrospinal fluid (CSF) as 
biomarkers to discriminate MSA from PD.
Methods: Using commercially available enzyme-linked immunoassays (ELISAs), we 
measured CSF levels of NFL, FLT3L and t-tau in a discovery cohort of 36 PD patients, 
27 MSA patients and 57 non-neurological controls and in a validation cohort of 32 PD 
patients, 25 MSA patients, 15 progressive supranuclear palsy (PSP patients, 5 patients with 
corticobasal syndrome (CBS) , and 56 non-neurological controls. Cut-offs obtained from 
individual assays and binary logistic regression models developed from combinations of 
biomarkers were assessed.
Findings: CSF levels of NFL were substantially increased in MSA and discriminated between 
MSA and PD with a sensitivity of 74% and specificity of 92% (AUC = 0.85) in the discovery 
cohort and with 80% sensitivity and 97% specificity (AUC = 0.94) in the validation cohort. 
FLT3L levels in CSF were significantly lower in both PD and MSA compared to controls in 
the discovery cohort, but not the validation cohort. T-tau levels were significantly higher 
in MSA than PD and controls. Addition of either FLT3L or t-tau to NFL did not improve 
discrimination of PD from MSA above NFL alone.
Interpretation: Our findings show that increased levels of NFL in CSF offer clinically relevant, 
high accuracy discrimination between PD and MSA. 
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Introduction
Parkinson’s disease (PD) is the most common movement disorder with a typical age of 
onset around 60 years although some patients (~3-5%) develop PD before the age of 401. 
PD is characterised by four cardinal motor features: involuntary tremor, postural instability, 
bradykinesia and rigidity 2. Non-motor features such as cognitive disturbances, depression, 
mild autonomic dysfunction (including orthostatic hypotension) and disordered sleep 
commonly accompany these motor symptoms 3.
Multiple system atrophy (MSA) is a relatively rare and sporadic adult-onset disease 
characterised by a variable combination of parkinsonism, cerebellar ataxia, autonomic 
dysfunction (particularly orthostatic hypotension), and pyramidal signs 4. MSA is 
commonly misdiagnosed as PD, particularly in early disease stages, because of overlapping 
symptoms, occasionally good responsiveness to dopaminergic treatment in MSA, and 
similar age of onset, typically around 60 years 1, 4. However, MSA progresses more rapidly 
than PD and is associated with a much poorer quality of life 5. Moreover, the response to 
levodopa, although variable, is generally poor and may lead to worsening of orthostatic 
hypotension in some MSA patients 6. A reliable biomarker capable of clearly distinguishing 
between MSA and PD would have great clinical and diagnostic value.
In a recent study, the fms-like tyrosine kinase ligand (FLT3L), was identified as a potential 
cerebrospinal fluid (CSF) biomarker to differentiate MSA from PD with high accuracy 7. In 
addition, CSF levels of neurofilament light chain (NFL) and total tau protein (t-tau) have 
been shown to discriminate MSA from PD 8, 9. However, these findings require confirmation. 
In the current study, we aimed to determine which of these CSF biomarkers (NFL, t-tau or 
FLT3L), or combination of biomarkers, could provide optimal discrimination of MSA from 
PD. 
Materials and Methods 
Patients
The present study was performed at the Radboud University Medical Centre (Nijmegen, 
the Netherlands). We studied patients initially referred to our tertiary movement disorder 
centre between December 2000 and November 2008 (Figure 1), with a hypokinetic 
rigid syndrome of uncertain diagnosis at presentation, and who received a subsequent 
diagnosis of PD or MSA. Initial clinical diagnosis was established by a neurologist 
specialised in movement disorders according to current diagnostic criteria for PD 10 and 
MSA 11 and underwent extensive neurological examination, including patients who had 
been enrolled in a previous study in which they were studied prospectively for three years 
(57% of MSA and 86.8% of PD patients). For these patients, diagnosis was established by 
two neurologists specialised in movement disorders and patients underwent extensive 
neurological examination together with imaging studies at initial visit and again after 
three years (Supplementary Methods). Ten MSA patients and 5 PD patients have been 
described earlier 9, 12 but the CSF parameters reported in the current study were not 
previously reported. The remaining 8 MSA and 4 PD patients were incidental cases for 
whom case review follow-up was performed by a neurologist (author MBA). 
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Disease severity was established using the (modified) Hoehn and Yahr (H&Y)13 stages and 
Unified Parkinson’s Disease Rating Scale (UPDRS)14; ataxia severity was assessed using the 
International Cooperative Ataxia Rating Scale (ICARS) 15. Final diagnosis was confirmed 
by case review of up to nine years after initial visit. Controls consisted of patients who 
had been referred to our Neurology Department during the period 2001 to 2009, who 
underwent lumbar puncture as part of the diagnostic process, and who had been 
confirmed as having no neurological disease.
For the discovery group we analysed CSF samples of PD and MSA patients obtained 
between 2001 and 2004, and controls consisted of patients confirmed as having no 
neurological disorder and with lumbar punctures obtained between 2001 and 2006. To 
validate our findings, we examined CSF in additional MSA and PD patients with lumbar 
punctures obtained between 2005 and 2008, and control CSF obtained between 2007 
and 2010. An additional group of patients with progressive supranuclear palsy (PSP, n= 
15) and corticobasal syndrome (CBS, n= 5) with previously unreported, retrospective 
CSF NFL levels were included to show differences in NFL levels between PD patients 
Figure 1. Flowchart of patient inclusion in this study. PD: Parkinson’s disease, MSA: multiple system 
atrophy, PSP: progressive supranuclear palsy, CBD: dorticobasal degeneration, CSF: cerebrospinal 
fluid, n: number. CSF was obtained during the initial diagnostic assessment upon presentation.
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and other atypical parkinsonisms (Supplementary Table 5 and Figure 1). Initial clinical 
diagnosis for these patients was established by a movement disorders specialist using 
current diagnostic criteria for PSP 16 and CBS 17. Lumbar puncture samples from all MSA 
and PD were analysed for all CSF parameters to determine and validate the utility of these 
parameters in discriminating PD from MSA. Controls in the discovery group were tested 
for all CSF parameters for comparison with PD and MSA patients. We also measured NFL 
and FLT3L levels in a second group of controls in the validation cohort to obtain additional 
reference values for these parameters. 
CSF samples and analysis
CSF samples obtained by lumbar puncture were collected in polypropylene tubes, 
centrifuged (5 minutes, 860g at room temperature), and stored at -80 °C. Patient information 
was decoded to maintain confidentiality. Undiluted CSF samples were measured in 
duplicate using commercially available enzyme-linked immunosorbent assays (ELISAs) 
for Human FLT3L (R&D Systems, Abingdon, UK), NFL (NF-light® Neurofilament ELISA RUO; 
a gift from UmanDiagnostics, Sweden) and t-tau (INNOTEST® hTau, Innogenetics N.V., 
Ghent, Belgium). ELISAs were performed according to manufacturer’s instructions except 
the capture antibody for the FLT3L ELISA was used at 1 µg/mL. 
Statistical Analysis
CSF parameters with non-Gaussian distribution were log transformed and between-group 
differences were tested using one-way analysis of variance (ANOVA) followed by Tukey’s 
post-hoc test. Mann Whitney U tests were used to compare data with a non-Gaussian 
distribution (NFL levels in the discovery group). Spearman rank correlation was used to 
determine correlations. We performed analysis of covariance (ANCOVA) to control for 
possible confounding variables (e.g. age, gender, disease duration, and disease severity). 
Binary logistic regression was used to identify variables contributing to discrimination of 
MSA from PD and receiver operator curves (ROCs) were used to determine the diagnostic 
accuracy of CSF parameters and models developed from the binary logistic regression. 
Statistical analyses were performed using GraphPad PRISM 5 software (San Diego, 
California) and SPSS software version 20.0 (Chicago, IL). Comparison of the ROC curves 
was performed using MedCalc® software version 12.5.0.0. Bootstrapping analyses using 
data from both cohorts was also performed for additional validation of the measures 
using Medcalc 12.7.0 9 Trial version.
Results
We had access to 233 CSF samples from 52 MSA patients, 68 PD patients and 113 non-
neurological controls. Of these, 61% (32/52) of the MSA and 87% (59/68) of the PD 
patients had been studied prospectively for three years. The discovery group consisted of 
36 PD, 27 MSA and 57 controls. Patient characteristics and CSF parameters are reported in 
Table 1. Lumbar puncture samples from controls were used to obtain reference values for 
NFL, FLT3L and t-tau. In order to confirm the use of NFL, FLT3L and t-tau in discriminating 
between PD and MSA we included a validation group consisting of 32 PD and 25 MSA 
patients. Since CSF measures of NFL and FLT3L are rather novel, we included 56 additional 
controls to obtain additional reference values. 
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NFL, t-tau and FLT3L levels in CSF of the discovery cohort
In the discovery group, CSF FLT3L levels were significantly lower in PD (38.4 +/- 11.9 
ng/L; p<0.01) and MSA (39.3 +/- 12.4 ng/L; p<0.05) compared with controls (47.8 +/-14.3 
ng/L) but similar in MSA and PD (Figure 2A). We found significantly higher levels of CSF 
NFL in MSA (4548 +/- 3206 ng/L) compared with both PD (1350 +/- 915 ng/L, p <0.001) 
and controls (1503 +/- 619 ng/L, p < 0.001) but no differences between PD and controls 
(Figure 2B). CSF t-tau levels were significantly higher for MSA (335 +/- 164 ng/L) than for 
PD (242 +/- 190 ng/L; p<0.05; Figure 2C) and compared with our reference values for t-tau 
in healthy controls 46% of MSA patients and 11.4% of PD patients had elevated (≥350 
ng/L) t-tau levels. 
We observed that FLT3L was correlated with both NFL and t-tau for the PD patients and 
controls but not in the MSA group. There was a moderate correlation between NFL and 
t-tau in PD (r=0.39, p<0.05) but not MSA (r=0.34, p=0.11) or controls (r=0.43, p=0.08). 
Details of the correlation data are provided in Supplementary Table 1. Four of the PD 
patients exhibited levels of t-tau that were markedly different from the remainder of the 
group (Figure 2C) but this was not correlated with MMSE since individual MMSE scores 
were 30 for 1 patient, 29 for 2 patients and 26 for 1 patient. Despite long-term clinical 
follow-up (3 to 8.8 years), we can neither rule out, nor confirm, subclinical tauopathy in 
these patients. 
NFL alone provided high discrimination (AUC 0.85) between MSA and PD patients with 
74.1% sensitivity and 91.7% specificity. The combination of t-tau and NFL developed in 
our previous study9 (Model 1: y = NFL+0.15* t-tau; AUC = 0.89) yielded similar sensitivity 
(75.0%) and specificity (91.2%; AUC = 0.90) for discriminating MSA from PD whereas the 
combination of FLT3L and NFL (Model 2: y = -1.646+0.001*NFL-0.0308*FLT3L) yielded a 
sensitivity of 81.8% and specificity of 94.8% (AUC = 0.89). The combination of NFL, FLT3L 
and t-tau (Model 3: y = -3.054 – 0.001*NFL + 0.003*t-tau – 0.028*FLT3L) yielded a higher 
AUC (0.92) with increased sensitivity (94.7%) but reduced specificity (83.3%). Comparison 
of the ROC analyses showed that this improvement was not significantly better at 
discriminating between MSA from PD than NFL alone (p>0.05). 
Gender was not correlated with any CSF parameter for any group. Age was correlated 
with, or tended to be correlated with, all CSF parameters in both PD and controls but 
Figure 2. CSF concentrations of FLT3L, NFL and t-tau for the MSA, PD and control groups: discovery 
cohort. (A) FLT3L levels are significantly reduced in MSA and PD as compared to controls. NFL (B) and 
t-tau (C) concentrations are significantly increased in the MSA group compared with the PD group.
MSA: multiple system atrophy; PD: Parkinson’s Disease; NS: non – significant difference; mean values 
are indicated by horizontal lines.
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was not correlated with any CSF parameter in MSA (Supplementary Table 2). Disease 
duration was not correlated with any CSF parameter for either PD or MSA in the discovery 
cohort. ICARS and H&Y scores were not correlated with any CSF parameter in either of the 
patient groups. UPDRS was not correlated with any CSF parameter in the PD group but, 
intriguingly, showed a significant negative correlation with NFL (r=-0.57, p<0.05) in MSA. 
Details of these correlations are provided in Supplementary Table 3. When we repeated 
our analyses controlling for these factors (age, gender, UPDRS, and disease duration) using 
ANCOVA, significance levels for NFL were maintained but significance levels for FLT3L and 
t-tau were not, suggesting that NFL levels are robust but that FLT3L and t-tau levels may 
be influenced by other factors giving rise to heterogeneity in values. 
Validation of the diagnostic markers
In the validation cohort we confirmed that CSF levels of NFL were higher in MSA (5938 
± 4267 ng/L) compared with both PD (1103 ± 442 ng/L; p<0.001) and controls (1290 ± 
664 ng/L; p<0.001; Supplementary Table 4). CSF NFL levels were also significantly higher 
in other atypical parkinsonsisms (AP; 15 PSP and 5 CBS) than in both PD and controls 
(Supplementary Table 5). This significance was maintained after controlling for age, 
gender and disease duration with ROC curves ≥ 0.9 (Supplementary Figure 1). FLT3L levels 
were non-significantly lower in both PD and MSA compared with the controls although a 
small significant difference between MSA and controls was found after controlling for age, 
gender, disease duration and disease severity (p<0.05). As with the discovery group, we 
also observed higher levels of t-tau in MSA than in PD but this failed to reach significance 
(p=0.06). We noted that t-tau levels in both PD and MSA in the validation groups were 
overall lower than in the discovery group and for MSA the difference t-tau levels in 
discovery (335 ± 164 ng/L) versus validation (244 ± 93 ng/L) was significant (p<0.05). 
The methodology used to measure t-tau (Innotest ELISAs) was the same for all patients 
but CSF samples collected prior to 2004 were analysed retrospectively, which may have 
influenced our results. 
Disease duration was significantly shorter in PD (25.1 months; range 6-84) than MSA (39.0 
months; range 12-106) in the validation group, but controlling for this variable using 
ANCOVA in the analysis of CSF parameters did not alter significance levels. 
The models developed using the CSF parameters from the discovery group were applied 
to the validation group and diagnostic values were calculated using cut-offs obtained 
from the discovery group. We were able to correctly identify the majority of MSA patients 
(sensitivity = 80% and specificity = 97%) using NFL alone (AUC = 0.94). Again, ROC curve 
comparison showed that none of the models significantly improved the discrimination of 
MSA from PD. 
Using bootstrapping analysis of the combined data to further validate our results, we 
produced an ROC curve for NFL (PD vs. MSA) that was highly comparable with ROC curves 
from the individual cohorts (AUC = 0.90; sensitivity = 77%; specificity = 96%, cut-off 
>2174ng/L). Bootstrapping of the combined FLT3L data revealed significantly lower levels 
of FLT3L in both the PD and MSA groups compared with controls as was observed only in 
the discovery group but not in the validation group. We found no significant differences in 
CSF FLT3L levels between PD and MSA patients in the individual cohorts nor when using 
bootstrapping of the combined data.
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Discussion
In the current study, we showed that CSF levels of NFL can be used for clinically relevant 
discrimination of MSA from PD. These results confirm our previous findings using a 
different method of detection for NFL 9 and the findings of a more recent large study using 
the same ELISA method 8. Higher t-tau levels for MSA patients in this study confirm similar 
observation in other studies 8, 9, 12 but the contribution of t-tau to the overall discrimination 
of PD from MSA was not significant. We noted high t-tau values in around 11% of our 
PD patients and 46% of our MSA patients in the discovery group. However, very few 
patients in the validation group had high t-tau levels (3% of PD and 8% of MSA). Since the 
diagnostic value of our previously developed model combining NFL and t-tau (model 1), 
did not differ between the discovery and validation groups, this variation probably did 
not adversely influence our results.
We found significantly decreased CSF FLT3L levels in both PD and MSA compared to 
controls in our discovery cohort, but were unable to confirm these results in the validation 
cohort. Bootstrapping of the combined data was consistent with the results of the discovery 
group, revealing significantly lower levels of FLT3L in both PD and MSA compared with 
controls but showing no significant differences in CSF FLT3L levels between PD and MSA. 
This contradicts an earlier study showing high accuracy discrimination between PD and 
MSA using FLT3L alone 7. As with the previous study, levels of CSF FLT3L were significantly 
lower in MSA than controls, but we did not observe higher levels of FLT3L in PD 7. Unlike 
the earlier study, we did not attempt to exclude patients with possible familial PD so 
variance could be partly attributable to the inclusion of younger PD patients (<50 yrs in 
15/52 PD patients) since we observed a strong correlation between age and FLT3L levels 
in both PD and controls. After subdivision of PD and MSA for age (i.e. >50 and <50 years), 
differences between PD and MSA were maintained and we found no differences between 
young vs. old PD or MSA patients (data not shown). 
Neurofilament proteins are essential for maintaining the neuronal cytoskeleton and 
increased levels of NFL in the CSF of MSA patients likely reflects extensive axonal 
degeneration 9. In keeping with earlier findings 8, 9, CSF NFL was increased in MSA and 
aided discrimination of MSA from PD 9 and, in the current study, NFL alone provided 
the best tool for discriminating between MSA and PD. The addition of FLT3L and t-tau 
to NFL analysis improved this discrimination only slightly. However, we observed strong 
correlations between NFL and FLT3L in PD and controls in both the discovery and 
validation phases that warrant further investigation to determine the potential function 
of FLT3L in the central nervous system. The lack of correlation between NFL and FLT3L in 
the MSA patients suggests that increased levels of NFL were not dependent on changes in 
FLT3L or vice versa and does not support a role for FLT3L in the pathology of MSA. 
FLT3L is a haematopoietic growth factor expressed in various tissues including the brain 18 
and has an important role in haematopoietic stem cell survival and proliferation 19. Although 
FLT3L has a neurotrophic function contributing to increased survival of a subset of post-
mitotic neurons 18, its role in neurodegenerative diseases is unknown. In amyotrophic 
lateral sclerosis (ALS), CSF levels of FLT3L are elevated compared with healthy controls 20. 
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Nerve growth factor (NGF), which normally synergises with FLT3L to exert its neurotrophic 
effect, also increases the expression of NFL. Since both NGF and NFL are increased in ALS 
21, 22, NGF may contribute to elevated levels of FLT3L and NFL as observed in ALS 20, 23, 24. In 
PD, levels of NGF are reduced 23 and possibly contribute to observed reductions in CSF 
FLT3L and NFL levels in some patients. However, contrary to previous observations, CSF 
FLT3L levels alone do not serve as a biomarker for differentiation of MSA from PD.
A major strength of our study is that diagnosis was made prospectively for the majority 
of PD and MSA patients using detailed neurological examination in combination with 
imaging studies, and final diagnosis was confirmed after long follow-up by case review. 
Our findings emphasise a consistency with other studies 8, 9, 25, 26 showing that CSF NFL 
levels could be a useful adjunct to clinical diagnosis for distinguishing PD from MSA 
and other atypical parkinsonisms. Since both ours and previous studies have shown 
significantly increased CSF NFL levels in atypical parkinsonism disorders other than MSA, 
including PSP and CBS 8, 25, 26, CSF NFL levels do not represent a specific marker for MSA but 
rather, may be more generally useful for distinguishing PD from atypical parkinsonisms 8, 
9. Our results will require confirmation in larger cohorts in future research, with (eventual) 
pathological confirmation of disease. Further, additional studies will also be required 
to determine whether NFL levels are influenced by other extraneous influences such as 
other non-neurological diseases (e.g. cancer) 27, 28 or familial versus sporadic forms of PD, 
and to determine whether increased NFL levels will be useful for differentiating PD from 
other APs at early stages of disease.
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Supplementary Data
Supplementary Table 1. Patient demographic and baseline characteristics – discovery 
cohort.
PD (n= 36) MSA (n=27) Controls  (n=57)
57.0 (11.5)
37 (64.9)
N/A
1503 (619)
47.8 (14.3)
251 (110)
Age in years (SD)x 60.1 (10.4) 62,6 (9.0)
Number of males (%)
Years of follow-up 
(range)
NFL (ng/L)
FLT3L (ng/L)
t-tau (ng/L)
22 (61.1)
5.5 (0-9.2)
1350 (915)
38.4 (11.9)
242 (190)
15 (55.6)
2.9 (0-7.9)
4548 (3206)
39.3 (12.4)
335 (164)
Disease duration, 
months (range)†
PD (n= 28)
43.8 (6 - 158)
MSA (n=14)
43.7 (8 – 96)
p-valuea
p = 0.508
Disease severity †
H&Y
UPDRS; mean (SD)
ICARS; mean (SD)
PD (n= 32)
2.0 (0.60); n=32
30.3 (11.5); n=27
2.9 (4.8); n=20
MSA (n=14)
2.7 (1.2); n=14
32.5 (16.7); n=14
12.1 (9.5); n=9
p-valuea
p = 0.014
p = 0.627
p = 0.020
Cognitive function
MMSE; mean (SD)
PD (n= 28)
28.5 (1.6)
MSA (n=14)
27.5 (3.5)
p-valuea
p >0.05
SD: standard deviation; H&Y: Hoehn and Yahr score; ICARS: International Cooperative Ataxia Rating 
Scale; UPDRS: Unified Parkinson’s Disease Rating Scale; N/A: not applicable
a Student’s t-test p-values for PD versus MSA; x At time of lumbar puncture; †At time of inclusion
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Table 2. Comparison of models for discriminating MSA from PD
CSF 
variables
Number of pa-
tientsa
Cut-off b 
point
Sensitivity
(%)
Specificity
(%)
AUC Youden 
indexc
Likelihood 
ratiod
Discovery 
NFL
Model 1e
Model 2f
Model 3g
PD=36, MSA=27
PD=34, MSA=20
PD=31, MSA=22
PD=29, MSA=15
>2315
>2388
>-0. 925
>-1.604
74.1
75.0
81.8
94.7
91.7
91.2
94.8
83.3
0.854
0.879
0.887
0.921
65.7
70.6
68.9
78.1
8.9
8.5
6.3
5.7
Validation
NFL
Model 1e
Model 2f
Model 3g
PD=32, MSA=25
PD=32, MSA=24
PD=32, MSA=23
PD=32, MSA=22
>2315
>2388
>-0. 925
>-1.604
80.0
76.1
82.6
81.8
96.9
96.9
96.9
96.9
0.938
0.932
0.969
0.948
76.9
76.1
79.5
75.6
25.6
25.3
26.4
26.2
a Due to missing data points, not all CSF parameters were available in all patients; b Cut-off refers 
to the selected value of the individual biomarker or the combination where the 2 groups can be 
separated at the indicated sensitivity and specificity; cYouden index: sensitivity + specificity – 100. d 
Likelihood ratio: sensitivity/(1-specificity) 
e Model 1: y = NFL+0.15* t-tau 
f Model 2: y = -1.646+0.001*NFL-0.03*FLT3L
g Model 3 : y = -3.054 – 0.001*NFL + 0.003*t-tau – 0.028*FLT3L
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Supplementary Methods
Prospective, longitudinal analysis of patients
During the period September 2003 until November 2006, consecutive new patients with 
a hypokinetic rigid syndrome who had been referred to the movement disorders clinic 
of the Department of Neurology at the Radboud University Medical Centre in Nijmegen, 
the Netherlands were recruited for a three year prospective study. Inclusion and exclusion 
criteria are provided in Table M1. Patients diagnosed with Parkinson’s disease (PD) and 
multiple system atrophy (MSA) were identified for inclusion in the study.
Table M1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Hypokinetic rigid syndrome of neurode-
generative origin
Instable comorbidity
Aged > 18 years Patients unfit to consent or participate
Thrombopenia A medical history of brain surgery
Informed consent was obtained and, within 6 weeks of the initial visit, all patients underwent 
a structured interview, detailed and standardized neurological examination, magnetic 
resonance imaging (MRI) scan, lumbar puncture, IBZM-SPECT and electromyography 
(EMG) of the anal sphincter. 
Ethics
Medical ethics approval was obtained from the local Institutional Review Board (2002). 
All patients signed informed consent forms after detailed explanation of the procedures.
Interview and neurological examination
Interview and neurological examination were performed by two independent physicians, 
not directly involved in patient care. Using a structured interview the following items 
were assessed: medical history, current medications, presenting complaints and disease 
progression, most affected body site, balance and fear of falling, activities in daily living, 
and quality of sleep. In addition, the following clinimetric scales were scored: Unified 
Parkinson’s Disease rating scale (UPDRS) III and IV and Hoehn and Yahr score,1 International 
Cooperative Ataxia Rating Scale (ICARS),2 Mini mental state examination (MMSE)3 and 
frontal assessment battery (FAB) 4 for cognitive assessment, and Composite Autonomic 
Symptom Scale (COMPASS)5 for autonomic dysfunction. 
Follow up
Three years after the inclusion visit, patients were seen in the outpatient clinic for a repeated 
structured interview and neurological examination by an independent physician.  These 
neurologists were blinded for the results of all ancillary investigations, except MRI which 
is now nearly routinely used in clinical practice and to the clinical notes of the treating 
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neurologist. A three year follow-up was chosen as previously published data show a very 
high concordance between neuropathological diagnosis and clinical diagnosis after at 
least 2 years follow up by a movement disorder specialist (PPV 99%) 6. 
Clinical diagnosis
The clinical diagnosis was established in a systematic fashion by two movement disorder 
specialists, blinded for test results. Patient information was decoded to maintain patient 
confidentiality and sequentially presented to the panel in the following order: 1) clinical 
data and clinimetrics (UPDRS, MMSE, FAB, ICARS) upon inclusion, 2) disclosure of MRI 
results, 3) description of the reaction to dopaminergic medication and 4) disclosure of the 
clinical data and clinimetrics (UPDRS, MMSE, FAB, ICARS) after 3 years follow-up. Each time 
the panel -in consensus- established a diagnosis (either PD or AP (not otherwise specified) 
and the corresponding degree of uncertainty (on a 0-100% rating scale), followed by a 
more specific diagnosis (e.g. PD, MSA or PSP) always according to the international clinical 
criteria. (UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria for PD,7 
NINDS-SPSP criteria for PSP, 8 Boeve criteria for CBS9 McKeith Criteria for DLB 10 Gilman 
criteria for MSA 11 and Zijlmans criteria for VaP12. For the purposes of the current study, 
final diagnosis was confirmed by case review at extended (up to 9 years) follow-up.
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"What does it matter where my body happens to be?  My mind goes on 
working all the same.  In fact, the more head downwards I am, the more 
I keep inventing new things"
Chapter 5
CSF levels of DJ-1 and tau distinguish MSA patients from PD
Megan K Herbert, Jorine M Eeftens, Marjolein B Aerts, Rianne AJ Esselink, 
Bastiaan R Bloem, H Bea Kuiperij, Marcel M Verbeek
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Abstract
Differential diagnosis between Parkinson's disease (PD) and multiple system atrophy 
(MSA) is difficult, particularly at early disease stages, but is important for therapeutic 
management. The protein DJ-1 is implicated in the pathology of PD but little is known 
about its involvement in MSA. We aimed to determine the diagnostic value of CSF DJ-1 
and tau proteins for discriminating PD and MSA. DJ-1 and total tau levels were quantified 
in the CSF of 43 PD patients, 23 MSA patients and 30 non-neurological controls matched 
for age and gender. Patients were part of a study with a 3-year prospective design with 
extended case-review follow-up of up to 9 years, ensuring maximum accuracy of the 
clinical diagnosis. Our results showed that CSF DJ-1 levels could distinguish MSA from PD 
with 78% sensitivity and 78% specificity (AUC = 0.84). The combination of DJ-1 and tau 
proteins significantly improved this discrimination to 82% and 81% specificity to identify 
MSA from PD (AUC = 0.92). Our results highlight the potential benefits of a combination of 
DJ-1 and total tau as biomarkers for differential diagnosis of MSA and PD.
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Introduction
Clinical differentiation of multiple system atrophy (MSA) from Parkinson's disease (PD) 
is important because progression of MSA is faster and prognosis is poorer than for PD 
1,2. However, differential diagnosis is difficult due to overlapping clinical symptoms, 
particularly at early stages of disease.
Neuropathologically, PD and MSA are associated with abnormal aggregation of misfolded 
alpha-synuclein (α-syn) in the characteristic Lewy bodies of PD and the glial cytoplasmic 
inclusions (GCI's) of MSA 3,4. However, as a biomarker, body fluid levels of α-syn have shown 
limited utility in discriminating between PD and MSA 5,6 although phosphorylated forms 
of the protein may have some potential in discriminating MSA from PD 7,8. DJ-1 and tau are 
implicated in the pathology of PD 9-11 and have been shown to interact with α-syn, making 
them potentially interesting biomarkers 12-15.
DJ-1 (PARK7) is a small (~20kDa) multifunctional protein that functions primarily as an 
anti-oxidant and has roles in the modulation of anti-apoptotic and anti-inflammatory 
pathways. Mutations in the PARK7 gene result in familial autosomal recessive forms 
of PD 16. DJ-1 is abundantly expressed in reactive astrocytes of both PD and MSA. Tau 
functions in the stabilisation and regulation of microtubule assembly and these functions 
are regulated by its phosphorylation state. In several neurodegenerative diseases, tau is 
accumulated and/or hyperphosphorylated which likely plays a role in the pathogenesis 
of disease 17.
Immunohistochemical studies of DJ-1 and tau show that the GCI's of MSA are reactive for 
both DJ-1 and tau whereas the Lewy bodies of PD show only halo reactivity, or are only 
reactive for antibodies directed against phosphorylated tau 18,19. This suggests differing 
pathological roles of DJ-1 and tau in PD and MSA. Studies investigating CSF levels of 
DJ-1 and tau as biomarkers for PD and MSA are limited, and variable with some showing 
increased DJ-1 in PD compared with controls and others showing reduced DJ-1 in both 
MSA and PD compared with controls 6,20-22. In this study, we aimed to determine the utility 
of CSF DJ-1 and tau levels for discriminating MSA from PD and controls.
Methods
Patients and controls
Age and gender matched patients referred to our tertiary Movement Disorder Centre 
between January 2003 and December 2006 with a hypokinetic rigid syndrome of uncertain 
diagnosis at presentation, and who received a subsequent diagnosis of PD or MSA, 
were included in this study. Consenting patients underwent neurological examination, 
imaging analysis (MRI) and lumbar puncture (details provided as Supplementary data). 
Patients were re-examined after 3 years and final diagnosis was confirmed by case 
review at extended (3-9 year) follow-up. Disease severity was established as outlined in 
the Supplementary data. Medical ethical approval for the study was obtained from the 
Institutional Review Board.
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Reference values were obtained from the CSF of patients referred to our Neurology 
Department in the period 2001-2009, who underwent lumbar puncture as part of the 
diagnostic process, and who were later confirmed as having no neurological disease. 
These controls included patients with subjective cognitive complaints not objectified 
by a neurologist (n=14); suspected of an (acute) neurological disorder which was not 
found (e.g. tension-type headache, lower back pain, etc.; n=4); without indication for a 
neurological disorder after investigation (n=6); depression or psychiatric problems (n=5); 
history of a cerebrovascular infarct (n=1).
CSF collection, storage and analysis
CSF samples obtained by lumbar puncture at the initial visit were collected in 
polypropylene tubes, transported to the laboratory, centrifuged (5min, 860x g at room 
temperature), transferred to clean polypropylene tubes and stored in aliquots at -800C. 
Patient information was decoded to maintain patient confidentiality.
Measurements of DJ-1 in undiluted CSF were quantified using a commercially available 
sandwich format ELISA (IC DuoSet for PARK7/DJ-1; R&D Systems, Abingdon, UK) according 
to the manufacturer's general ELISA protocol. Internal controls were included to ensure 
consistency between ELISA plates. Measurements of total (t-tau) and phosphorylated tau 
(p-tau) were performed using the Innotest ELISA kits (INNOTEST® hTau Ag and phospho-
tau(181p), Innogenetics N.V. Ghent, Belgium) according to the manufacturer's instructions. 
To examine correlations between DJ-1 and α-syn we used previously published α-syn 
levels for our PD and MSA patients 5. The ELISA method used for these α-syn levels is 
reported in the Supplementary data file.
Statistical analysis
Data showed a non-Gaussian distribution and was log-transformed prior to further analysis 
in order to meet the assumption of Gaussian distribution. Between-group differences 
were tested using one-way analysis of variance (ANOVA) followed by Tukey's multiple 
comparison post-hoc test or Student t-tests in the case of two-group comparisons. 
Pearson's correlation was used to test correlations between DJ-1, log-transformed tau, 
α-syn, hemoglobin (Hb), disease duration, and age. Binary logistic regression analysis 
and receiver operator curves (ROCs) were used to determine the diagnostic value of CSF 
parameters. All statistical analyses were performed using GraphPad PRISM 5 software (San 
Diego, California) or SPSS software version 20.0 (Chicago, IL). MedCalc® version 12.7.0.0 
was used for ROC curve comparison.
Results
Forty-three patients with PD, 23 with MSA and 30 age- and gender-matched, non-
neurological controls were included in the study. Patient characteristics and CSF 
parameters are provided in Table 1. Consistent with previous reports 20, we observed 
a strong correlation between DJ-1 and Hb >0.10 µmol/L (r = 0.65; p < 0.01) leading to 
falsely elevated DJ-1 levels. Although this did not alter the outcome (data not shown), we 
excluded all samples with a Hb ≥ 0.10 µmol/L (our lowest limit of detection) from further 
analysis to remove this confounder. This left 37 PD, 18 MSA and 23 control CSF samples 
for DJ-1 analysis. DJ-1 levels were significantly higher in MSA patients (710 ± 156 ng/L; Fig. 
1) compared with PD patients (525 ± 117 ng/L; p < 0.001) and controls (418 ± 131 ng/L; 
p < 0.001), and significantly higher in PD patients than controls (p< 0.01). DJ-1 was not 
correlated with age, gender, disease duration or any measure of disease severity although 
DJ-1 discriminates multiple system atrophy from Parkinson's disease
89
there was a trend towards higher DJ-1 with increased age in the PD patients (r = 0.315, p 
= 0.062).
T-tau levels were significantly reduced in PD (206 ± 116 ng/L) compared with MSA (283 ± 
132 ng/L; p <0.001) but not controls (241 ± 94 ng/L; p = 0.11). P-tau did not differ betwen 
the groups (p = 0.35). Age correlated with t-tau in the PD group and with p-tau in the 
controls. After controlling for age and gender, all significant differences reported above 
were maintained. Neither t-tau nor p-tau correlated with gender, disease duration, disease 
severity or MMSE.
DJ-1 discriminated MSA from controls with a sensitivity of 78% and a specificity of 100% 
(at a cut-off of >0.615.0; AUC = 0.84). DJ-1 could distinguish PD from controls at a cut-
off of >416.9 and AUC = 0.71, with a sensitivity of 81% and specificity of 52%. Binary 
logistic regression with block entry using DJ-1, t-tau and p-tau levels from MSA and PD 
patients, provided a model (Model 1: -8.409 + 0.018*DJ-1 + 0.024*t-tau - 0.184*p-tau) that 
significantly improved the ability to distinguish  MSA from PD with a sensitivity of 82% 
specificity of 81% (AUC = 0.92: ROC curve comparison; p < 0.05). DJ-1 levels were not 
correlated with α-syn levels (Table S2) in either PD (p = 0.33) or MSA (p = 0.107). Adding 
α-syn to the model did not improve the discrimination between PD and MSA (AUC = 0.92).
Discussion
In the current study we assessed the utility of CSF levels of DJ-1, t-tau and p-tau in 
discriminating MSA from PD and controls. CSF levels of DJ-1 were significantly elevated in 
PD, and even more so in MSA, compared with controls. This allowed discrimination of MSA 
from both PD and controls with moderate to high sensitivity and specificity. Furthermore, 
the diagnostic accuracy for discriminating MSA from PD could be improved by combining 
measures of DJ-1 with t-tau and p-tau. Our results confirm earlier findings of elevated DJ-1 
levels in PD patients 21 but the markedly elevated CSF DJ-1 levels in MSA in our study is 
unique and supports a role for DJ-1 in the pathogenesis of MSA.
PD MSA Control p-Valuesa
N
Gender: m/f (%male)
Age at LP (yrs)
Disease Duration (mths)
Follow-up time: yrs (range)
DJ-1 (ng/L)b
t-tau (ng/L)c
p-tau (ng/L)c
43
29/14 (67%)
58.9 (9.8)
37.4 (30.9)
4.6 (3 - 8.1)
525 (117), n = 36
206 (116)
46.7 (18.1)
23
14/9 (61%)
60.5 (7.5)
33.6 (21.6)
3.7 (2.2 - 6.8)
710 (156), n = 18
284 (131)
49.3 (15.8)
30
22/13 (63%)
57.0 (11.7)
N/A
N/A
418 (134), n = 23
241 (94), n = 23
52.3 (18.4), n = 21
p = 0.32
p = 0.87
p = 0.09
p = < 0.001
p = < 0.01
p = 0.35
LP: lumbar puncture; N/A: not applicable.
a Significance using Student t-tests in the case of 2 groups, or one-way ANOVA with Tukey post-hoc test for 3-group comparisons.
b Number of cases remaining after removal of samples with Hb > 0.10 mmol/L (for DJ-1) is indicated in italic text.
c Not all controls samples had been tested for t-tau and p-tau; available numbers indicated in italic text.
Table 1.  Patient characteristics and CSF DJ-1 and tau levels.
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Although DJ-1 levels are maintained at normal levels in neurons, they are up-regulated 
in reactive astrocytes in both PD and MSA, which may occur as a compensatory 
neuroprotective response to oxidative stress 23. Both DJ-1 and tau colocalise with α-syn 
in the GCIs of MSA but less so in PD Lewy bodies which are reactive to antibodies against 
phosphorylated tau but poorly reactive to phosphorylation-independent tau antibodies. 
This may provide a clue to the differing levels of CSF DJ-1 and tau in MSA and PD.
Our results contradict findings form another group in which lower levels of DJ-1 were 
observed in both MSA and PD compared with controls 6,20 but support another study 22 in 
which levels of DJ-1 in MSA were slightly, albeit non-significantly, higher compared with 
PD. While some studies support our finding of decreased t-tau in PD compared with MSA 
and controls 24,25, others show no differences between PD and controls 26,27. Comparison 
between individual studies is complicated by different methods and antibodies used to 
detect DJ-1 and tau proteins. This is supported by findings from an immuno-histochemical 
study which showed that various anti-DJ-1 antibodies reveal non-identical staining 
patterns  for DJ-1 19 and suggests the presence of more than a single isoform of DJ-1. 
These DJ-1 proteins, in turn, may be differentially recognised in ELISAs using different 
combinations of antibodies.
Recent studies have shown that levels of α-syn are reduced in PD compared with controls 
28-30 but not compared to MSA 31,32. Previously 5, we described the absence of differences in 
α-syn levels between PD, MSA and controls and now we report the absence of a correlation 
between DJ-1 and α-syn in PD and MSA. Also, addition of CSF α-syn levels to our model 
did not improve the discrimination of PD from MSA. Recently it has been shown 29 that 
differences between studies on CSF α-syn may arise due to the different platforms used 
in the different studies. Lack of suitable CSF refrained us from repeating the CSF α-syn 
analysis with a different type of assay. Therefore, additional studies investigating α-syn 
levels and correlations between α-syn and DJ-1 in PD, MSA and controls will be required 
to confirm our results.
Disparities in CSF parameters between studies could arise due to differences in control 
selection since we used non-neurological, but not necessarily healthy, controls whereas 
other studies used healthy controls 6, or (other) neurological patients 33. Alternatively, age 
differences or possible neurological comorbidity in the various patient cohorts may have 
influenced results of the various studies. Furthermore, the extent of clinical follow-up may 
be a significant factor in assigning patients to a disease category. Indeed, an earlier study 
of a broader group of parkinsonism disorders with shorter follow-up than the current 
Figure 1. CSF DJ-1 (A), t-tau (B) and p-tau (C) levels in PD and MSA patients, and controls. Horizontal 
lines indicate mean values; **p < 0.01, ***p < 0.001
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study, reported that 30% of patients had changed diagnosis from inclusion to follow-up 
with most shifting from one parkinsonism disorder to another 22. Likewise, we observed 
that clinical diagnosis of some of our PD and MSA patients changed even after more than 
three years of follow-up. Therefore, misdiagnosis due to a more constricted follow-up may 
be a significant factor in these clinical studies. Although other previous studies on CSF DJ-1 
reported longitudinal follow-up of controls with a median 3 year follow-up, the duration 
of follow-up for the PD and MSA patients was not specified, making it difficult to compare 
those results with ours 6,20. Regardless, we believe that combining a 3-year prospective 
study with extended case-review follow-up in each patient group is a major strength of 
our study and may have limited the rate of clinical misdiagnosis especially since previous 
studies have shown that differential diagnosis of PD from other atypical parkinsonism 
disorders after several years of follow-up correlates highly with neuropathological 
diagnosis upon post-mortem examination with misdiagnosis occurring mostly at initial 
diagnosis 22,34. Together, the high variation in DJ-1 levels between studies highlights the 
need for a validation and harmonisation of the methodologies used for the measurement 
of DJ-1.
In conclusion, our result show that levels of DJ-1 in CSF represent a possible biomarker for 
the differentiation of MSA from PD, particularly when used in combination with measures 
of t-tau and p-tau. Independent studies with clinical diagnoses after long-term follow-
up or with neuropathological verification of the diagnosis are required to confirm these 
results and to determine whether levels of DJ-1 and/or tau proteins may also be able to 
discriminated MSA and PD from other atypical parkinsonisms.
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Supplementary Data
Supplementary Methods – Patients
Prospective, longitudinal analysis of patients
During the period September 2003 until November 2006, consecutive new patients with 
a hypokinetic rigid syndrome who had been referred to the movement disorders clinic 
of the Department of Neurology at the Radboud University Medical Centre in Nijmegen, 
the Netherlands were recruited for a three year prospective study. Inclusion and exclusion 
criteria are provided in Table M1. Patients diagnosed with Parkinson’s disease (PD) and 
multiple system atrophy (MSA) were identified for inclusion in the study.
Table M1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Hypokinetic rigid syndrome of neurode-
generative origin
Instable comorbidity
Aged > 18 years Patients unfit to consent or participate
Thrombopenia A medical history of brain surgery
Informed consent was obtained and, within 6 weeks of the initial visit, all patients underwent 
a structured interview, detailed and standardized neurological examination, magnetic 
resonance imaging (MRI) scan, lumbar puncture, IBZM-SPECT and electromyography 
(EMG) of the anal sphincter. 
Ethics
Medical ethics approval was obtained from the local Institutional Review Board (2002). 
All patients signed informed consent forms after detailed explanation of the procedures.
Interview and neurological examination
Interview and neurological examination were performed by two independent physicians, 
not directly involved in patient care. Using a structured interview the following items 
were assessed: medical history, current medications, presenting complaints and disease 
progression, most affected body site, balance and fear of falling, activities in daily living, 
and quality of sleep. In addition, the following clinimetric scales were scored: Unified 
Parkinson’s Disease rating scale (UPDRS) III and IV and Hoehn and Yahr score,[1] International 
Cooperative Ataxia Rating Scale (ICARS),[2] Mini mental state examination (MMSE)[3] and 
frontal assessment battery (FAB) [4] for cognitive assessment, and Composite Autonomic 
Symptom Scale (COMPASS)[5] for autonomic dysfunction. 
Follow up
Three years after the inclusion visit, patients were seen in the outpatient clinic for a repeated 
structured interview and neurological examination by an independent physician.  These 
neurologists were blinded for the results of all ancillary investigations, except MRI which 
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is now nearly routinely used in clinical practice and to the clinical notes of the treating 
neurologist. A three year follow-up was chosen as previously published data show a very 
high concordance between neuropathological diagnosis and clinical diagnosis after at 
least 2 years follow up by a movement disorder specialist (PPV 99%) [6]. 
Clinical diagnosis
The clinical diagnosis was established in a systematic fashion by two movement disorder 
specialists, blinded for test results. Patient information was decoded to maintain patient 
confidentiality and sequentially presented to the panel in the following order: 1) clinical 
data and clinimetrics (UPDRS, MMSE, FAB, ICARS) upon inclusion, 2) disclosure of MRI 
results, 3) description of the reaction to dopaminergic medication and 4) disclosure of the 
clinical data and clinimetrics (UPDRS, MMSE, FAB, ICARS) after 3 years follow-up. Each time 
the panel -in consensus- established a diagnosis (either PD or AP (not otherwise specified) 
and the corresponding degree of uncertainty (on a 0-100% rating scale), followed by a 
more specific diagnosis (e.g. PD, MSA or PSP) always according to the international 
clinical criteria. (UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria for 
PD,[7]  NINDS-SPSP criteria for PSP, [8] Boeve criteria for CBS[9] McKeith Criteria for DLB 
[10] Gilman criteria for MSA [11] and Zijlmans criteria for VaP[12]. For the purposes of the 
current study, final diagnosis was confirmed by case review at extended (up to 9 years) 
follow-up.
Supplementary Methods- Alpha-synuclein ELISA method (van Geel et al., 2008 [13])
The ELISA assay is based on a previously described procedure with several important 
modifications [14]. A disposable flat-bottom microtiter plate (Nunc Maxisorp F96, Roskilde, 
Denmark) was coated with 100 µl antibody 211 (0.2µg/ml in 0.20M carbonate buffer pH 
9.6) overnight at 4°C. A plate washer (BioTek, Beun de Ronde, Abcoude, the Netherlands) 
was used to wash the plate five times with 250µl PBS containing 0.05% Tween-20 (PBS 
washing buffer). All further incubations were performed at 37°C, unless stated otherwise, 
and all measurements were performed in duplicate. Two hundred and fifty microliters of 
blocking buffer (2.5% gelatin in PBS washing buffer) was added and incubated for 2 h and 
the plate was subsequently washed for five times with PBS washing buffer. Next, 100µl 
aSyn solution (from 0 to 500 ng/ml diluted in PBS) or CSF was added to each well and 
incubated for 2.5 h (in duplicate). Then, the plate was washed five times with PBS washing 
buffer and 100 µl of antibody FL-140, diluted 1:1000 in blocking buffer was added for 1.5 
h. Again, the plate was washed five times and 100µl of the peroxidase labeled goat-anti 
rabbit antibody (dilution 1:5000 in blocking buffer) was added and incubated for 1 h. After 
a final washing step 100 µl of a freshly prepared solution of tetramethyl benzidine (TMB) 
was applied and incubated for 15 min in the dark at room temperature. The reaction was 
stopped by addition of 50 µl 2N H2SO4 and the absorbance was measured at 450 nm in a 
ELISA plate reader (Tecan Sunrise, Salzburg, Austria).
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Supplementary Table S1
PD MSA α-syn Controlsa p-valuesb
N
Gender: m/f (% male)
Age at LP (yrs)c
α-Syn (ng/mL)c
43
29/14 (67%)
58.9 (9.8)
28.6 (12.8)
23
14/9 (61%)
60.5 (7.5)
26.3 (8.1)
57
30/27 (53%)
61.3 (8.8)
30.4 (19.1)
p = 0.43
p = 0.95
a Control values as reported in Aerts et al., 2012 [15]; b Using ANOVA for 3-way comparisons and t-tests for 2-group comparisons; 
c results reported as average (standard deviation).
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Chapter 6
Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular 
parkinsonism compared to Parkinson’s disease and controls
"Well, no wonder you're late! Why this clock is EXACTLY two days slow!"
Megan K Herbert, H Bea Kuiperij, Bastiaan R Bloem, Marcel M Verbeek
Journal of Neurology 2013; 260(12): 3129-3133.
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Abstract
The neurochemical abnormalities underlying vascular parkinsonism (VP) have not 
been well characterised. A better understanding may help to optimise pharmacological 
interventions. Since VP patients generally have a poorer response to L-Dopa than Parkinson's 
disease (PD) patients, we investigated whether levels of relevant CSF neurotransmitter 
metabolites may be differentially altered in VP and PD and assessed the potential of 
neurotransmitter metabolites as biomarkers. We compared CSF levels of homovanillic 
acid (HVA), 5-hydroxyindolacetic acid, and 3-methoxy-4-hydroxyphenylethyleneglycol 
(MHPG), in 16 VP patients, 57 PD patients and 60 non-neurological controls. We found 
that levels of HVA were reduced in PD compared with both VP and controls but did not 
differ significantly between VP and controls indicating that dopamine deficiency was less 
pronounced in VP.
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Introduction
Vascular parkinsonism (VP) arising from ischaemic cerebrovascular disease typically 
presents with lower body involvement, pyramidal signs and gait difficulties, and an 
absence of a resting tremor can help distinguish VP from Parkinson's disease (PD) 1-3. 
However, the pathophysiology of VP remains poorly understood and heterogeneous 
clinical symptoms most likely reflect variable underlying pathology 4. Imaging studies 
(MRI and CT) frequently show small vessel disease (SVD) with diffuse white matter 
ischaemic lesions associated with multiple small lacunar infarcts (frequently occurring 
in basal ganglia or thalamus). The VP can also arise from subcortical arteriosclerotic 
encephalopathy (Binswanger's disease) or a single infarct of the basal ganglia 2,5-7. 
Symptoms often overlap with those of PD 4 and, notably, the latter can give a clinical 
picture indistinguishable from PD, making clinical diagnosis particularly challenging.
While the most important neurochemical feature of PD is well characterised as a marked 
loss of dopamine 8 and, to a lesser extent, serotonin (5-HT) and noradrenaline 9,10, the 
extent to which these changes occur in VP is not well studied. Levodopa (L-Dopa), the 
first-line treatment for counteracting dopamine deficiency in PD, is also used to treat 
VP 11. L-Dopa is efficacious in treating dopamine deficiency, but evidence for dopamine 
deficiency in VP is lacking. Although some VP patients (20-40%) respond to L-Dopa 
therapy, this is poor compared with PD responders (~80%), and treatment is often 
less effective and shorter-lived. We investigated CSF levels of homovanillic acid (HVA), 
5-hydroxyindolacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylethyleneglycol 
(MHPG), the catabolic end products of dopamine, serotonin and adrenaline degradation, 
to determine whether these parameters are differentially altered in VP compared with 
PD and could represent potential biomarkers for distinguishing between VP and PD 
and controls.
Methods
Patients
Data from clinically defined VP and PD patients collected by the Department of 
Neurology and Laboratory Medicine at the Radboud University Medical Centre 
between May 1996 and December 2009, were retrospectively analysed together with 
data collected between 1993 and 2002 from non-neurological controls. Patients for 
whom lumbar puncture was performed as part of the diagnostic work-up and from 
whom informed consent was obtained, were included in the study. At presentation 
consenting patients underwent a detailed medical history, imaging studies, lumbar 
puncture and extensive neurological examination by a movement disorder specialist.
Clinical diagnosis was established according to current diagnostic criteria for PD 13. The 
VP patients fulfilled all of the following inclusion criteria: older than 60 years, because 
older age at onset favours a vascular cause 6,14,15; parkinsonism (such as rigidity and 
bradykinesia) predominantly of the lower body, with only mild involvement of the 
upper limbs 14,16; a frontal gait disorder 6; and neuroradiological evidence (CT scan) of 
vascular disease. Disease severity was established using the (modified) Hoehn & Yahr 
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stages 17 and the Unified Parkinson's Disease Rating Scale 18. Final diagnosis was confirmed 
by case review with clinical follow-up up to 8.5 years after initial visit.
We analysed data for CSF levels of HVA, 5-HIAA and MHPG. The CSF samples were collected 
in polypropylene tubes, centrifuged (5 min, 860 g at RT), and stored at -800C. Patient 
information was decoded to maintain confidentiality. The HVA and 5-HIAA are dependent 
on the CSF fraction 19; thus only CSF samples from a separate 8th to 10th mL fraction were 
included. The methods of analysis of HVA 5-HIAA and MHPG in CSF have been previously 
described 19,20.
In brief, 1 mL CSF from this fraction was adjusted to pH 2.5 with formic acid and applied to 
a Sephadex G-10 (Sigma, St Louis, MO)  column. After successive washing with formic acid 
and phosphate solution the metabolites were eluted with an ammonia solution into a tube 
containing both formic acid and ascorbic acid. High performance liquid chromatography 
(HPLC) was carried out using a mobile phase of phosphate-solution, citric acid and 
methanol on a Hypersil ODS-1 column (ThermoQuest, Breda, The Netherlands) with an 
amperometric detection.
The MHPG was measured by using the same method with some minor modifications. 
Namely, 0.5 mL of CSF was added to the column and this was successively washed with 
ammonia solution and formic acid, and eluted with 2 mL formic acid. The assays were linear 
within the following ranges: HVA, 0-4 µM; 5-HIAA, 0-2 µM; MHPG, 0-125 nM. Interassay 
variation coefficient was <4.8% in all three assays.
Statistical Analysis
Non-Gaussian distributed data was log transformed and between-groups analysis 
was performed using one way ANOVA with Tukey's post hoc analysis and Pearson's 
correlations. The CSF parameters were controlled for potential confounding factors (age 
and gender) using ANCOVA. All data were analysed using GraphPad Prism, version 5 and 
SPSS Statistical software, Version 20.
Results
Patient characteristics and CSF neurotransmitter metabolite levels from 57 PD patients, 
16 VP patients and 52 control patients are shown in Table 1. Average age at time of 
lumbar puncture was significantly higher in the VP group (70.1 years) than the PD group 
(58.3 years; p < 0.0001) but not compared with controls (62.4 years; p = 0.061). Gender 
distribution was similar between the VP and PD groups (67 and 75% males, respectively). 
Although we had a lower percentage (48%) of males in the control group, the difference 
was not significant (χ2 = 5.64; p = 0.060). The CSF levels of HVA, 5-HIAA and MHPG for the 
PD, VP and control groups are provided in Table 1 and Supplementary Figure S1.
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Table 1. Patient demographic characteristics and neurotransmitter metabolite 
concentrations
Patients PD (n = 57) VP (n = 16) Controls (n = 52)
Age in years (SD)
Number of males (%males)
Disease duration 
(months, range)
58.3 (11.2)
38 (67%)
PD (n = 53)
35.0 (6-158)
70.1 (8.2)
12 (75%)
VP (n = 14)
48.7 (8-108)
62.4 (13.0)
25 (48%)
p = 0.109a
Disease severity
H&Y; mean
UPDRS; mean
PD (n = 52)
1.8 (0.56)
23.8 (10.6)
VP (n = 7)
3.0 (0.60)
34.6 (12.0)
p <0.01a
p<0.001a
CSF parameter
HVA, nM (mean; range)
5-HIAA, nM (mean; range)
MHPG, nM (mean), range
PD (n = 57)
185 (108; 58-608)
98 (40; 26-178)
47 (11; 27-89)
VP (n = 16)
338 (384; 36-1684) *
122 (48; 22-188)
51 (14; 29-70)
Controls (n = 52)
230 (106; 51-511)# 
125 (53; 43-239)*
47 (10; 29-69)
* p <0.05 versus PD
# p=0.07 versus VP (using ANOVA with Tukey post hoc)
a Student t-test for difference between PD and VP
HVA levels were significantly lower in PD (185 ± 108 nM) compared with VP (337 ± 384; p = 
0.018) and showed a tendency towards lower values than controls (230 ± 106; p = 0.067). 
These differences were maintained after controlling for age and gender:  PD versus VP (p 
= 0.017) and controls (p = 0.094). No differences in HVA levels were observed between VP 
and controls. Levels of 5-HIAA tended to be negatively correlated with age in PD (r = -0.26; 
p = 0.052) but not in VP (r = 0.26; p = 0.323) nor controls (r = 0.128; p = 0.365). Significantly 
lower levels of 5-HIAA were observed in PD (98 ± 40 nM) compared with controls (125 ± 
53 nM; p = 0.010) and this was maintained after controlling for age and gender (p = 0.027). 
There were no significant differences in levels of 5-HIAA between VP and PD (p = 0.247) 
although  there was a trend towards lower 5-HIAA levels in PD compared with VP after 
controlling for age and gender (p = 0.072). No significant differences in MHPG levels were 
found between any groups before or after controlling for confounding factors.
The CSF neurotransmitter levels in L-Dopa medicated versus unmedicated or non-L-Dopa 
medicated (together referred to as non-L-Dopa) patients are provided in Supplementary 
Table S1. L-Dopa treated VP patients (n = 8)  had higher levels of HVA than L-Dopa medicated 
PD patients, even exceeding the maximum concentration (372 nM) of our normal range 19. 
This was maintained after reanalysing the data with one outlier removed, suggesting that 
VP patients may not have had a preceding dopamine deficiency. Although not significant, 
higher concentrations of HVA were observed in L-Dopa treated patients compared with 
non L-Dopa patients, for both PD and VP, suggesting that L-Dopa treatment boosts 
dopamine levels, as expected. Levels of 5-HIAA were significantly lower in the L-Dopa 
medicated  PD patients (70 ± 33 nM) compared with both the L-Dopa medicated VP 
patients (117 ± 34nM, p < 0.001) and non L-Dopa PD patients   (105 ± 38 nM; p < 0.01), but 
no differences in 5-HIAA between L-Dopa and non L-Dopa medicated VP patients were 
observed. No significant differences in MHPG levels were detected for PD and VP or for 
medicated versus non-medicated analyses.
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We observed a trend (p = 0.09) towards longer disease duration in VP (48 ± 35 months; n 
= 14) than PD (35 ± 29 months; n = 53) and disease duration tended to be correlated with 
HVA levels in PD (r = 0.259; p = 0.061) and negatively correlated with HVA in VP (r = -0.462; 
p = 0.096). The HVA levels were negatively correlated with H&Y scores in the PD group (r = 
-0.351, p < 0.05), but no other correlations between disease severity (UPDRS or H&Y) were 
found, regardless of medication status (data not shown).
Discussion
Analysis of monoamine neurotransmitter metabolites in CSF revealed a significant 
reduction of HVA in the CSF of PD compared with both VP and controls after controlling for 
age and gender. The significantly lower level of HVA in PD compared with VP is consistent 
with another, similar study 21. These results suggest that dopamine is more depleted 
in PD than VP. To our knowledge, we are the first to use correct CSF fractions 19 for the 
measurement of these neurotransmitter metabolites for comparison between VP and PD. 
Differences in HVA levels were not useful as a biomarker to distinguish VP patients from 
PD patients, but animal studies show decreased CSF HVA levels only when striatal lesions 
cause 50% or greater loss of dopamine 22, so this may not be unexpected.
We observed rather high heterogeneity in the levels of neurotransmitter metabolites in 
all groups. This could be partly due to the correlation of age and gender with some of the 
CSF parameters observed in the current study, In addition, other as yet unknown external 
factors may influence the results. For example, it has previously been shown that seasonal 
changes, circadian rhythms, levels of cognition and glucose may all have an effect on 
CSF levels of neurotransmitter metabolites 23-26. Several earlier papers have shown that 
dopamine levels are elevated in patients with chronic ischaemic damage (discussed in 21). 
Theoretically, this could subsequently lead to alterations in levels of its metabolite, HVA. 
Therefore, heterogeneity may have arisen due to comorbid ischaemic damage in the PD 
patients and controls, particularly given that our control group were 'non-neurological 
controls' rather than 'healthy controls' thus increasing the possibility of including controls 
with underlying ischaemic damage. In contrast, the heterogeneity seen among VP 
patients was not entirely unexpected as there is already a high degree of heterogeneity 
among these patients with regard to the location and degree of underlying pathology 
that likely contributed to the variability in HVA levels in these patients. 
Recent studies show a relationship between white matter lesions and parkinsonism in 
patients with both mild parkinsonian signs 25 and vascular parkinsonism 4, particularly 
when vascular damage occurs in relevant brain regions such as basal ganglia-
thalamocortical circuits 25. Thus, vascular damage to white matter tracts may contribute to 
parkinsonism symptoms even when dopaminergic  nuclei are relatively preserved. Animal 
model studies of corpus striatum showed large increases in production of deaminated 
catecholamine metabolites during reperfusion following ischaemic assault and indicated 
that catecholamines may be released in large amounts during initial ischaemic insult 
26.  This could also explain why CSF HVA levels were higher in VP compared with PD and 
controls. This is also supported by other studies, which found higher levels of dopamine 
in patients with VP compared with controls that may account for the increase in the 
dopamine metabolite (HVA) levels ( as discussed in 21). 
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L-Dopa is prescribed for the purpose of combating dopamine loss. The HVA levels in our 
VP patients, regardless of medication status, were not different from controls, and may 
partly explain limited responsiveness to L-Dopa in VP. These finding are supported by 
other studies showing that VP patients with lesion affecting areas rich in dopaminergic-
producing neurons, such as the nigrostriatal pathway or substantia nigra, tend to respond 
better to L-Dopa therapy than patients with lesions in other brain areas not involved in 
dopamine release 27. Furthermore, VP patients with normal uptake on striatal DAT, and, 
thus, relatively normal dopamine uptake, do not benefit from L-Dopa medication 4. Taken 
together these studies suggest that dopamine depletion may occur in VP patients only 
when specific brain areas affecting dopamine production are damaged, and response to 
L-Dopa therapy may be higher in this group. This could also account for some of the high 
variability in L-Dopa responsiveness among VP patients reported in the literature (20 and 
78%) 14,28, and may reflect extensive variability in underlying pathology.
We observed significantly reduced 5-HIAA levels in PD compared with controls. These 
findings are consistent with findings of serotonergic disturbances in PD, particularly in 
median raphe and caudate nucleus 9,29. Others suggest that L-Dopa treatment stimulates 
serotonergic neurons to preferentially release dopamine and, thus, reduce serotonin 
release 30,31 so reduced 5-HIAA levels in CSF might be expected to reflect L-Dopa treatment. 
Indeed, L-Dopa treated PD patients had lower levels of 5-HIAA than non L-Dopa treated 
PD patients (Supplementary Table S1). However, 5-HIAA levels were also reduced in the 
L-Dopa treated PD patients compared to the L-Dopa treated VP patients and controls. 
Therefore, reduced 5-HIAA levels in PD patients could also partly reflect serotonergic 
deficits rather than effects induced by L-Dopa. Although others showed reduced 5-HIAA 
levels in the brains and CSF of VP compared with PD, the CSF fraction used for analysis was 
not reported 21 and may not have accurately reflected true CSF levels of 5-HIAA.
In conclusion, modestly higher concentrations of HVA in the CSF of VP compared with PD 
patients may indicate more severe dopaminergic cell loss in PD and may partly clarify why 
VP patients have a poorer L-Dopa responsiveness. We would expect that patients with 
lower levels of HVA may respond more positively to L-Dopa medications than those with 
normal levels.  Much larger patient groups with (eventual) neuropathological confirmation 
of disease will be required to clarify our results and to elucidate the relationship between 
neurotransmitter metabolites levels and underlying pathophysiology of vascular 
parkinsonism.
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Supplementary Data
Supplementary Table S1. Neurotransmitter metabolite levels according to patient 
medication
HVA (nM)
mean (s.d.)
5-HIAA (nM)
mean (s.d.)
MHPG (nM)
mean (s.d.)
PDa
Non L-Dopa medications; n=44
L-Dopa; n=12
170 (73)
233 (187)
105 (38)
70 (33)
47 (9)
47 (17)
VPa
Non L-Dopa medications; n=8
L-Dopa; n=8
207 (121)
506 (502)
121 (57)
117 (34)
46 (14)
58 (17)
aMedication status was unknown for 1 PD and 1 VP patient and are not included in the analysis
Supplementary Figure S1
Figure S1. Levels of neurotransmitters metabolites in CSF. CSF 5-HIAA (A) and HVA (B) 
levels were higher in VP patients compared with PD patients but no differences in MHPG 
levels (C) were observed.
CSF neurotransmitter metabolites in parkinsonism disorders
107
References
1. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: 
a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184
2. Zijlmans JCM, Daniel SE, Hughes AJ, Re´ve´sz T, Lees AJ (2004) Clinicopathological investigation of vascular 
parkinsonism, including clinical criteria for diagnosis. Mov Disord 19:630–640
3. Aerts MB, Esselink RAJ, Post B, van de Warrenburg BPC, Bloem BR (2012) Improving the diagnostic accuracy in 
parkinsonism: a three-pronged approach. Pract Neurol 12:77–87
4. Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U et al (2012) The relationship between cerebral 
vascular disease and parkinsonism: the VADO study. Parkinsonism Rel Disord 18:775–780
5. Chang CM, Yu YL, Ng HK, Leung SY, Fong KY (1992) Vascular pseudoparkinsonism. Acta Neurol Scand 86:588–
592
6. Zijlmans JCM, Thijssen HOM, Vogels OJM, Kremer HPHMP, Poels PJE, Schoonderwaldt HC et al (1995) MRI in 
patients with suspected vascular parkinsonism. Neurology 45:2183–2188
7. van Zagten M, Lodder J, Kessels F (1998) Gait disorder and parkinsonian signs in patients with stroke related to 
small deep infarcts and white matter lesions. Mov Disord 13:89–95
8. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E et al (2009) Initial clinical manifestations 
of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol 8:1128–1139
9. Halliday GM, Blumbergs PC, Cotton RGH, Blessing WW, Geffen LB (1990) Loss of brainstem serotonin- and 
substance P-containing neurons in Parkinson’s disease. Brain Res 510: 104–107
10. Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and 
noradrenaline innervation in the limbic system. Brain 128: 1314–1322
11. Constantinescu R, Richard I, Kurlan R (2007) Levodopa responsiveness in disorders with parkinsonism: a 
review of the literature. Mov Disord 22:2141–2148
12. Gupta D, Kuruvilla A (2011) Vascular parkinsonism: what makes it different? Postgrad Med J 87:829–836
13. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in 
a specialist movement disorder service. Brain 125:861–870
14. Winikates J, Jankovic J (1999) Clinical correlates of vascular parkinsonism. Arch Neurol 56:98–102
15. Critchely M (1929) Arteriosclerotic parkinsonism. Brain 52:23–83
16. FitzGerald PM, Jankovic J (1989) Lower body parkinsonism: evidence for vascular etiology. Mov Disord 4:249–
260
17. Hoehn MMMD, Yahr MDMD (2001) Parkinsonism: onset, progression, and mortality. Neurology 57(10):S11–
S26
18. Fahn S, Elton RL (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB 
(eds) Recent developments in Parkinson’s Disease. Macmillan Healthcare Information, Florham Park, pp 153–163
19. Brautigam C, Wevers RA, Jansen RJ, Smeitink JA, de Rijk-van Andel JF, Gabreels FJ, Hoffmann GF (1998) 
Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 44: 1897–1904
20. Abdo WF, van de Warrenburg BPC, Munneke M, van Geel WJA, Bloem BR, Kremer HPH et al (2006) CSF analysis 
differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 67:474–479
21. Tohgi H, Abe T, Saheki M, Yamazaki K, Murata T (1997) Concentration of catecholamines and indoleamines in 
the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson’s disease patients. J Neural 
Transm 104:441–449
22. Espino A, Ambrosio S, Bartrons R, Bendahan G, Calopa M (1994) Cerebrospinal monoamine metabolites 
and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP?. J Neural Transm 
7:167–176
23. Hartikainen P, Soininen H, Reinikainen KJ, Sirvio¨ J, Soikkeli R, Riekkinen PJ (1991) Neurotransmitter markers 
in the cerebrospinal fluid of normal subjects effects of aging and other confounding factors. J Neural Transm 
84(1–2):103–117
24. Nilsson C, Stahlberg F, Thomsen C, Henriksen O, Herning M, Owman C (1992) Circadian variation in human 
cerebrospinal fluid production measured by magnetic resonance imaging. Am J Physiol Regul Integr Comp 
Physiol 262(1):R20–R24
Chapter 6
108
25. de Laat KF, van Norden AGW, Gons RAR, van Uden IWM, Zwiers MP, Bloem BR et al (2012) Cerebral white 
matter letions and lacunar infarcts contribute to the presence of mild parkinsonian signs. Stroke 43:2574–2579
26. Eisenhofer G, Kopin IJ, Goldstein DS (2004) Catecholamine metabolism: a contemporary view with 
implications for physiology and medicine. Pharmacol Rev 56:331–349
27. Zijlmans JCM, Katzenschlager R, Daniel SE, Lees AJL (2004) The L-Dopa response in vascular parkinsonism. J 
Neurol Neurosurg Psychiatry 75:545–547
28. Glass PG, Lees AJ, Bacellar A, Zijlmans J, Katzenschlager R, Silveira-Moriyama L (2012) The clinical features of 
pathologically confirmed vascular parkinsonism. J Neurol Neurosurg Psychiatry 83:1027–1029
29. Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang L-J, Guttman M et al (2008) Preferential loss of serotonin 
markers in caudate versus putamen in Parkinson’s disease. Brain 131:120–131
30. Reed MC, Best JA, Nijhout HF (2012) Mathematical insights into the effects of levodopa. Front Integr Neurosci 
6:21
31. Navailles S, De Deurwaerdere P (2012) Contribution of serotonergic transmission to the motor and cognitive 
effects of highfrequency stimulation of the subthalamic nucleus or levodopa in Parkinson’s disease. Mol 
Neurobiol 45:173–185
CSF neurotransmitter metabolites in parkinsonism disorders
109
110
Demyelinating disorders such as multiple sclerosis are characterised by nervous system 
damage that is disseminated in time and place. The photo series in part 4 is intended to 
represent the recurrence of disease at different places and at different times.
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Part 4 
The use of CSF biomarkers for the 
differential diagnosis of demyelinating disorders
“How puzzling all these changes are! I'm never sure what I'm going to 
be, from one minute to another.”
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Chapter 7
Optimisation of the quantification of glutamine synthetase 
and myelin basic protein in cerebrospinal fluid by a combined 
acidification and neutralisation protocol.
“I know who I was when I got up this morning, but I think I must have 
changed several times since then”
Megan K Herbert, H Bea Kuiperij, Marcel M Verbeek
Journal of Immunological Methods 2012; 381(1-2): 1-8
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Abstract
The measurement of proteins in cerebrospinal fluid (CSF) by enzyme-linked 
immunosorbent assays (ELISAs) is becoming increasingly important in the diagnosis of 
many neurodegenerative diseases such as Alzheimer's Disease. However, detection of 
proteins in these immunoassays can be hampered by confounding factors either present 
in the sample matrix or inherent to the protein of interest. These confounding factors 
may, for example, include protein aggregation or binding to other proteins resulting in 
epitope masking. Furthermore, the pH of CSF may vary considerably amongst different 
samples which may limit standardisation of CSF analysis. Pretreatment of CSF to liberate 
epitopes or optimise conditions for antibody binding may enhance protein detection. In 
the current study we investigated whether CSF acidification followed by neutralisation (in 
short: AFBN) or neutralisation alone prior to measurement might improve the detection of 
a panel of brain-specific proteins. We demonstrate that the AFBN pre-treatment protocol 
for CSF significantly enhances the measurement of glutamine synthetase (GS) and myelin 
basic protein (MBP) in CSF but does not affect detection of glial fibrillary protein (GFAP), 
amyloid β 42 (Aβ42), total tau (t-tau) or phosphorylated tau (p-tau). Neutralisation alone 
did not improve detection of any of the proteins tested. Based on our results, we suggest 
including the AFBN protocol in the evaluation of new biomarker development protocols 
to avoid confounders such as CSF pH or epitope-masking of the target protein.
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Introduction
The quantification of proteins in CSF is becoming increasingly important in the diagnosis 
of neurodegenerative diseases such as Alzheimer's Disease (AD) (Dubois et al., 2007; 
McKhann et al., 2011). Changes in the levels of brain-specific proteins in CSF have been 
shown to be associated with disease pathogenesis and brain dysfunction (Verbeek et 
al., 2003; Olsson et al., 2011). Proteins of interest for AD include amyloid beta protein 
(Aβ42), total and phosphorylated tau protein, and glutamine synthetase  (GS). Aβ42 and 
tau are well known to aggregate and deposit in the brain to form extracellular senile 
plaques and intra-neuronal fibrillary tangles respectively and are considered to be the 
neuropathological hallmarks of AD (Ittner and Götz, 2011). GS, an enzyme which converts 
potentially toxic glutamate and ammonia to non-toxic glutamine, is also of interest as its 
activity is reduced in the brains of patients with AD and may thus contribute to increased 
neuronal excitotoxicity (Prince et al., 1995; Olabarria et al., 2011).
CSF proteins can be measured by relatively simple, efficient methods. Sandwich-format 
enzyme-linked immunosorbent assays (sELISAs) are a commonly used platform for sensitive 
and specific measurement of proteins in CSF and several commercially available kits have 
shown high utility in the diagnosis of specific diseases. Indeed, the commercially  available 
kits for the measurement of brain specific proteins total tau, (t-tau), phosphorylated tau 
(p-tau) and amyloid β42 protein (Aβ42) in CSF are currently being considered for addition 
to diagnostic criteria for AD (Mattsson et al., 2009; Mattsson, 2011). 
However, accurate measurement of CSF proteins by ELISA can be adversely affected by 
extraneous factors. Those that  have been shown to influence the detection of t-tau, p-tau 
and Aβ42 include CSF storage conditions, adsorption of CSF proteins to collection tubes, 
and batch-to-batch variations in ELISA kits, leading to inconsistencies in reference ranges 
and clinical characteristics of the assays between analytical centres (Bjerke  et al., 2010). As 
a result, recommendations for the standardisation of CSF collection have been suggested 
(Bjerke et al., 2010; Teunissen et al., 2010) and, under the auspices of the American 
Alzheimer Association, a harmonisation process for the (pre-) analytical analysis of these 
biomarkers has been started.
In addition to the aforementioned factors, other confounding factors inherent to the 
protein of interest or to the CSF sample  matrix may lead to reduced immunological 
detection by  individual antibodies (Hnasko et al., 2011). The binding of  other substances 
(e.g. autoantibodies, lipids, or other proteins)  may cause a change in protein conformation 
that alters epitope conformation and/or ‘masks’ the epitope thus preventing the binding 
of individual antibodies (Okragly and Haak-Frendscho, 1997; Bibl et al., 2004). This epitope 
masking by binding substances has been suggested as one of the factors underlying the 
relative large variability in the quantification of brain-specific  proteins in CSF (Bjerke et 
al., 2010). Furthermore, the specificity or epitope binding of commercial antibodies is not 
generally well-characterised and the optimal conditions for antibody binding in ELISA 
must be examined for individual antibodies (Hnasko et al., 2011).
In the past, several pre-treatment methods for CSF have been considered for improved 
detection of proteins in ELISA. These included detergent treatments (e.g. SDS, Tween-20) 
and heat denaturation of proteins (Groome et al., 1986; Bibl et al., 2004). However, 
repeated measures showed inconsistencies, possibly due to other types of interference. 
For example, the presence of SDS at high concentrations can interfere with ELISA assays 
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by introducing non-specific antibody binding (Julian et al., 2001) whereas applying 
low concentrations of SDS may be insufficient to fully denature proteins for improved 
detection (Hnasko et al., 2011).
An alternative pre-treatment of CSF for epitope unmasking involves the acidification of 
CSF followed by neutralisation prior to analysis (Lyons et al., 1988). The detection of the 
active form of transforming growth factor-β (TGF-β) requires this step to enable release 
from its proform (Lyons et al., 1988). Myelin basic protein (MBP) is an essential component 
of myelin that is degraded in multiple sclerosis (MS) and high CSF levels of the protein 
may indicate acute exacerbation or progression of disease (Lamers et al., 1998). Similarly, 
MBP autoantibodies have been investigated for their role in nerve demyelination, a key 
pathological feature in MS (Belogurov et al., 2008). However, sandwich ELISAs for the 
detection of MBP and MBP autoantibodies seem to be affected by epitope masking. Hence 
an acid pre-treatment of CSF to release MBP auto-antibodies that are bound to the MBP 
protein are often incorporated into sELISA protocols (Warren and Catz, 1987; Mastroianni 
et al., 1991). This also suggests that epitope-masking may play a role in the quantification 
of MBP itself in CSF.
Other proteins tested using an acidification followed by neutralisation (AFBN) pre-
treatment of CSF include glial cell derived neurotrophic factor (GDNF), cyclic guanidine 
5'-monophosphate (cGMP) and nerve growth factor (NGF), where improved protein 
detection was also observed (Lyons et al., 1988; Zettler et al., 1996; Okragly and Haak-
Frendscho, 1997; Grundström et al., 2000; Iłżecka, 2004). The mechanism of action of 
AFBN-enhanced detection of proteins such as GDNF and NGF may be a result of the 
irreversible dissociation of target proteins from other proteins, or substrates, or through 
the  disassembly of larger multimeric forms of the protein into  smaller oligomeric and 
monomeric forms (Lyons et al., 1988; Zettler et al., 1996; Okragly and Haak-Frendscho, 
1997; Bibl et al., 2004).
In this study we investigated whether AFBN pre-treatment would improve the detection 
of several brain-specific proteins, including MBP, GS, glial fibrillary acidic protein (GFAP), 
Aβ42, t-tau and p-tau, to study if the detection of these proteins is hindered by binding 
substances. In addition, since naïve CSF may have a very high pH, we determined whether 
simply adjusting the CSF pH to physiological levels (pH 7.0 to 7.4) prior to measurement 
would improve the standardisation of CSF protein analysis by ELISA.
Methods
CSF samples
CSF samples were obtained by lumbar puncture and  collected in polypropylene tubes 
followed by 5 min of centrifugation (860 ×g at room temperature) within 2 h after 
collection. Following centrifugation, samples were transferred to clean polypropylene 
tubes. Samples were stored at −80 °C until day of testing and no sample had more than 
one freeze/thaw cycle prior to testing. Separate aliquots taken from the same sample were 
used for assessing the effects of pH on the measurement of proteins in one and the same 
ELISA. All patient information was decoded to maintain patient confidentiality. Informed 
consent was obtained from the patient or his legal representative.
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Neutralisation of CSF samples
Aliquots of CSF for all ELISAs, except for GS, were diluted in 250 mM potassium phosphate 
buffer (PPB), pH 7.2 at a ratio of 4:1 in PPB to adjust the CSF pH to neutral. For GS ELISAs, 
aliquots of CSF were diluted 1:1 with 0.1% BSA in 50 mM PPB,  pH 7.8 to adjust the pH to 
neutral. pH measurements were performed using a standard pH meter (PHM210 Meterlab, 
Radiometer Analytical, France).
Pre-treatment of CSF samples using an acidification followed  by neutralisation (AFBN) 
protocol
An aliquot of each CSF was acidified to pH ≤3 by the addition of 4.8 μL 2M HCl per 120 
μL of CSF and incubated for 10 min at room temperature (RT). Samples were neutralised 
by the addition of 3.2 μL 2M NaOH and 250 mM PPB (pH 8.4) to give a final CSF:PPB ratio 
of 4:1. In the case of GS, 0.1% BSA in  50 mM PPB, pH 7.8 was added at a ratio of 1:1 after 
addition of NaOH, in order to neutralise the samples.
Protein expression and purification of GS
GS with an N-terminal His-tag (His-GS) was expressed in Escherichia coli cells followed 
by purification under native conditions using a Nickel Nitrilotriacetic acid (Ni-NTA) 
chromatography column (Qiagen, Hilden, Germany). The purified protein was transferred 
to a Slide-A-Lyzer cassette (12–30 mL, MWCO 10 K, Thermo Scientific, Rockford, IL, USA) 
and dialysed  in native lysis buffer (NLB; 50 mM NaH2PO4; 300 mM NaCl, pH 8) to reduce the 
imidazole content. The dialyzed protein was concentrated in the dialysis cassette using 
solid polyethylene glycol (PEG; 20–35 kDa).MnCl2 and ATP (final concentration of 1 mM 
each) were added to a separate cassette containing  dialyzed protein to help stabilise the 
protein (Krajewski et al.,2008) prior to concentration using a 9 kDa cut-off Pierce® protein 
concentrator (Thermo Scientific). The final protein concentration was determined using a 
bicinchoninic acid  (BCA) protein assay kit (Thermo Scientific, Rockford, IL, USA).
CSF ELISAs
Undiluted, neutralised and AFBN treated CSF samples were tested for GS, MBP, GFAP, t-tau, 
p-tau, and Aβ42 as follows:
Sandwich ELISA for GS
A homemade sandwich ELISA using His-GS for the standard curve was set up for the 
measurement of GS. Wells of a 96-well flat-bottom ELISA plate (F96 cert. MaxiSorp™ 
Immuno-plate: Nunc, Roskilde, Denmark) were coated with monoclonal mouse antibody 
directed against human GS (Abnova, Taipei City, Taiwan) at 0.05 μg/mL in coating buffer 
(PBS, pH 7.2-7.4) and incubated overnight (O/N) at 4 °C. Plates were washed 5 times with 
300 μL of 0.05% Tween-20 in phosphate buffered saline (PBST) between all incubation 
steps. The plate was blocked with 250 μL/well of 1% BSA in 0.1 M PPB, pH 7.8 and incubation 
at RT for 1 h. All subsequent incubations were performed at 37 °C with agitation at 650 
rpm. First, 100 μL of standards, blanks (0.1% BSA in 50 mM PPB. pH 7.8) plus untreated 
and pre-treated CSF samples were incubated for 2 h. Wells were then incubated with 
100 μL of polyclonal rabbit antibody directed against human GS (0.3 μg/mL; Proteintech 
Group, Chicago, IL, USA) in antibody buffer (AbB1; 0.05% Tween-20/0.1% BSA in 50 mM 
PPB) for 1 h. The secondary antibody, 100 μL per well of biotinylated goat anti-rabbit 
antibody (Dako, Glostrup, Denmark; 1:3000 in AbB1), was incubated for 1 h followed by 
a subsequent incubation with 100 μL of streptavidin-HRP complex (Life Technologies, 
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Camarillo, CA, USA; 1:60,000 in AbB1) for 30 min. The colour reaction was developed using 
3,3-,5,5-tetramethylbenzidine (TMB) and hydrogen peroxide incubated for 10–30 min at 
RT, in the dark. The reaction was stopped using 0.5 M sulphuric acid and the plate was read 
at 450 nm using the Tecan Sunrise ELISA plate reader and Magellan program.
MBP sandwich ELISA
MBP analysis was performed using a homemade sandwich ELISA in which wells of an ELISA 
plate were coated O/N at 4 °C with a mixture of mouse monoclonal antibody directed 
against MBP (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA)  and monoclonal rat 
anti-MBP (1:500 Millipore, Billereca, CA, USA) diluted in coating buffer (0.1 M NaHCO3, pH 
9.5). All subsequent incubations were performed at RT. Washing was performed between 
each incubation step using five 300 μL washes of PBST and plates were blocked with 
1%BSA/PBS for 1 h. Purified human MBP (a gift from Dr Sindic, Leuven,  Belgium) in the 
range 0.1 to 6.25 μg/L (used as standards) or pre-treated, neutralised and untreated CSF 
samples (diluted 1:1 in AbB2; 1% BSA/0.05% Tween-20/sodium phosphate buffer (64.6 
mM Na2HPO4.2H2O; 21 mM NaH2PO4.H2O, pH 7.4) were added to wells and incubated for 
2 h at 25 °C. Polyclonal rabbit anti human-MBP (1:3000 in AbB2; Dako) was added with 
incubation for 1 h at 25 °C. After removing unbound antibody, HRP-conjugated goat anti-
rabbit antibody (1:5000 in AbB2; Jackson, Bar Harbour, ME, USA) was added. The colour 
reaction and data collection were performed as for the GS sELISA.
Sandwich ELISAs for GFAP, Aβ42 and tau
GFAP was quantified using a homemade sandwich ELISA (linear up to 250 μg/L; interassay 
variation coefficient <14%) as described previously (van Geel et al., 2002; Abdo et al., 2004). 
Aβ42, t-tau, and p-tau concentrations were determined using commercially available 
ELISA kits (INNOTEST®, Innogenetics N.V., Ghent, Belgium). All assays were performed 
according to manufacturer's instructions. However, for the measurement of t-tau we 
included additional standards with concentrations 1200 pg/mL and 2400 pg/mL.
GS Depletion experiments
Aliquots of AFBN-treated and neutralised CSF were incubated with monoclonal mouse 
antibody (IgG) directed against  GS (final concentration of 0.5 μg/mL) for 1 h at RT with 
gentle rolling. Samples were added to pre-washed Protein G agarose beads and incubated 
for a further 1 h with gentle rolling, to allow binding of the GS/anti-GS-IgG antibody 
complex. Finally, GS-depleted sample was obtained by centrifugation for 1 min at 5200 
rpm before its use in ELISA.
Analysis of decameric and monomeric forms of GS using transglutaminase cross-linking and 
western blot analysis
His-GS proteins were crosslinked using transglutaminase from guinea pig liver (TG) as 
follows: a mixture of 16 μL 2X cross-linking buffer (0.1 M Tris–HCl, 300 mM NaCl, 30 mM 
DTT and 40% glycerol, pH 7.5) was pre-incubated with 3.2 μL of 1 mg/mL TG (Sigma, St 
Louis, MO, USA) for 15 min at 37 °C to activate the enzyme (Boros et al., 2004). Aliquots 
containing 3.5 μg of His-GS protein were added to the cross-linking mixture together 
with 3.2 μL of 50 mM CaCl2, in a final volume of 32 μL, and incubated for a further 2 h 
at 37 °C. Immediately following cross-linking, 10 μL of 4X reducing sample buffer (25% 
(w/v) glycerol, 2% (w/v) SDS, 62.5 mM  Tris–HCl, pH 6.8, 32 mM DTT and 0.005% (w/v) 
bromophenol blue)were added to the mixture. Aliquots were heated to 95 °C for 5 min 
and loaded onto a 12% SDS-PAGE gel. The gel was electrophoresed in running buffer (25 
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mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) at 200 V for 1 h. Proteins were transferred 
to PVDF membranes for 1 h at 100 V in transfer  buffer (2.5 mM Tris, 19.2 mM glycine, 
20% methanol). The  membrane was blocked with blocking buffer (1:1 PBS: Odyssey 
blocking buffer (LiCor, Lincoln, Nebraska, USA)) followed by an O/N incubation at 4 °C 
with polyclonal rabbit anti-GS (1:1000)  in blocking buffer. After 5 washes with PBST, the 
membrane was then incubated for 1 h at RT with goat anti-rabbit Alexa 680 (1:5000; Life 
Technologies) in blocking buffer. Fluorescence was visualised using an Odyssey scanner at 
700 nm. The membrane was then re-incubated O/N at 4 °C with monoclonal mouse anti-
GS (1:1000) and, following washing, further incubated with goat anti-mouse IRDye® 800 
(1:5000; LiCor) in blocking buffer. The membrane was then rescanned at 800 nm.
Statistics
GraphPad PRISM 5 software (San Diego, California) was used for statistical analysis. 
Comparison of differences in CSF protein concentrations between untreated and treated 
(AFBN or neutralisation only) samples was performed using paired t-test analysis. The 
Spearman rank correlation was used for correlations.
Results
CSF pH analysis following AFBN or neutralisation alone
Prior to treatment, the pH of CSF samples varied from 7.7 to 9.2 (mean pH 8.5, standard 
deviation (SD) 0.4; Fig. 1A and  B). After applying the GS neutralisation protocol (Fig. 1A) 
the mean pH was 7.3 (SD 0.15; n=10) and, after AFBN, the final pH was 7.3 (SD 0.11; n=40). 
The neutralisation protocol for all other proteins (Fig. 1B) resulted in a mean pH of 7.2 (SD 
0.06; n=40), whereas AFBN treatment resulted in a mean pH of 7.3 (SD 0.21; n=40).
Detection of GS in CSF requires AFBN pre-treatment
GS was rarely detectable in either untreated or neutralised CSF samples but could be 
detected in 73% of AFBN treated CSF samples, with a mean concentration of 0.21 μg/mL 
(SD 0.06) (Fig. 2). A typical standard curve for GS can be seen in Fig. 3. The assay is linear 
between 0.06 and 1 μg/mL (r2=0.9975). The lower detection limit of the assay was 0.019 
μg/mL.
Figure 1. Final pH values for untreated, neutralised and AFBN-treated CSF samples. Figure A shows 
the pH Values obtained following neutralisation and AFBN treatment following the GS protocol. 
Figure B illustrates the values obtained following the neutralisation and AFBM treatments used for 
all other proteins. Boxes represent median values with upper and lower quartiles. Whiskers represent 
minimal and maximal values.
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To determine the specificity of the assay, GS was depleted from CSF. This resulted in a 
reduction of GS concentration of up to 80% in AFBN-treated samples, suggesting that the 
ELISA was indeed specific for the detection of GS in CSF.
Analysis of decameric and monomeric forms of GS using TG cross-linking and western blot 
analysis
The increased detection of GS after AFBN treatment may be caused by release of individual 
GS units from the decameric protein complex. In order to ensure that decameric GS 
would remain in this form under the reducing conditions of SDS-PAGE gel, we cross-
linked the protein with TG, to stabilise the decameric form of GS without affecting the 
monomeric form of GS. Our results showed that the His-GS purified in the absence of 
Mn/ATP was predominantly present as monomers and this was relatively unchanged 
following the cross-linking procedure (Fig. 4). In stark contrast, the His-GS purified in the 
presence of Mn/ATP and cross-linked thereafter remained predominantly in the stacking 
gel even under reducing conditions. This suggests that it is predominantly present in a 
high molecular weight (decameric) form in contrast to the non-cross-linked form which 
was predominantly present as monomers. In line with this finding, and as seen with CSF 
samples, the (decameric) His-GS purified in the presence of Mn/ATP was not detectable in 
the sELISA unless first treated using the AFBN protocol (data not shown).
AFBN treatment improves MBP, but not GFAP, detection in CSF
Detection levels for MBP were significantly improved by the AFBN protocol with an 
average 50% increase in signal (p<0.005) (Fig. 5). Neutralisation alone did not confer an 
effect on MBP quantification, indicating that the acidification step of the AFBN protocol 
is necessary for the signal increase.  CSF levels of GFAP were significantly lowered by an 
average 32% by the buffer neutralisation of CSF prior to analysis (p<0.05) and the AFBN 
protocol conferred no significant change in the levels of GFAP detected in CSF (Fig. 6).
Quantification of Aβ42, t-tau and p-tau is significantly reduced by pre-treatment of CSF
There was a small but consistent and significant reduction in measured levels of Aβ42, 
t-tau and p-tau following both neutralisation alone and AFBN (pb0.05 in all cases; Fig. 7). 
In the case of Aβ42, neutralisation alone caused a greater reduction  (~25%) than that for 
AFBN (~11%) (Fig. 7A). Levels of t-tau (Fig. 7B) were reduced both by neutralisation alone 
(~9%) and  by AFBN (~14%). Finally, levels of p-tau   Fig. 7C) were equally reduced by either 
neutralisation alone (~11%) or AFBN (~10%).
Fig. 2. GS levels of untreated and AFBN 
pre-treated CSF samples. GS levels 
were measured by sELISA in CSF (n=7).
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Fig. 3. Standard curve for GS in the range 0.06 μg/mL to 1 μg/mL.His-GS: Histagged recombinant 
human glutamine synthetase; OD450: optical density at 450 nm.
Fig. 4. Transglutaminase (TG) cross-linking of His-GS 
purified in the presence or absence of Mn/ATP. Pre- 
and post-TG cross-linked His-GS (with or without 
Mn/ATP; 3.5 μg) were separated by SDS-PAGE and 
immunoblotted with an antibody directed against 
GS. Prior to cross-linking, both the His-GS withoutMn/
ATP (lane 1) and the His-GS with Mn/ATP (lane 3) 
were predominantly present in a monomeric form. 
Following cross-linking, the His-GS withoutMn/ATP 
(lane 2) retained its predominantly monomeric form 
whereas the His-GSwith Mn/ATP (lane 4) can be seen 
in a predominantly decameric form.
Fig. 5. Effect of neutralisation (CSF(N)) 
and AFBN treatment (CSF(A)) on the 
measurement of MBP in CSF (n=18). 
Results for untreated CSF are shown 
as “CSF”. Bars indicate standard error 
of themean. ns=non-significant, 
**=p<0.01.
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Discussion
Numerous extrinsic and intrinsic factors can confound the  identification and measurement 
of proteins in biological fluids prohibiting standardisation of analyses and explaining 
the observed discrepancies in inter- and intra-laboratory measurements of CSF proteins 
(Hühmer et al., 2006; Bjerke et al., 2010).  Variation in CSF pH and epitope masking may 
be such confounders and were investigated in our study. Our main findings are: 1) An 
AFBN pre-treatment of CSF can be used to improve the detection of some brain-specific 
proteins such as MBP and GS, likely by improving antigen–antibody interactions and 
2) Neutralisation alone of CSF prior to analysis by sELISA could not be shown to confer 
improved protein detection but rather leads to impaired detection of most proteins (i.e. 
GFAP, Aβ42, t-tau and p-tau).
Antibody-based detection of proteins in CSF is influenced by the accessibility of antibody-
specific epitopes of the target protein and by the conformation of the epitope for antibody 
binding. Thus the improvement we observed in GS and MBPdetection after AFBN is most 
likely due to unmasking of hidden epitopes or alterations in epitope conformation that 
facilitate improved antigen–antibody interactions and binding. Factors that can contribute 
to epitope-masking include the association of proteins with other binding proteins (e.g. 
lipids, carrier proteins, auto-antibodies), self-aggregation of the target protein (e.g. in the 
case of aggregating proteins like Aβ and tau) (Groome et al., 1986; Okragly and Haak-
Frendscho, 1997),  or the secretion/release of proteins from a latent proform (Douglas et 
al., 2009). Various techniques have been utilised to  facilitate the unmasking of epitopes 
including detergent or heat denaturation (Lechtzier et al., 2002; Bibl et al., 2004; Bjerke et 
al., 2010) and pre-treatment of samples with acid  (Groome et al., 1986; Okragly and Haak-
Frendscho, 1997).
It has previously been demonstrated that the detection of MBP auto-antibodies in CSF can 
be improved by pre-treatment with AFBN (Groome et al., 1986; Mastroianni et al., 1991). 
Thus, the improved detection of MBP in the AFBN-treated CSF tested  in our sandwich ELISA 
likely arises from the release of MBP autoantibodies from antigen-antibody complexes. 
This would  release the MBP epitopes to facilitate binding of the capture and detection 
antibodies used in the sandwich ELISA format. Alternatively, the binding of lipids or other 
proteins to MBP may lead to epitope masking, as has been previously suggested  (Macklin 
et al., 1981), and the acidification of CSF may release these lipids binding to MBP protein 
thus exposing otherwise hidden epitopes. Further investigation is required to determine 
whether the improved detection of MBP in CSF can also improve its utility as a biomarker 
for MS.
A recent study demonstrated that the detection of GS by indirect ELISA format (iELISA) 
was improved by denaturation of the protein most likely due to a conformational change 
in the protein that enhanced the binding of the protein to the ELISA plate (Hnasko et al., 
2011). Since in our study AFBN treatment was essential for enabling detection of GS in CSF 
samples, we performed additional experiments with cross-linking and western blotting to 
further explore the possible mechanisms of action. It is known that GS may occur both in a 
monomeric and decameric form and that the latter is stabilised by the presence of Mn and 
ATP (Krajewski et al., 2008). We demonstrate that different conformations of recombinant 
His-tagged GS are possible and our findings suggest that the improved detection of GS in 
CSF by sandwich ELISA following AFBN treatment may arise from a conformation change 
in the protein. In this case, a  likely conformational change from a (decameric) native form 
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of  the protein to a smaller, monomeric form of the protein improved the detection of the 
protein in our sandwich ELISA.
GS concentrated in the absence of Mn and ATP appeared predominantly in a monomeric 
form whereas the GS concentrated  in the presence of Mn and ATP was predominantly 
present in a multimeric form which more closely reflects the expected physiological form 
of the protein. Furthermore, the monomeric form (obtainedwithout AFBN treatment) 
was used to produce a standard with good linear fit for the sELISA. Thus AFBN treatment 
most likely reduces the native (decameric) GS in CSF to a monomeric form that could 
then be detected by the  sELISA. Previously developed sELISAs which use a single 
monoclonal antibody for both capture and detection of GS in CSF are capable only of 
measuring decamers of the protein (Tumani et al., 1995; Tumani et al., 1999). While these 
sELISAs identified an increase in GS in AD patients compared with controls, they could 
not distinguish AD patients from patients with other neurodegenerative diseases such 
as vascular dementia and amyotrophic lateral sclerosis (Tumani et al., 1995; Tumani et al., 
1999). It may therefore be interesting for future studies to combine these indicated assays 
with our newly developed sELISA, which is capable of measuring total GS content in CSF 
using the AFBN protocol, to determine the ratio of decameric versus total GS protein for 
potential additional discriminatory value.
Although the AFBN protocol improved the detection of MBP and GS, no significant 
improvement was detected for the measurement of GFAP. This was unexpected as GFAP 
is often present in multimeric forms (Shaw and Hawkins, 1992) and may be expected 
to show improved detection upon AFBN treatment as observed for GS. However, the 
failure of the AFBN treatment to improve the detection of GFAP may indicate that a 
conformational change in the epitope resulting from AFBN treatment may have occurred 
that was detrimental to binding of the antibodies used in our sELISA or that the antibodies 
bind more optimally to the native form of the protein in the untreated CSF. Alternatively, 
the acidification of GFAP may not be irreversible and the multimers may reform rapidly 
enough to prevent antibody binding and thus prevent improved detection, or acidification 
is insufficient to reduce the GFAP to monomers.
AFBN slightly diminished the measurement of Aβ42, t-tau and p-tau in CSF whereas 
others have shown that the measurement of Aβ42 can be enhanced by the pretreatment 
of CSF samples with detergent or heat, presumably by dissociation of Aβ oligomers to 
liberate hidden or masked epitopes (Bibl et al., 2004; Bjerke et al., 2010). We anticipated 
that the AFBN may improve the detection of Aβ42 either due to release of oligomeric 
or aggregated forms into smaller forms of the protein or by the release of amyloid β 
autoantibodies (Li et al., 2007). However, this was not observed in our experiments.  The 
AFBN treatment seems to be insufficient to resolve oligomeric or fibrillar forms of Aβ into 
smaller oligomeric or monomeric forms, or may even have stimulated its aggregation. It is 
also possible that, after initial resolution of Aβ aggregates,  the subsequent neutralisation 
of CSF may have permitted the re-aggregation of Aβ42. Although acid treatment of CSF 
has been shown to improve the detection of autoantibodies to amyloid β (Li et al., 2007), 
any release of autoantibodies that may have occurred during our AFBN protocol did 
not lead to improved detection of Aβ42. Finally, it is also possible that the oligomeric or 
fibrillar fraction of total Aβ42 is simply too small to confer improved detection following 
AFBN treatment, or that this is already achieved by the buffers supplied with the kits.
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When left at room temperature, the pH of CSF quickly rises after withdrawal as a function 
of time until a peak is reached and it is also affected by freeze/thaw cycles (Bjerke et 
al., 2010). Furthermore, the efficiency of an antibody to bind to solid phases, such as 
a microtitre plate, is influenced by the pH of the coating buffer independent of buffer 
concentration or formulation (Goldblatt et al., 1993). It is suggested that the optimal pH 
for antibody and antigen binding lies somewhere between the isoelectric point (pI) of 
the antibody and the antigen (Boenisch, 2006). Hence, the pH of the environment may 
worsen antigen binding if the pH of the buffer system varies too dramatically from the 
pI of the antibody. Thus, the efficiency of antibody–antigen binding in ELISAs might be 
diminished by a high CSF pH. Hence, it could be expected that antigen–antibody binding 
will be enhanced by neutralisation of the antigen prior to addition to the microtitre plate. 
Contrary to expectations, this was not observed in any of the homemade or kit ELISAs that 
we tested.
It can be assumed that the reagents supplied with the kits for Aβ42, t-tau and p-tau have 
been pre-optimised. Indeed we did not see any improvement in the detection of these 
proteins with the addition of either a pre-neutralisation step or the  AFBN protocol. Rather, 
we observed a slight worsening of protein detection in some cases.
Conclusion
In summary, neutralisation alone of CSF prior to protein measurement was not effective 
in improving the detection of any of the proteins tested. However, we have demonstrated 
the utility of an AFBN pre-treatment of CSF for the optimised detection of both MBP 
and GS suggesting that the denaturing (acidification) step is required to enhance the 
detection of these proteins by altering protein and/or epitope conformation. Further 
investigation is required to determine whether the improved detection of these proteins 
will also enhance their sensitivity and specificity in detecting specific neurodegenerative 
diseases as suggested for the detection of GDNF (Okragly and Haak-Frendscho, 1997) 
and cyclic guanosine 5'- monophosphate (cGMP) which have been investigated for use 
as biomarkers in the diagnosis of amyotrophic lateral sclerosis (ALS) (Grundström et al., 
2000; Iłżecka, 2004).
Although we showed that AFBN pre-treatment may not be useful for enhancing the 
detection of all CSF proteins, it may be a useful protocol to evaluate the possibility of 
epitope-masking in new biomarker development where similar types of confounders may 
be expected.
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“Oh, I'm not particular as to size," Alice hastily replied: "only one doesn't 
like changing so often, you know." 
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Abstract
Objective: Neuromyelitis optica (NMO) is often misdiagnosed as multiple sclerosis (MS) due 
to similarities in the initial neurologic presentation. Some treatments used for MS patients 
may exacerbate NMO and thus biomarkers to clearly distinguish between NMO and MS 
are important. NMO patients with a negative result on screening for aquaporin-4 (AQP4) 
antibodies are difficult to define clinically. Since NMO pathology is primarily astrocyte-
mediated, astrocyte secretory proteins may serve as useful biomarkers for NMO. The aim 
of this study was to determine whether secretion of the astrocytic enzyme glutamine 
synthetase (GS) is altered in NMO patients (both seropositive and seronegative) compared 
with controls, MS patients and patients with optic neuritis (ON) in the absence of MS or 
NMO.
Methods: Using a novel enzyme-linked immunoassay, we measured levels of GS in the 
cerebrospinal fluid (CSF) of 68 patients with MS, 44 with NMO, 6 with ON, and 37 controls.
Results: Levels of GS were significantly increased in the CSF of NMO and MS patients 
compared with controls and ON patients.
Conclusions: Levels of GS are significantly increased in NMO and MS but do not distinguish 
NMO from MS regardless of AQP4 serological status.
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Introduction
Inflammatory, demyelinating disorders of the central nervous system such as neuromyelitis 
optica (NMO) and, in particular, multiple sclerosis (MS) are the major causes of non-
traumatic disability in young adults 1. In early stages of disease, NMO is often misdiagnosed 
as MS as a result of similar initial neurologic presentation  2. However, misdiagnosis has 
significant implications for management of patients since some MS treatments (such as 
interferon beta) are contraindicated in NMO 3.
Both MS and NMO are believed to involve an immunologic component but the exact 
underlying mechanisms causing MS and NMO are not understood. The circulating IgG 
antibody (NMO-IgG) against aquaporin 4 (AQP4) in the serum and cerebrospinal fluid 
(CSF) of NMO patients has been identified as a useful biomarker for differentiating NMO 
from optic neuritis (ON) and MS. This antibody is rarely present in ON (without a diagnosis 
of MS or NMO) and is absent in MS patients and controls 4, 5. Although the presence of 
the antibody in most NMO patients indicates that NMO is distinct from MS 6, 10-25% 
of patients diagnosed with NMO are seronegative for this antibody even with the most 
sensitive assays 2, 7. Therefore identifying additional biomarkers to distinguish NMO, 
especially seronegative NMO, from MS would be of significant benefit 8, 9. Since anti-AQP4 
antibodies are directed against receptors in the astrocytic endfeet, this suggests that NMO 
pathology is primarily astrocyte-mediated. Thus other astrocyte-specific biomarkers may 
be useful in the detection of NMO, even in the absence of AQP4-Abs.
Recent evidence suggests that glutamate excitotoxicity has a role in the pathophysiology 
of both MS and NMO 10. Glutamine synthetase (GS), a primarily astrocytic enzyme, has an 
important role in glutamate regulation by catalysing the conversion of glutamate and 
ammonia to non-toxic glutamine 11, 12. In NMO, evidence suggests that astrocytes are 
the primary target of disease and that demyelination is secondary to oligodendrocyte 
death arising from loss of trophic support from astrocytes 13-15. Thus, we hypothesised that 
destruction of astrocytes may cause release of GS into the extracellular space subsequently 
leading to increased concentrations of GS in the CSF of NMO patients. The aim of this 
study was to examine the potential for CSF GS levels to distinguish NMO patients from 
patients with MS, ON (in the absence of MS or NMO), and controls.
Methods
Patients
This retrospective study included 44 NMO and 68 MS patients from 5 centres in Nijmegen 
(the Netherlands), Lyon (France), San Paolo (Brazil), Barcelona (Spain) and Ulm (Germany). 
From our databases in Nijmegen we retrieved data from the medical files of 281 patients 
who attended the MS Centre Nijmegen and who had undergone lumbar puncture (LP) as 
part of the diagnostic procedure between 1 January 2005 and 11 June 2008. Diagnosis at 
the time of LP was assessed according to previously described criteria 16. MS Patients for 
whom CSF was available were selected from our CSF database in Nijmegen for inclusion 
in the study (n=60). Among these patients we studied 37 patients with remitting relapsing 
MS (RR-MS), 15 with secondary progressive MS (SP-MS), and 8 patients with primary 
progressive MS (PP-MS). We also included CSF from an additional 8 MS patients from 
Brazil, for whom diagnosis was established using the same criteria as described above, 
and 6 ON patients from Nijmegen (n=4) and Sao Paolo (n=2) with inclusion diagnosis as 
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previously described 17.
Our NMO spectrum disorder (NMOSD) group consisted of 29 seropositive and 15 
seronegative patients. The inclusion criteria for NMO (which includes NMOSD for the 
purposes of this paper) were as published by Wingerchuk et al (2007) 2. The age-matched 
non-neurological controls (n=37) were selected from a separate database of patients 
referred to our Neurology Department (Radboud UMC) during the period 2001 to 2009, 
who underwent LP as part of the diagnostic process, and who were confirmed as having 
no neurological disease. For these patients routine CSF parameters such as cell count, 
protein and glucose, were assessed as normal.
Standard protocol approvals, registrations, and patient consents
CSF samples were collected according to standard protocols with local ethics approval. 
At the time of collection all patients from the Radboud UMC gave informed consent to 
lumbar punctures, including later use for scientific purposes but written consent from the 
patients was legally not required for our analyses. Informed written consent for lumbar 
puncture was obtained from all patients from the other participating centres.
CSF samples
CSF samples were collected in polystyrene or polypropylene tubes, centrifuged (5 minutes, 
860 g at room temperature), and stored at -80 °C. For storage purposes, 20 MS samples 
had been moved to storage at -20°C, but not more than 6 months prior to analysis. Patient 
information was decoded to maintain confidentiality. Aliquots of CSF from 7 French NMO 
patients were received from London on ice but thawed. Although this may have affected 
the results, we have previously observed that CSF levels of GS are unchanged following at 
least 3 freeze-thaw cycles (unpublished data).
GS ELISA
GS levels in CSF were measured using our previously published home-made sandwich 
ELISA incorporating an acidification and neutralisation step for enhanced detection 18. 
However, for the current study we used a smaller sample volume (75μl) for standards, 
blanks, controls, and patient samples.
NMO-IgG antibody assay
The serostatus for NMO-IgG was determined using recently described methods 6, 19, 20. 
NMO serostatus was confirmed in the French patients by a more recent cell-based assay 
for AQP4-IgG 21 and for the Brazilian cohort by a second cell-based assay method 22.
Statistical analysis
Levels of GS showed a non-Gaussian distribution for controls and were log-transformed. 
Between-groups analysis was performed on transformed data using ANOVA and, when 
controlling for potential confounding factors (age and gender), ANCOVA. Data were 
analysed using GraphPad Prism, version 5 and SPSS Statistical software, Version 20.
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Results
Patient demographics and GS levels are provided in Table 1. Age (p=0.49) and gender 
(p=0.09) did not differ significantly across the disease groups although the difference in 
age between the MS and control groups approached significance (p=0.06; Table 1). GS 
levels were not influenced by storage conditions (-20⁰C versus -80⁰C; data not shown). GS 
levels were associated with age only in the MS group (p=0.02), and tended to be correlated 
with gender in the control group (p=0.06).
Using ANOVA, we found significantly higher levels of CSF GS for both NMO (p <0.001) 
and MS (p <0.001) compared with controls (Figure 1) and this was maintained after 
controlling for age and gender using ANCOVA (p <0.001 for both groups, Table 1). GS did 
not differ significantly between MS and NMO using ANOVA (p =0.17) but, after controlling 
for age and gender effects using ANCOVA, we found a small, significant increase in 
NMO compared with MS (p <0.05). When we further separated the NMO patients into 
seronegative and seropositive, we found that this effect was true for MS compared with 
the NMO seropositive patients (p <0.05) but not compared to the seronegative patients 
(p =0.36). Differences between NMO seropositive and seronegative patients also did not 
reach significance (p =0.36). CSF GS levels in the ON patients did not differ significantly 
from controls (p =0.80). Compared with ON, NMO tended to have higher CSF GS levels (p 
=0.05) and this effect became significant after controlling for age and gender (p <0.01). In 
this case the effect was observed for both NMO seropositive (p <0.01) and seronegative 
patients (p  <0.05). Levels of total protein in CSF were slightly elevated in the NMO group 
compared with all other groups (Table 1) but this difference was not significant even after 
controlling for age and gender.
Table 1. Patient demographics and CSF parameters.
Controls MS NMO ON p value
No. of patients
Age; yrs (s.d.)
Gender; M/F (%male)
GS (μg/L); mean (s.d.)
Total Protein (μg/mL); 
mean (s.d.)
37
43.2 (11.1)
18/19 (49%)
243 (143)
0.50 (0.16)
68
42.4 (10.7)
17/51 (25%)
411 (255)***
0.47 (0.21)
43
45.1 (17.4)
12/31 (28%)
500 (250)***
0.64 (0.69)
6
37.4 (10.6)
2/4 (33%)
242 (109)
0.37 (0.17)
nsa
nsa
<0.001b
nsb
a p-value calculated using ANOVA; ***p<0.001 compared with controls; b calculated using ANCOVA controlling for 
age and gender. GS: Glutamine synthetase; MS: multiple sclerosis; NMO: neuromyelitis optica; ON: optic neuritis; 
s.d.: standard deviation; ns: not significant
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Discussion
In this study we compared levels of GS in the CSF of MS, NMO, ON and control 
patients. Degradation of astrocytes is a key pathophysiological feature of NMO and we 
hypothesised that GS released from damaged astrocytes may be reflected as elevated GS 
in the CSF of NMO patients compared with controls and MS patients. Indeed we observed 
increased levels of GS in NMO compared with controls with the greatest differences seen 
for seropositive patients. This could indicate that GS is released into the CSF as a result 
of astrocyte damage, particularly in the seropositive NMO patients and could suggest a 
relationship between GS and the presence of NMO-IgG antibody.
However, the increase in GS levels we observed in NMO is far less striking than expected 
given the more pronounced increases observed for other astrocytic markers such 
as glial fibrillary acidic protein (GFAP) and S100b 9, 15, 23-25. Although CSF GS levels were 
more prominent in NMO seropositive than NMO seronegative patients compared with 
the MS patients, we did not find significant differences between the seronegative and 
seropositive NMO patients. Moreover, levels of CSF GS were also significantly higher in 
the MS patients than controls and these increases in GS levels and could not be used to 
distinguish between MS and NMO patients.
The observed elevation in GS levels in the CSF of MS patients was intriguing and it is uncertain 
why GS should be increased in these patients. In the brain, GS is a primarily astrocytic 
enzyme but there are several studies showing expression of GS in oligodendrocytes 10, 13, 
26, 27. Oligodendrocytes are severely damaged in MS and GS immunoreactivity is reduced 
in both active and silent MS brain lesions compared with unaffected and control tissues 26. 
Hence release of GS due to oligodendrocyte damage could potentially account for some 
of the increase in CSF GS levels observed in our MS group. Hypomyelination in brain white 
matter is associated with a reduction in GS activity caused by metal toxicity as was shown in 
a recent animal study 28. Thus loss of GS activity could further exacerbate oligodendrocyte 
damage leading to demyelination or reduced remyelination 29. This notion is supported 
by studies showing that GS is highly susceptible to oxidative modification and may play 
a role in glutamate excitotoxicity in MS 26, 30, 31. Additionally, GS has been recently shown 
to be important for regulating Schwann cell differentiation and promoting remyelination 
following injury 32 and it has also been speculated from animal models that GS activity in 
oligodendrocytes may play a role in myelin regulation 33.
Figure 1. GS levels in CSF of controls, 
MS, NMO and ON. Higher levels of 
GS were observed in NMO and MS 
patients compared with controls and 
ON.
*** p<0.001 compared with controls; 
§ seropositive (closed triangles) 
and seronegative (open triangles) 
NMO subgroups. GS: glutamine 
synthetase; MS: multiple sclerosis; 
NMO: neuromyelitis optica; ON: optic 
neuritis.
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The increased levels of GS in the CSF of MS and NMO patients could also potentially be 
explained by leakage of GS from blood into the CSF since GS is also highly expressed 
in kidney, liver, skeletal muscle, spleen, and heart. Although, it has been estimated that 
less than 2% of GS in the CSF arises from non-intrathecal origin 34, leakage of GS from 
blood into CSF in patients with a compromised blood-CSF barrier, is highly likely. Both 
MS and NMO have been associated with compromised blood-CSF barrier dysfunction, 
particularly in NMO patients, where CSF total protein levels are frequently elevated. This 
may potentially have contributed to the higher levels of GS seen in the NMO patients 
compared with the MS patients 35-37. Although CSF total protein was higher in the NMO 
group (particularly the NMO- seropositive patients) than all other groups (Table 1), the 
values were highly variable and no significant between-group differences in CSF total 
protein levels were observed to support this hypothesis.
A major strength of our study is the inclusion of a large well-defined group of NMO patients 
from a number of different institutions. However, we acknowledge that the retrospective 
nature of our study may somewhat limit our ability to generalise our findings to other 
patient populations, particularly since the time of lumbar puncture with respect to clinical 
symptoms was not known for most patients. This may have implications for our findings 
given that others have shown that levels of other CSF proteins can differ between relapse 
and remission 23, 24. Finally, previous studies have shown that NMO-IgG is absent in MS 
patients and controls and rarely present in ON 4, 5 but NMO-IgG analysis was neither 
analysed in the majority of our MS and ON patients nor in controls. Therefore, we cannot 
entirely exclude that anti-AQP4-positive, non-NMO patients may have been included in 
these groups, thereby influencing the interpretation of our results.
In summary, we showed that CSF GS concentrations are increased in MS and NMO 
compared with controls. However, a larger prospective study with the inclusion of a 
broader range of diseases with large patient numbers will be required to determine the 
extent to which GS is altered in demyelinating diseases.
Chapter 8
136
References
1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple Sclerosis. New England Journal of 
Medicine 2000;343:938-952.
2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. 
The Lancet Neurology 2007;6:805-815.
3. Kim S-H, Kim W, Li XF, Jung I-J, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica 
spectrum disorder? Multiple Sclerosis Journal 2012;18:1480-1483.
4. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in 
patients with optic neuritis. Journal of the Neurological Sciences 2010;298:158-162.
5. Kim S-M, Waters P, Woodhall M, et al. Utility of aquaporin-4 antibody assay in patients with neuromyelitis 
optica spectrum disorders. Multiple Sclerosis Journal 2013.
6. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction 
from multiple sclerosis. The Lancet 2004;364:2106-2112.
7. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG 
assays. Neurology 2012;78:665-671.
8. Storoni M, Verbeek MM, Illes Z, et al. Serum GFAP levels in optic neuropathies. Journal of the Neurological 
Sciences 2012;317:117-122.
9. Petzold A, Marignier R, Verbeek MM, Confavreux C. Glial but not axonal protein biomarkers as a new supportive 
diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological 
diseases. Journal of Neurology, Neurosurgery & Psychiatry 2011;82:467-469.
10. Matute C, Alberdi E, Domercq Ma, Pérez-Cerdá F, Pérez-Samart1 n A, Sánchez-Gómez MaV. The link between 
excitotoxic oligodendroglial death and demyelinating diseases. Trends in neurosciences 2001;24:224-230.
11. Tumani H, Shen GQ, Peter JB. Purification and immunocharacterization of human brain glutamine synthetase 
and its detection in cerebrospinal fluid and serum by a sandwich enzyme immunoassay. Journal of Immunological 
Methods 1995;188:155-163.
12. Meister A. Glutamine Synthetase of Mammals. In: Paul DB, ed. The Enzymes: Academic Press, 1974: 699-754.
13. Marignier R, Nicolle A, Watrin C, et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin 
G via astrocyte injury. Brain 2010;133:2578-2591.
14. Bukhari W, Barnett MH, Prain K, Broadley SA. Molecular Pathogenesis of Neuromyelitis Optica. International 
Journal of Molecular Sciences 2012;13:12970-12993.
15. Fujihara K, Misu T, Nakashima I, et al. Neuromyelitis optica should be classified as an astrocytopathic disease 
rather than a demyelinating disease. Clinical and Experimental Neuroimmunology 2012;3:58-73.
16. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 
“McDonald Criteria”. Annals of Neurology 2005;58:840-846.
17. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, Plant GT. Neuromyelitis optica-IgG (aquaporin-4) 
autoantibodies in immune mediated optic neuritis. Journal of Neurology, Neurosurgery & Psychiatry 2010;81:109-
111.
18. Herbert MK, Kuiperij HB, Verbeek MM. Optimisation of the quantification of glutamine synthetase and 
myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol. Journal of 
Immunological Methods 2012;381:1-8.
19. Marignier R, De Sèze J, Vukusic S, et al. NMO-IgG and Devic's neuromyelitis optica: a French experience. 
Multiple Sclerosis 2008;14:440-445.
20. Takahashi T, Fujihara K, Nakashima I, et al. Establishment of a New Sensitive Assay for Anti-Human Aquaporin-4 
Antibody in Neuromyelitis Optica. The Tohoku Journal of Experimental Medicine 2006;210:307-313.
21. Marignier R, Bernard-Valnet R, Giraudon P, et al. Aquaporin-4 antibody–negative neuromyelitis optica: 
Distinct assay sensitivity–dependent entity. Neurology 2013;80:2194-2200.
22. Sato DK, Nakashima I, Takahashi T, et al. Aquaporin-4 antibody–positive cases beyond current diagnostic 
criteria for NMO spectrum disorders. Neurology 2013;80:2210-2216.
23. Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar 
acidic protein in neuromyelitis optica: an astrocytic damage marker. Journal of Neurology, Neurosurgery & 
Psychiatry 2009;80:575-577.
Glutamine synthetase levels in neuromyeltitis optica and multiple sclerosis
137
24. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than 
demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75:208-216.
25. Uzawa A, Mori M, Sawai S, et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are 
increased during initial neuromyelitis optica attacks. Clinica Chimica Acta 2013;421:181-183.
26. Werner P, Pitt D, Raine CS. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with 
oligodendrocyte and axonal damage. Annals of Neurology 2001;50:169-180.
27. D'Amelio F, Eng LF, Gibbs MA. Glutamine synthetase immunoreactivity is present in oligodendroglia of 
various regions of the central nervous system. Glia 1990;3:335-341.
28. Rai NK, Ashok A, Rai A, et al. Exposure to As, Cd and Pb-mixture impairs myelin and axon development in rat 
brain, optic nerve and retina. Toxicology and Applied Pharmacology In Press.
29. Dutta R, Chang A, Doud MK, et al. Demyelination causes synaptic alterations in hippocampi from multiple 
sclerosis patients. Annals of Neurology 2011;69:445-454.
30. Castegna A, Palmieri L, Spera I, et al. Oxidative stress and reduced glutamine synthetase activity in the 
absence of inflammation in the cortex of mice with experimental allergic encephalomyelitis. Neuroscience 
2011;185:97-105.
31. Cambron M, D'Haeseleer M, Laureys G, Clinckers R, Debruyne J, De Keyser J. White-matter astrocytes, axonal 
energy metabolism, and axonal degeneration in multiple sclerosis. J Cereb Blood Flow Metab 2012;32:413-424.
32. Saitoh F, Araki T. Proteasomal Degradation of Glutamine Synthetase Regulates Schwann Cell Differentiation. 
The Journal of Neuroscience 2010;30:1204-1212.
33. Baas D, Fressinaud C, Vitkovic L, Sarlieve LL. Glutamine synthetase expression and activity are regulated 
by 3,5,3-TRIODO-l-THYRONINE and hydrocortisone in rat oligodendrocyte cultures. International Journal of 
Developmental Neuroscience 1998;16:333-340.
34. Tumani H SGPJBBW. Glutamine synthetase in cerebrospinal fluid, serum, and brain: A diagnostic marker for 
alzheimer disease? Archives of Neurology 1999;56:1241-1246.
35. Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic’s 
Neuromyelitis Optica. J Neurol 2004;251:47-52.
36. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis 
optica: Results from 211 lumbar punctures. Journal of the Neurological Sciences 2011;306:82-90.
37. Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis. Neurology 
2004;63:1966-1967.
138
139
Part 5 
Concluding Remarks
Alice thought to herself "I don't see how he can ever finish, if he doesn't 
begin.”
140
141
“No, no! The adventures first, explanations take such a dreadful 
time.”
Chapter 9
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Chapter 9
142
General discussion and future perspectives
143
General discussion and future perspectives
Neurodegenerative diseases are chronic and frequently debilitating disorders of the 
nervous system that usually have an insidious onset. A major challenge in diagnosing 
neurodegenerative diseases arises from symptom profiles that exhibit not only high 
variability among patients with the same disease, but which frequently mimic other 
neurodegenerative disorders with similar symptoms. Another major problem in the 
diagnostic process is the early identification of disease. There is increasing evidence 
that the pathological processes underlying neurodegenerative diseases may begin to 
develop many years prior to the onset of overt symptoms 1-3. This so-called ‘pre-clinical 
stage’ of disease, in which there is an absence of clinical signs and symptoms, can occur 
in the face of extensive underlying pathological damage 4.  Therefore, for many patients, 
disease diagnosis remains uncertain for extended time periods (up to years). Definitive 
confirmation of the diagnosis is often only possible during post mortem examination of 
the brain to reveal the distinguishing hallmark pathological features characteristic of an 
individual neurodegenerative disease. Since it is not possible to easily obtain brain biopsy 
samples during the life of the patient for confirmation of disease, biomarkers from other 
appropriate sources are needed. In this thesis we focused on the assessment of potential 
cerebrospinal fluid (CSF) biomarkers for their use in the differential diagnosis of selected 
neurodegenerative diseases. 
Biomarkers of disease
Biomarkers have been defined as “…cellular, biochemical or molecular alterations that 
are measurable in biological media such as human tissues, cells or fluids” (Hulka et al., 
1990, cited in 5). They can involve direct measurement of certain components of body 
fluid (e.g. blood, urine, CSF) or indirect measurements such as brain imaging (e.g. MRI, 
computed tomography scan), which estimate changes in composition or function of the 
relevant components. Based on the close anatomical relationship between the brain and 
CSF it has been postulated that the composition of the CSF might reflect early ongoing 
disease processes occurring in the brain 6-8. Thus, we hypothesised that some well-
chosen CSF constituents might represent diagnostic biomarkers for neurodegenerative 
diseases and their differential diagnosis. Although CSF collection requires a procedure 
that involves minor risks it has the advantage over blood or urine of being less susceptible 
to contamination arising from systemic infections and biological degradation in the liver 
or kidney 5, 9, 10. Therefore, CSF represents an important medium for the identification 
and development of biomarkers of neurodegenerative disease. 
CSF biomarkers for differential diagnosis
Dementia disorders
In recent years there have been great advances in the development and evaluation of 
CSF biomarkers for the diagnosis of Alzheimer’s dementia. The three most rigorously 
investigated biomarkers for Alzheimer’s disease - amyloid beta (Aβ1-42), tau and 
phosphorylated tau proteins – are increasingly being considered for diagnostic purposes 
in clinical practice 11-14. While none of these biomarkers show sufficiently high utility as 
a stand-alone biomarker for Alzheimer’s disease, combinations of these biomarkers have 
been shown to have high sensitivity and specificity for separating Alzheimer’s disease 
from non-demented patients and healthy controls, providing up to 92% sensitivity for the 
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detection of Alzheimer’s disease and up to 89% specificity for Alzheimer’s disease 14, 15. 
Despite the utility of these biomarkers in detecting and predicting Alzheimer’s disease 
based on the underlying neural basis of the disease, they have poorer clinical utility for 
discriminating Alzheimer’s disease from other forms of dementia 8, 16-18. The primary 
differential diagnoses for Alzheimer’s disease include dementia with Lewy bodies, vascular 
dementia and frontotemporal dementia 19. Difficulty distinguishing between these 
dementia forms has significant clinical implications because the medications used in the 
treatment of one dementia disorder can be contraindicated in another dementia disorder. 
For example, neuroleptics used for the treatment of behavioural disorders in Alzheimer’s 
disease can lead to worsening of symptoms, or even death, in patients with dementia with 
Lewy bodies who often show a pathological sensitivity to these medications 20, 21. 
A second lesson these studies teach us is that an individual biomarker meeting all the 
criteria required of a stand-alone biomarker may not be feasible, and that combinations 
of biomarkers may be necessary to provide optimal diagnosis and differential diagnosis of 
dementia disorders 1, 16, 22, 23. In keeping with this notion, in Chapter 2, we examined 
the utility of adding 3-methoxy-4-hydroxyphenylglycol (MHPG), a metabolite of the 
neurotransmitter noradrenaline, to the traditional CSF biomarkers for Alzheimer’s disease 
to differentiate dementia with Lewy bodies from Alzheimer’s disease and other forms of 
dementia. Our choice of MHPG, was based on observations in other investigations 24-
26 showing that metabolism of noradrenaline is altered in patients with dementia with 
Lewy bodies, a disease that shares many similar clinical features of Alzheimer’s disease. 
In a previous study 24, we showed that using MHPG in combination with Aβ1-42 and 
tau proteins improved the ability to distinguish DLB from Alzheimer’s disease above 
the traditional combination of biomarkers alone 24. Furthermore, the results indicated 
an altered noradrenaline metabolism in dementia with Lewy bodies that was different 
from that of Alzheimer’s disease. A review of the literature suggested that this might also 
be the case for frontotemporal dementia and vascular dementia 26-30. Thus, in Chapter 
2, we examined whether this same combination of biomarkers might also be useful in 
discriminating dementia with Lewy bodies from other forms of dementia. In the study 
we found that the addition of MHPG to the signature biomarkers improved the sensitivity 
for correctly detecting dementia with Lewy bodies in our study participants from 62% to 
65% and improved our ability to distinguish Alzheimer’s disease from dementia with Lewy 
bodies from 92% to 100% specificity among our study participants. Thus we confirmed 
our previous findings that MHPG combined with traditional biomarkers could improve 
the distinction between Alzheimer’s disease and dementia with Lewy bodies, which 
supports the idea that combinations of biomarkers may be required for optimal diagnosis 
of disease. However, we were unable to show that this combination of biomarkers could 
aid in the differential diagnosis of dementia with Lewy bodies from frontotemporal 
dementia or vascular dementia, indicating that additional yet-to-be-identified biomarkers 
are required for this purpose.
A further weakness of the traditional combination of Aβ1-42, tau and phosphorylated 
tau in the diagnosis of Alzheimer’s disease is in that detection of Alzheimer’s disease in 
early stages of disease remains difficult. Although combinations of biomarkers can help 
to predict the progression of cognitively normal individuals or those with mild cognitive 
impairment to Alzheimer’s disease 1, 31, 32, additional biomarkers would be useful. The 
peptidyl-prolyl isomerase, Pin1, has been shown to be involved in the regulation of both 
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Aβ1-42 and tau, and loss of activity of Pin1 during conditions of oxidative stress may 
be involved in the pathophysiology of Alzheimer’s disease 33. Therefore, we aimed to 
examine the potential of Pin1 as an alternative diagnostic marker for Alzheimer’s disease 
that might also identify Alzheimer’s disease in its early stages (Chapter 3). We were able 
to develop and apply an immunoassay to detect oxidised Pin1 in brain tissues and found 
that levels of oxidised Pin1 were increase by about 9%, and the ratio of oxidised Pin1 to 
Pin1 by approximately 20%, in early stages of disease compared with controls, which is 
consistent with previous studies 34, 35. However, we were not able to determine the value 
of (oxidised) Pin1 in CSF as a biomarker for the differential diagnosis of dementia due to 
undetectable levels in the CSF. Therefore, additional research will be required to develop 
more sensitive measures of detection to determine whether levels of oxidised Pin1 might 
differ between the various forms of dementia.
Movement disorders
In case of movement disorders, the major differential diagnoses for Parkinson’s disease 
are other conditions associated with a hypokinetic-rigid syndrome including the atypical 
parkinsonisms: multiple system atrophy, progressive supranuclear palsy and corticobasal 
syndrome. Several reports have now shown that CSF levels of neurofilament protein can 
differentiate PD and controls from patients with atypical parkinsonisms but can neither 
differentiate between controls and Parkinson’s disease nor between the different forms 
of atypical parkinsonism 36-39. The results presented in Chapter 4 have confirmed these 
findings in an independent study strengthened by the inclusion of both discovery and 
validation cohorts. Using NFL alone we were able to detect the presence of MSA with a 
sensitivity of 74% and could distinguish MSA from PD with 92% specificity in our patient 
cohort. Together these findings support the use of NFL as an adjunct to clinical practice 
for improving the diagnostic accuracy through enhanced discrimination of Parkinson’s 
disease from atypical parkinsonisms. However, although NFL clearly distinguishes atypical 
parkinsonisms from Parkinson’s disease, its inability to be used as a specific biomarker for 
a single disease can be viewed as a major short-coming of this biomarker. In particular, its 
inability to distinguish Parkinson’s disease from control subjects highlighted the need for 
additional disease-specific biomarkers.
For the purpose of identifying disease-specific markers for Parkinson’s disease we 
attempted, in Chapters 4 and 5, to verify previous findings that fms-like tyrosine kinase 
receptor ligand (FLT3L), a recently identified novel biomarker, and DJ-1, a moderately 
well-studied biomarker, could be used to distinguish Parkinson’s disease from controls 
and multiple system atrophy. One previous study using western blot experiments showed 
increased levels of DJ-1 in Parkinson’s disease compared to controls 40 and this finding 
was supported by our own findings using ELISA assays (Chapter 5). In this study we found 
an increase of about 26% in Parkinson’s disease above that of controls that allowed us to 
detect Parkinson’s disease with rather high accuracy (81%) but more moderate specificity 
for Parkinson’s disease (52%). Interestingly, we found for the first time that levels of DJ-1 
were 70% higher in multiple system atrophy than in controls and 35% higher than those 
with Parkinson’s disease, thus enabling a clear distinction between controls and multiple 
system atrophy (sensitivity of 78% and specificity of 100%), and, to a lesser extent, between 
multiple system atrophy and Parkinson’s disease (sensitivity of 78% and specificity of 78%). 
In contrast to the DJ-1 findings, we were unable to confirm a previous finding 41 that CSF 
levels of FLT3L could distinguish between these diseases (chapter 4). While DJ-1 showed 
Chapter 9
146
promise for use as a biomarker, our results contradict other studies which show lower 
levels of CSF DJ-1 in both Parkinson’s disease and multiple system atrophy compared with 
controls, but no differences between Parkinson’s disease and multiple system atrophy 41, 
42. Our results were even more contradictory compared with yet another study showing 
significantly lower levels of CSF DJ-1 that distinguished both Parkinson’s disease and 
multiple system atrophy from controls but not from each other 41. Additional research 
will be required to determine the reason for these discrepancies, which possibly arise from 
differences in the methodologies used for DJ-1 and FLT3L quantification in CSF. 
Alterations in neurotransmission, particularly altered levels of the neurotransmitter 
dopamine, can have significant impact on the initiation of movement and have significant 
implications in the (patho)physiology of Parkinson’s disease and related disorders. In 
another parkinsonian disorder, vascular parkinsonism, the clinical symptoms arise due to 
vascular insults, such as transient ischaemic attacks or cerebrovascular accident (stroke). 
We hypothesised that the subsequent vascular injury caused by these insults is likely to 
have a very different effect on neurotransmitter metabolism compared with Parkinson’s 
disease in which degeneration occurs in a very specific subset of neurons. Very few studies 
have compared differences in neurotransmitter dysfunction in these two disorders. Thus, 
we investigated whether physiological differences in CSF levels of neurotransmitters 
could represent possible biomarkers for differentiating between Parkinson’s disease and 
vascular parkinsonism. For this purpose (Chapter 6), we examined differences in CSF levels 
of neurotransmitter metabolites from three of the most abundant and physiologically 
important neurotransmitters - 3-methoxy-4-hydroxyphenylglycol (MHPG), a metabolite 
of the neurotransmitter noradrenaline; homovanillic acid (HVA) a metabolite of dopamine; 
and 5-hydroxyindolacetic acid (5-HIAA), a metabolite of serotonin. We found no significant 
differences in MHPG levels between the patient groups but did observe small, significant 
differences in CSF levels of 5-HIAA and HVA between Parkinson’s disease and vascular 
parkinsonism although these differences were not sufficiently significant to warrant 
further investigation of these indices as potential biomarkers. However, in the patients 
with vascular parkinsonism CSF levels of the dopamine metabolite, HVA, were generally 
elevated compared with controls. This finding may help to partly explain why many 
patients with vascular parkinsonism generally respond more poorly to the Parkinson’s 
disease medication, levodopa (a dopamine replacement medication) since the normal 
to slightly elevated CSF HVA levels are not consistent with dopamine deficiency in 
patients with the vascular parkinsonism in our study. This has important implications for 
management of patients with vascular parkinsonism and warrants further investigation.
Demyelinating disorders
Multiple sclerosis is the most common chronic demyelinating disorder of the central 
nervous system.  However, neuromyelitis optica, a severe inflammatory demyelinating 
disease principally targeting the optic nerves and spinal cord, is often difficult to 
distinguish from multiple sclerosis, particularly when these diseases are in their early 
stages. Recently, autoantibodies against the water-channel receptor aquaporin 4 (AQP4) 
were found in large numbers of patients with neuromyelitis optica 43, 44.  These AQP4 
receptors are associated with astrocytic end-feet and damage to the receptors was found 
to be associated with the release of high levels of glial fibrillary acidic protein (GFAP) and 
S100b from astrocytes into the CSF 45, 46. While AQP4 antibodies are not found in all 
patients with neuromyelitis optica, markedly increased CSF levels of GFAP and S100b are 
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frequently observed in patients with neuromyelitis optica patients, suggesting that these 
parameters may be more specific for neuromyelitis optica but they do not distinguish 
seropositive from seronegative neuromyelitis optica patients. It remains unknown 
whether seronegative neuromyelitis optica patients represent a separate disease entity, 
with different underlying pathology or aetiology than seropositive patients, or whether 
the levels of autoantibodies are, as yet, too low to be detected in these patients. We 
hypothesised that other astrocytic proteins might also be elevated in neuromyelitis optica 
and we were curious to see whether levels of glutamine synthetase may differ between 
seronegative and seropositive patients, thus giving possible clues to pathological 
differences between these two groups. 
Glutamine synthetase, an enzyme involved in the conversion of glutamate and ammonia 
to glutamine, was chosen as it is generally considered to be an astrocyte-specific enzyme 
in the brain. We developed an assay for the detection of glutamine synthetase in CSF 
(Chapter 7) and used this assay to measure levels of glutamine synthetase in the CSF 
of patients with neuromyelitis optica compared with multiple sclerosis and controls 
(Chapter 8). While we were able to show that glutamine synthetase levels in patients with 
neuromyelitis optica were double that of the controls and approximately 22% greater in 
neuromyelitis compared with multiple sclerosis after controlling for confounding factors, 
we found high heterogeneity in the levels measured, particularly for the neuromyelitis 
and multiple sclerosis groups. Furthermore, there were no significant differences in 
glutamine synthetase levels between seronegative and seropositive neuromyelitis optica. 
Therefore, glutamine synthetase was not useful as a biomarker for neuromyelitis optica. 
Furthermore, multiple sclerosis patients also had significantly higher levels of glutamine 
synthetase than the control group, again with considerable overlap between multiple 
sclerosis and controls. 
Although not useful as a biomarker for either neuromyelitis optica or multiple sclerosis, the 
elevated levels of glutamine synthetase may be able to provide some insight into possible 
underlying mechanisms of pathology of multiple sclerosis and/or neuromyeltitis optica. 
There is some debate in the literature regarding the specificity of glutamine synthetase as 
a purely astrocytic enzyme, with several papers indicating significant levels of glutamine 
synthetase in myelin-producing oligodendrocytes. Thus the high levels of CSF glutamine 
synthetase measured in our multiple sclerosis patients may be indicative of damage to 
oligodendrocytes and subsequent release of glutamine synthetase into the CSF. However, 
additional studies will be required to confirm or refute this hypothesis.
CSF biomarkers – what are the pitfalls?
CSF biomarkers – still missing the diagnostic mark
To date the most well studied biomarkers for any neurodegenerative disease are the 
signature biomarkers of Alzheimer’s disease, Aβ1-42, tau and phosphorylated tau. These 
biomarkers have been shown to correlate highly with AD-associated pathology – senile 
plaques and neurofibrillary tangles – and may have potential as early markers of disease. 
On the other hand, they do not correlate well with the severity of cognitive dysfunction 
which would give an indication of disease progression. The poor correlation of signature 
biomarkers with the clinical symptoms shows that Alzheimer’s disease-type pathology 
can occur in the absence of clinical symptoms and, conversely, significant clinical signs 
and symptoms may occur in patients with less extensive brain pathology, possibly 
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indicating a different disease aetiology 4, 47. In other cases, changes in brain pathology 
have been shown to occur in patients who later go on to develop Alzheimer’s disease 48. 
Thus, while the signature biomarkers of Alzheimer’s disease seem to be good at detecting 
Alzheimer-type brain pathology, they miss the mark in terms of their correlation with 
clinical symptoms, showing more accuracy in ruling the disease out rather than confirming 
the presence of clinical disease. That is, if the signature biomarkers do not indicate the 
presence of Alzheimer-type pathology, then the patient is unlikely to have – or develop in 
near future - dementia of the Alzheimer type. On the other hand, when biomarker levels 
suggest the presence of Alzheimer-type brain pathology, this will not necessarily indicate 
the presence of clinical Alzheimer’s disease. Since optimal biomarkers can be used not 
only to validate the presence or absence of disease but can also be used for monitoring 
disease progression and treatment effects, the above-mentioned signature biomarkers 
seem to be not more than poor predictors.
Disease diversity – the problem of mixed pathology
Disease diversity adds an additional complexity to our search for biomarkers for 
differential diagnosis. Firstly, there have been many cases in which patients are found 
to have mixed brain pathology 49-53. That is, they show signs of having more than one 
neurodegenerative disease. For example, Alzheimer’s disease can occur together with 
another form of dementia and, similarly, dementia often occurs in patients with Parkinson’s 
disease. Secondly, for most neurodegenerative disorders, multiple neurotransmitter 
systems are involved, but their extent varies from patient to patient, and also depends on 
the disease stage and on the age at onset of the disease. For example, Parkinson’s disease 
is typically equated with a dopaminergic lesion, but certainly in more advanced disease 
stages, additional neurotransmitter systems become affected as well. Thirdly, vascular risk 
factors such as hypertension, diabetes and hypercholesterolemia not only increase with 
age but are associated with an increased risk for the development of neurodegenerative 
disease. Examples include both Parkinson’s disease and Alzheimer disease 54. Moreover, 
vascular factors often contribute to the severity of neurodegenerative disease symptoms, 
particularly cognitive impairment or dementia 55-57. This adds a new layer of complexity 
to clinical symptoms and likely contributed to the heterogeneity in CSF values that we 
observed in the studies conducted in Chapters 2 and 6 in which we compared disorders 
with a vascular component (vascular dementia and vascular parkinsonism) with their 
neurodegenerative counterparts (Alzheimer’s dementia and Parkinson’s disease, 
respectively). 
Vascular damage is highly heterogeneous (variable) and individual patients have unique 
vascular damage. Although imaging techniques are useful for identifying vascular 
lesions, vascular damage can occur in 30-60% of patients with Alzheimer’s disease and 
between 25 to 80% of patients with vascular dementia will have comorbid Alzheimer’s 
disease 58 and so identifying vascular lesions has little diagnostic value in distinguishing 
between Alzheimer’s disease and vascular dementia. Imaging studies can be prone to 
overestimation of the presence of vascular dementia and underestimation of the presence 
of neurodegenerative co-pathology 59. In this respect, use of the signature biomarkers of 
Alzheimer’s disease in conjunction with clinical assessment and imaging studies, have been 
shown to improve the differential diagnosis between vascular dementia and Alzheimer’s 
disease, and to detect the presence of co-pathology. In other cases, vascular pathology 
can be so localised (focal) as to cause clinical symptoms that are indistinguishable from its 
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neurodegenerative counterpart. For example, focal lesions of the basal ganglia can result 
in symptoms of Parkinson’s disease 60, and co-morbid vascular lesions are more common 
in Parkinson patients compared to the normal population 54. Since vascular damage is 
unique to individuals and will lead to diverse clinical phenotypes among patients, specific 
biomarkers may be more feasible for dementias with a neurodegenerative component 
whereby all patients with the same type of dementia may be expected to have the same 
deficit (e.g. a protein deficiency).
Biomarkers for diagnosis and differential diagnosis
Ultimately, we aim to use biomarkers to determine the specific disease faced by an 
individual patient. That is, we aim to determine the patient’s ‘diagnosis’.  Diagnosis is based 
on the identification of the patient’s signs (objective measures) and symptoms (subjective 
measures) and their fit with internationally established criteria for a particular disease 
entity. However, an important part of diagnosis is ‘differential diagnosis’, which is the 
process of identifying all possible diagnoses and then ruling out individual diseases until 
only one possibility remains. This is a particularly necessary part of the diagnostic process 
when patients present with signs and symptoms that can be attributed to more than one 
disease. While biomarker research often places emphasis on the role of biomarkers in 
distinguishing disease from a healthy condition, less emphasis is placed on biomarkers 
that can be used to distinguish between diseases with similar signs and symptoms. In 
this respect, neurofilament protein appears to have substantial potential as a biomarker 
for differential diagnosis since it clearly distinguished Parkinson’s disease from all other 
atypical parkinsonisms studied (Chapter 4). However, it lacked potential as a specific 
diagnostic marker since it could neither discriminate Parkinson’s disease from controls 
nor distinguish between the atypical parkinsonisms studied. All atypical parkinsonisms 
were consistently associated with elevated levels of neurofilament protein, whereas 
Parkinson’s disease had levels of neurofilament proteins that were comparable to levels 
found in both healthy controls and controls with non-neurodegenerative disorders 36, 37, 
39, 61. Whereas clinical diagnosis based on the patient’s signs and symptoms indicated 
the presence of Parkinson’s disease, control-comparable levels of neurofilament protein 
excluded the likelihood of an atypical parkinsonism and added weight to a more likely 
diagnosis of Parkinson’s disease.
With respect to Alzheimer’s disease, the signature biomarkers have been shown to be 
diagnostic for Alzheimer’s pathology and can distinguish Alzheimer’s disease and other 
dementias from controls. However, biomarkers for differential diagnosis with the specificity 
and sensitivity required to distinguish between different forms of dementia are still lacking. 
Alternative combinations of the signature biomarkers, such as the ratio of p-tau/ Aβ1-42 
62 have been shown to have some utility in distinguishing Alzheimer’s disease from other 
forms of dementia and, as mentioned previously, we found that the addition of MHPG to 
the signature biomarkers showed enhanced differentiation of Alzheimer’s disease from 
dementia with Lewy bodies but not from frontotemporal dementia or vascular dementia 
(Chapter 2). 
Unlike the biomarkers tested for use in movement disorders and dementia, autoantibodies 
against the aquaporin-4 water channel receptor appear to represent a biomarker that is not 
only specific, and diagnostic, for neuromyelitis optica but also distinguishes neuromyelitis 
optica from multiple sclerosis. Unfortunately, AQP4 also falls short as a biomarker with 
regard to its sensitivity in that a subset of patients with neuromyelitis optica is negative 
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for these autoantibodies. It is uncertain whether the currently available assays simply 
lack the sensitivity to measure low levels of autoantibodies in these patients, or whether 
these patients represent a different form of neuromyelitis optica. Our attempt to resolve 
this issue using measures of glutamine synthetase to distinguish between seropositive 
and seronegative neuromyelitis patients (Chapter 8) hinted that seronegative and 
seropositive neuromyelitis optica may represent separate disorders but the differences 
were much too small to be conclusive. Therefore, these markers are still insufficient for 
distinguishing seronegative and seropositive neuromyelitis optica from each other and 
from multiple sclerosis so additional research will be required to resolve this incongruity 
and supplementary biomarkers will be required to differentiate between the individual 
disorders, in the case that future research shows that seronegative and seropositive 
neuromyelitis are indeed separate disorders. 
Technical barriers
In addition to the shortfalls in diagnostic performance, researchers are faced with a 
multitude of technical issues that can arise in biomarker research.  Clear evidence of 
altered brain protein levels in a particular disease condition compared to controls is not 
always reflected in the levels measured in CSF. Examples can be found in Chapter 3 where 
we observed that levels of the proteins (Pin1 and oxidised Pin1) were (almost certainly) 
too low to be measured in the CSF, and in Chapter 7 where we found that epitope 
masking seemed to prevent the binding of the antibody to the antigen thus requiring 
acid treatment to unmask the epitope. Therefore, additional (pre-analytical) processing 
or more sensitive technologies will be required to improve the detection of proteins, 
particularly those present in very low levels. Secondly, different methods available for the 
measurement of the same protein often seem to provide different results. This may have 
explained the differences in results we found using ELISA methods for the measurement 
of FLT3L (Chapter 4) and DJ-1 (Chapter 5) compared with other papers in which either a 
different ELISA method or an alternative methods (using Luminex technology) were used 
for the measurement of the same proteins. Therefore, the implementation of biomarkers 
for use in clinical practice will require strict evaluation and standardisation of the methods 
used for detection.
Limitations of the research
The retrospective nature of the studies performed presents a limitation for the work 
performed in this thesis. Firstly, the Radboud University Medical Centre is a teaching 
hospital highly focussed not only on high standard health care provision as part of routine 
healthcare, but also acts as a tertiary referral centre for complex cases. As such, many more 
referrals are received for the investigation of patients with complex symptomatology, 
and for whom diagnosis is not clear-cut based on the presenting clinical symptoms, than 
might be expected in smaller hospital settings. Furthermore, lumbar puncture is generally 
performed only in cases where diagnosis is uncertain, or as part of dedicated research 
protocols in selected cases. This likely biased the selection of patients included for the 
studies particularly given that we only included patients for whom lumbar puncture had 
been performed as part of the diagnostic procedure. In addition, we excluded patients 
for whom the diagnosis remained uncertain despite extensive follow-up. Although this 
study design ensured that we had the most accurate diagnosis possible, this resulted in 
lower numbers of patients available for inclusion in the studies and reduced our ability 
to generalise our findings to a wider population. Finally, the lack of neuropathological 
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confirmation of disease meant that we could not confirm whether our diagnoses based 
on extensive neurological assessment and protracted follow-up were indeed as accurate 
as expected from post-mortem examination.
Ultimately, these issues will need to be addressed by additional evaluations of much larger, 
more general populations to accurately determine the true sensitivity and specificity 
of these biomarkers and final diagnoses will require additional confirmation with post-
mortem neuropathological assessment of the patients. Unfortunately, this will require 
extensive resources, complex multi-centre institutions and extended periods of time that 
will require thorough coordination and monitoring that may be impractical.
Future perspectives
Despite the current lack of specific CSF biomarkers for diagnosis and differential diagnosis 
of neurodegenerative diseases, the outlook for future biomarker discoveries remains 
optimistic. 
Prospective study design
As mentioned in the limitations section, the retrospective nature of the studies performed 
for this thesis may have introduced biases that could have influenced the analysis of 
the data. In addition, the CSF data were analysed in isolation, not in conjunction with 
clinical symptoms, and we were dependent upon clinical records for the most recent and 
accurate diagnoses. Thus, we were unable to adequately assess the correlation between 
the assessed biomarkers and clinical symptoms.  In order to address these issues, we 
currently have prospective studies on parkinsonism  in progress that have been designed 
to evaluate and compare the initial diagnosis with the final diagnosis (after 3 years) of each 
patient and to evaluate the predictive value of ancillary markers (including CSF biomarkers 
and imaging methods) taken at baseline with the final diagnosis 63, 64 (van Rumund et al, 
paper in preparation). This will enable us to develop optimal diagnostic models based on 
baseline characteristics and clinical variables in combination with ancillary investigations 
where these are assessed as having added value in the diagnostic model. Furthermore, 
the prospective nature of the study is also predicted to yield additional insights into 
the disease progression and succession of symptoms that may help us to identify the 
prognostic value of the CSF biomarkers measured.
The ‘-omics’ to identify potential biomarker targets
Recent research has focussed on the development of ‘-omics’ techniques investigating 
changes in metabolism (metabolomics), expression profiling (transcriptomics), proteins 
(proteomics) and genes (genomics) using both targeted and untargeted approaches as a 
means of biomarker discovery 65. These techniques generate enormous amounts of data 
used to identify potential biomarkers of disease and, although approaching biomarker 
discovery from different perspectives, are often successful in identifying potential disease 
related protein biomarkers. Causative genetic mutations for familial diseases discovered 
by genomics has often directed research towards the specific proteins affected by these 
gene mutations and how these proteins are altered in sporadic forms of disease. One of 
the first examples of this was the discovery of missense mutations in the alpha-synuclein 
(SNCA) gene in 1997 66-69. In Alzheimer’s disease three highly penetrate genes, amyloid 
beta precursor protein, PSEN1, and PSEN2, have been shown to account of a small 
number of familial cases of Alzheimer’s disease which are not shown in non-Mendelian 
inherited disease 70-73. In sporadic cases, persons who inherit apolipoprotein 4 (APOE4) 
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alleles have an increased risk (3 times for one allele or 10 times if they have inherit alleles 
from both parents) compared with persons who don’t carry APOE4 alleles 74. Although 
genome wide association studies have found other susceptibility genes associated with 
non-Mendelian inherited Alzheimer’s disease, they confer only a small increase in disease 
risk and only account for a small part of the genetic risk of Alzheimer’s disease 75.
Proteomics is the study of the structure and function of proteins which can be performed 
using a variety of methods including 2-dimensional gel electrophoresis or combined 
liquid chromatography and mass spectrometry 76, 77. These approaches together 
with sophisticated computational software analyses provide an attractive approach for 
identifying potential novel biomarkers for the diagnosis and differential diagnosis of 
neurodegenerative diseases 78, 79. These techniques enable the analysis of large amounts 
of data from single experiments that can be used to identify changes in molecular profiles 
between patient groups thus identifying novel biomarkers. Using these approaches 
multiple proteins have been identified as potential biomarker candidates 78. Most of 
these approaches use a bottom-up approach involving enzyme digestion of the sample 
followed by mass spectrometry for the identification of resultant peptides from which the 
protein composition of the samples can be inferred 80. These techniques are now highly 
developed and provide a convenient tool for identifying potential biomarker candidates. 
However, technologies available for analyzing whole proteins (top-down proteomics) 
are increasingly being developed. The advantage of these approaches is that proteins 
can be examined in their intact state without enzymatic digestion enabling better 
characterization of the composition and structure of individual protein molecules and 
likely improves the identification of post-translational modifications that may be present 
80. 
‘Biomarker panels’ for diagnosis and differential diagnosis of neurodegenerative 
diseases
In the absence of single biomarkers for the diagnosis of disease, there are indications 
that a set of biomarkers may more accurately differentiate between individual diseases 
17, 36, 81. Indeed different combinations of the signature AD biomarkers have a better 
diagnostic performance than individual biomarkers 14, 82, 83. As previously discussed, 
this may come in the form of additional CSF parameters such as we show with the addition 
of MHPG to the signature Alzheimer disease biomarkers (Chapter 2) which improved the 
discrimination of Alzheimer’s disease from dementia with Lewy bodies 24. Indeed many 
of the CSF biomarkers tested to date remain sub-optimal, and the development of panels 
of biomarkers to improve the diagnosis and differential diagnosis of neurodegenerative 
disease seems viable. While we currently rely on CSF as a source of fluid biomarkers, 
future combinations of other non-signature biomarkers 84, 85 in various body fluids may 
also play an important role in the differential diagnosis of neurodegenerative disorders 
such as miRNAs in blood 86. Furthermore, the use of fluid biomarkers in combination 
with advanced imaging techniques such as positron emission tomography, magnetic 
resonance imaging may also help to resolve some of the difficulties with differential 
diagnosis 87-89
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Assays for measurement of modified proteins
A different approach to identifying potential biomarkers involves the analysis of alterations 
in protein structure, conformation or activity. Many of the proteins identified as potential 
biomarkers for neurodegenerative diseases have been shown to be modified in individual 
diseases compared with controls. These can include changes in conformation such as 
occurs with unfolding or misfolding of proteins 90-92, increases in the oligomeric forms 
of the protein compared with monomeric forms 93-95, or structural changes occurring 
due to post-translational modifications of the protein such as oxidation, glycation or 
phosphorylation 33, 35, 96, 97. Hence new methods will have to be developed to detect 
these altered proteins, such as the ELISA we designed to measure the oxidised form of 
Pin1 (Chapter 3). Other ELISAs have been developed for the measurement of protein 
isoforms (e.g. Aβ 38, 40 and 42) 98, 99, phosphorylated proteins 96, 100  and oligomeric 
forms of proteins 101, 102 and some of these methods may be promising for future use 
as biomarkers.
Development of more sensitive assay methodologies
There are continual developments in technologies to improve the detection and 
quantification of proteins even at extremely low concentrations in the CSF. Some of the 
techniques that have shown promising advances include: Mass-spectrometry approaches 
or SRM-MS combined with top-down proteomics 103-108; nanoparticle technology 
platforms 109, 110; magnetic and gold particle bead technologies 86, 110. Ongoing 
development of these techniques will further improve the range of proteins that can be 
studied and may improve the sensitivity of available biomarkers. 
Conclusions
There is a real need for reliable biomarkers that can be used to assist in the differential 
diagnosis of neurodegenerative diseases, preferably in early clinical or even preclinical 
stages. In this thesis we explored the biomarker potential of several CSF proteins and 
metabolites, and we assessed this for three groups of neurodegenerative disorders: 
dementias; the various forms of parkinsonism; and demyelinating diseases. Some of 
these CSF biomarkers showed potential to become useful as adjuncts to clinical practice 
to improve the differential diagnosis of neurodegenerative disorders. However, individual 
biomarkers for specific diagnosis seem to be elusive. In their absence, panels of fluid 
biomarkers, in conjunction with clinical assessment and neuroimaging, may provide 
suitable substitutes. On the optimistic front, there remains hope that emerging candidate 
biomarkers used alone or in conjunction with other biomarkers, may provide ideal 
diagnostic tools in the future so that affected patients and their relatives will be able to 
name their disease rather than facing an uncertain diagnosis.
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As discussed in Chapter 1 (Part 1 of the thesis), establishing biomarkers for the differential 
diagnosis of neurodegenerative diseases is of paramount importance for ensuring optimal 
medical management of patients. Currently, distinguishing one neurodegenerative 
disease from another can be rather difficult when using clinical symptoms alone, certainly 
in early disease stages when the clinical picture is often still incomplete. Moreover, in the 
early phases of disease, many neurodegenerative diseases share common symptoms, the 
rate of disease progression is not yet apparent, and the response to medical treatment 
is often not yet fully clear. Therefore, additional tools to help clinicians in the differential 
diagnosis of neurodegenerative diseases are needed. The primary aim of this thesis was 
to examine the diagnostic potential of a selection of CSF proteins that were identified 
from the literature as biomarkers for some of the most common neurodegenerative 
diseases. Moreover, we looked at the utility of these biomarkers in distinguishing one 
neurodegenerative disease from another with similar symptomatology at the time of CSF 
acquisition. In this thesis the use of CSF biomarkers for differential diagnosis of dementia 
(Part 2), the differential diagnosis of movement disorders (Part 3), and the differential 
diagnosis of demyelinating disorders (Part 4).
In order to develop a biomarker, it first needs to be measurable. One of the obstacles 
faced by researchers looking for biomarkers in cerebrospinal fluid is the difficulty faced 
in detecting individual proteins in complex biological matrices like cerebrospinal fluid. 
There may be interactions between proteins, or post-translational modifications of 
proteins that can hamper protein detection, or target proteins may exist in such low 
levels in the biological samples that the assay being used is insufficiently sensitive to 
detect the protein at such low levels. Hence, in Chapter 7 we investigated a technique 
to enhance the detection and quantification of a selection of relevant proteins using a 
pre-treatment protocol designed to enhance the detection of proteins in enzyme-linked 
immunosorbent assay based (ELISA) methods.  Indeed, we were able to improve the 
measurement of some of the proteins tested by applying a technique which appeared 
to act by exposing additional antigen epitopes, thus enhancing antibody binding and 
subsequent detection. This technique seemed to be particularly useful for larger proteins, 
particular those normally present in oligomeric forms. 
Part 2 of the thesis focussed on improving the differential diagnosis of dementias. We 
first investigated how we could build upon the already well-established biomarkers (Aβ, 
tau and phosphorylated tau) for Alzheimer’s disease by adding an extra measure. In a 
previous study we had determined that the addition of 3-methoxy-4-hydroxyphenylglycol 
(MHPG; a metabolite of the neurotransmitter norepinephrine) to the traditional Alzheimer 
biomarkers (Aβ, tau and phosphorylated tau) could aid in the differentiation of Alzheimer’s 
disease from dementia with Lewy bodies. In Chapter 2, we examined whether we could 
confirm these results in independent groups of patients and we addressed the question 
of whether this combination of biomarkers could also improve the differentiation of 
dementia with Lewy bodies from frontotemporal dementia and vascular dementia. 
Indeed we showed that the addition of MHPG to the signature biomarkers improved 
the sensitivity for correctly detecting the disease in our study participants from 62% 
to 65% and also improved the ability to differentiate between Alzheimer’s disease 
and dementia with Lewy bodies. This confirmed our previous results, showing that 
the addition of MHPG to the traditional combination of markers may be useful in the 
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differential diagnosis of Alzheimer’s disease and dementia with Lewy bodies. However, 
this combination of biomarkers did not improve the discrimination of dementia with Lewy 
bodies or Alzheimer’s disease from either frontotemporal dementia or vascular dementia. 
Regardless, the study findings indicated that the use of a panel of biomarkers may assist in 
the distinguishing between different forms of dementia. Additional biomarkers are yet to 
be identified for the purpose of distinguishing Alzheimer’s dementia from frontotemporal 
and vascular dementia. 
Although stand-alone biomarkers for the diagnosis of an individual neurodegenerative 
disease are highly desirable, to-date there are no individual stand-alone biomarkers 
for Alzheimer’s disease. Another aim in Part 2 of this thesis was to develop a means of 
measuring a potential novel, specific biomarker for Alzheimer’s disease. The identification 
of potential stand-alone biomarkers often arises from research of literature investigating 
the underlying mechanisms of individual diseases. It has been shown, for example, that 
oxidative stress often brings about alterations in the structure and function of proteins 
that lead to death of the affected cells and initiating the initial pathology of many 
neurodegenerative diseases 1, 2. In different neurodegenerative diseases, different proteins 
are affected by oxidative stress. For example, the protein Pin1 is oxidised in patients with 
Alzheimer’s disease, but not in patients with other forms of neurodegenerative disease 
3. We were interested to determine whether measurement of oxidised Pin1 in biological 
samples might provide a specific and early disease stage biomarker for Alzheimer’s 
disease. In Chapter 3, we describe the development of an ELISA for measuring oxidised 
Pin1 in extracts of human brain tissue and used the assay to compare levels of oxPin1 in 
samples of brain tissue from healthy controls and patients with Alzheimer’s disease. We 
were able to show that the ratio of oxidised Pin1 to total Pin1 was increased by about 
20% in patients with early pathological changes indicative of Alzheimer’s disease. This 
alludes to the possibility that, with further optimisation of the assay, measurement of 
oxidised Pin1 in biological fluids such as cerebrospinal fluid may be useful for identifying 
early pathological changes in the brains of patients with suspected Alzheimer’s disease. 
Future development of the ELISA for measurement of oxidised Pin1 in CSF will be required 
to determine its potential as an indicator of early disease pathology or perhaps as a 
biomarker of disease.
In Part 3 of the thesis we investigated the use of a panel of biomarkers for the differentiation 
of Parkinson’s disease from multiple system atrophy, a disease which can resemble 
Parkinson’s disease at early stages but which progresses much more quickly. Patients 
with multiple system atrophy may present with specific and sometimes life-threatening 
symptoms (e.g. nocturnal stridor) which – to some extent – requires a different medical 
management strategy than Parkinson’s disease. In the first of two studies (Chapter 4), 
we investigated the combination of two previously established, but not validated, 
biomarkers, i.e. neurofilament light chain protein and tau protein, together with a more 
recently identified potential biomarker, FLT3L. We aimed to investigate which of these 
biomarkers, or combination of biomarkers, might provide maximal discrimination of 
Parkinson’s disease from multiple system atrophy. We found no evidence to support 
the use of FLT3L or tau as stand-alone biomarkers for discriminating between multiple 
system atrophy and Parkinson’s disease. However, neurofilament light chain alone was 
shown to be useful as a stand-alone biomarker for the discrimination of multiple system 
atrophy from Parkinson’s disease.  Using neurofilament light chain alone we were able 
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to detect the presence of multiple system atrophy with a sensitivity of 74% and could 
distinguish multiple system atrophy from Parkinson’s disease with approximately 92% 
specificity in our patient cohort. Furthermore, we were able to validate these findings 
in a separate cohort of patients (80% sensitivity and 97% specificity). Combinations of 
neurofilament light chain and tau, and neurofilament light chain, tau and FLT3L slightly 
improved the discrimination of multiple system atrophy from Parkinson’s disease but this 
diagnostic improvement was not statistically significant. Prior to use in clinical practice 
additional validation studies using neurofilament light chain to discriminate other atypical 
parkinsonisms from multiple system atrophy and Parkinson’s disease will be required, 
particularly since levels of neurofilament light chain in Parkinson’s disease did not differ 
significantly from controls.
In a separate study (Chapter 5), we combined the analysis of DJ-1 protein, known to be 
altered in patients with genetic forms of the disease, with levels of tau. We were able 
to demonstrate that DJ-1 was also useful as a stand-alone biomarker for discriminating 
Parkinson’s disease from controls with high sensitivity (81%) but more moderate specificity 
(52%). More interestingly, we showed for the first time that levels of DJ-1 were increased 
by about 70% in multiple system atrophy compared with controls and could distinguish 
between the two groups with high accuracy (sensitivity of 78% and specificity of 100%). 
Since DJ-1 levels were also about 35% higher in multiple system atrophy than Parkinson’s 
disease they were also useful for discriminating between these two groups and the 
combination of DJ-1 and tau significantly improved the discrimination of multiple system 
atrophy from Parkinson’s disease (82% sensitivity and 81% specificity). Our observations 
that DJ-1 is useful in discriminating between Parkinson’s disease and multiple system 
atrophy, contradicts the findings of other researchers and will require further investigation. 
This will need to be combined with additional studies enabling validation of the methods 
used for the measurement of DJ-1 as the assays used in this and other studies have not yet 
been fully validated for use in CSF. 
Using a different approach to biomarker discovery, we also attempted to identify 
physiological differences between Parkinson’s disease and vascular parkinsonism that 
might lead to the identification of potential biomarkers for discriminating these disorders. 
For this purpose, we decided to examine differences in levels of the metabolites of three 
of the most abundant and physiologically important neurotransmitters. Alterations in 
neurotransmission, particularly altered levels of the neurotransmitter dopamine, can have 
significant impact on the initiation of movement and have significant implications in the 
(patho)physiology of Parkinson’s disease and related disorders. The clinical symptoms of 
vascular parkinsonism arise due to vascular insults, such as transient ischaemic attacks 
or cerebrovascular accident (or stroke), which is likely to have a very different effects on 
neurotransmitter metabolism due to more widespread injury compared with Parkinson’s 
disease in which degeneration occurs in a very specific subset of neurons. Very few studies 
have compared differences in neurotransmitter dysfunction in these two disorders. 
Thus, in Chapter 6 we investigated the levels of several neurotransmitter metabolites to 
determine whether any differences in levels of these metabolites might indicate potential 
biomarkers of disease. Although we observed small differences between the two patient 
groups in their levels of 5-HIAA and HVA, the neurotransmitter metabolites of serotonin 
and dopamine, respectively, the differences were not sufficiently significant to warrant 
further investigation of these indices as potential biomarkers. However, our findings were 
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useful in identifying some possible reasons why patients with vascular parkinsonism 
generally respond more poorly to the Parkinson’s disease medication, levodopa - used 
as a dopamine replacement - since the patients with vascular parkinsonism in our study 
did not have significantly reduced levels of dopamine. This has important implications for 
management of patients with vascular parkinsonism and warrants further investigation.
In Part 4 of the thesis we developed a method for measuring glutamine synthetase in 
CSF (Chapter 7) and investigated the potential of glutamine synthetase as a biomarker 
for the differentiation of neuromyelitis optica from multiple sclerosis (Chapter 8). Since 
glutamine synthetase is a primarily astrocytic enzyme in the brain, and neuromyelitis 
optica is a disease involving extensive damage to astrocytes, we hypothesised that we 
might find increased levels of glutamine synthetase in patients with neuromyelitis optica. 
Furthermore, since multiple sclerosis is a disease primarily affecting oligodendrocytes 
rather than astrocytes, we hypothesised that levels of glutamine synthetase would be 
much greater in neuromyelitis optica than in multiple sclerosis in which we did not expect 
levels of glutamine synthetase to be altered and might thus be useful in discriminating 
neuromyelitis optica from multiple sclerosis. We did, indeed find that levels of glutamine 
synthetase in the CSF of the neuromyelitis patients were approximately double that found 
for controls and ~22% higher than in multiple sclerosis. Although this effect was greater in 
patients who tested positive for auto-antibodies directed against the protein aquaporin 
4, which regulates the transport of water in astrocytes, levels of glutamine synthetase 
were also elevated by approximately 69% in multiple sclerosis compared with controls, 
thus reducing the usefulness of CSF glutamine synthetase as a specific biomarker for 
neuromyelitis optica.
In general, our studies support the use of CSF biomarkers for the differential diagnosis 
of neurodegenerative disorders and these findings are discussed in Chapter 9. As with 
many of the biomarkers already described in the literature, many more studies will be 
required to confirm the validity of these studies using pathologically confirmed disease 
and, ultimately, to determine the true utility of these biomarkers in clinical practice.
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Veel neurodegeneratieve ziekten kenmerken zich vaak door heterogene symptomen 
waardoor het moeilijk kan zijn om  neurodegeneratieve ziekten van elkaar te onderscheiden, 
met name in de beginstadia van deze ziekten.  Zoals aangegeven in hoofdstuk 1 (Deel 1 
van dit proefschrift) is het ontwikkelen van biomarkers voor de differentiële diagnose van 
neurodegeneratieve ziekten van uiterst belang voor het optimaliseren van de medische 
behandeling van patiënten. Momenteel is het onderscheiden van neurodegeneratieve 
ziekten zeer moeilijk, met name in de beginstadia van de ziekten wanneer het klinische 
beeld vaak nog niet compleet is. Ook is dan vaak nog niet duidelijk hoe snel een ziekte 
zich zal ontwikkelen of hoe de reactie op medicatie zal zijn. Daarom is het van belang 
om nieuwe diagnostische methodes te ontwikkelen die een beter onderscheid mogelijk 
maken tussen de verschillende ziekten. Het hoofddoel van het onderzoek in dit proefschrift 
was om de diagnostische potentie te bepalen van een selectie van eiwitten in hersenvocht 
(cerebrospinale vloeistof, CSF) die eerder beschreven zijn in de literatuur als potentiële 
biomarkers voor het differentiëren van enkele van de meest bekende vormen van 
neurodegeneratieve ziekten. Daarnaast was het doel te onderzoeken of deze biomarkers 
al direct bruikbaar waren bij het onderscheiden van neurodegeneratieve ziekten met 
vergelijkbare symptomen op het moment van de CSF opname. In dit onderzoek hebben 
we naast elkaar onderzocht of CSF biomarkers gebruikt kunnen worden voor het 
onderscheiden van verschillende vormen van dementie (Deel 2), bewegingsstoornissen 
(Deel 3) en demyeliniserende aandoeningen (Deel 4).
Voordat een biomarker ontwikkeld kan worden moet het detecteerbaar zijn. Maar detectie 
van afzonderlijke eiwitten in complexe matrices zoals CSF blijkt vaak zeer moeilijk te zijn 
en vormt daarom een uitdaging voor onderzoekers. Interacties tussen eiwitten of post-
translationele modificaties van eiwitten kunnen van invloed zijn op de detectie van een 
eiwit en deze bemoeilijken. Daarnaast kan de concentratie van het eiwit in CSF zo laag 
zijn dat het eiwit niet detecteerbaar  is, omdat de detectie methode niet gevoelig genoeg 
is. Daarom hebben we onderzocht of een pré-incubatie stap met zuur een verbetering 
oplevert in de detectie van het eiwit in enzyme-linked immunosorbent assays. Dit deel 
van het onderzoek staat beschreven in hoofdstuk 7. We laten zien dat de pré-incubatie 
met zuur een verhoging van het detectiesignaal geeft voor sommige eiwitten. Dit wordt 
waarschijnlijk veroorzaakt doordat de pre-incubatie stap extra epitopen van het antigeen 
vrij maakt voor herkenning door antilichamen en daarmee detectie van het antigeen. 
Deze pré-incubatie stap lijkt met name nuttig voor grote eiwitten, en dan met name 
eiwitten die oligomeren vormen. 
In deel 2 van dit proefschrift is aandacht besteed aan de verbetering van differentiële 
diagnose van dementie. In eerste instantie hebben we gekeken naar mogelijkheden om 
de traditionele biomarkers voor de ziekte van Alzheimer te verbeteren door het toevoegen 
van een extra biomarker parameter. In een eerdere studie is bewezen dat het toevoegen 
van 3-methoxy-4-hydroxyphenylglycol (MHPG; de metaboliet van de neurotransmitter 
epinefrine) aan de traditionele Alzheimer biomarkers kan helpen in het differentiëren van 
de ziekte van Alzheimer en dementie met Lewy lichaampjes. In hoofdstuk 2 hebben we 
onderzocht of we dit ook konden bevestigen in een onafhankelijke groep patienten en 
of deze combinatie van eiwitten ook een beter onderscheid kon geven voor dementie 
met Lewy lichaampjes en vasculaire of frontotemporale dementie. Deze biomarker 
combinatie bleek inderdaad een beter onderscheid te geven tussen de ziekte van 
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Alzheimer en dementie met Lewy lichaampjes dan de traditionele Alzheimer biomarkers 
alleen. De detectiegevoeligheid van de ziekte van Alzheimer was door het toevoegen van 
MHPG aan de traditionele biomarkers ook met een lichte stijging in sensitiviteit van 62% 
naar 65% verbeterd en deze combinatie vormt daardoor een mogelijk nuttige biomarker 
voor de differentiële diagnose tussen de ziekte van Alzheimer en dementie met Lewy 
lichaampjes. Deze biomarker combinatie gaf echter geen verbetering in het kunnen 
onderscheiden tussen dementie met Lewy lichaampjes en vasculaire of frontotemporale 
dementie. Desondanks is het gebruik van een panel biomarkers voor het onderscheiden 
van verschillende vormen van dementie door deze resultaten wel aangetoond. Wij 
concluderen dat toevoeging van nog meer biomarkers noodzakelijk zijn voor de 
differentiatie tussen de ziekte van Alzheimer en/of dementie met Lewy lichaampjes en 
vasculaire en frontotemporale dementie.
Hoewel zelfstandige biomarkers zeer gewenst zijn voor de diagnose van individuele 
neurodegeneratieve ziekten, zijn er tot nu toe nog geen zelfstandige biomarkers voor de 
ziekte van Alzheimer. Een ander doel van dit proefschrift was de ontwikkeling van een 
nieuwe en specifieke diagnostische test voor de ziekte van Alzheimer gebaseerd op het 
meten van slechts één eiwit in CSF. Het onderzoek naar potentiële zelfstandige biomarkers 
is gebaseerd op eerder, in vakliteratuur beschreven, onderzoek naar onderliggende 
mechanismen van individuele ziekten. Het is bijvoorbeeld bekend dat oxidatieve stress 
een rol kan spelen in ongewenste wijzigingen in de structuur en de functie van eiwitten, 
dat kan leiden tot het afsterven van cellen en de pathologie van veel neurodegeneratieve 
ziekten kan initiëren. In een neurodegeneratieve ziekte kunnen specifieke, verschillende 
eiwitten aangetast zijn door oxidatieve stress. Het eiwit Pin1 bijvoorbeeld is geoxideerd 
bij patiënten met de ziekte van Alzheimer maar niet bij patiënten met andere 
neurodegeneratieve ziekten. Wij waren geïnteresseerd of geoxideerd Pin1 in biologisch 
materiaal een specifieke biomarker voor de ziekte van Alzheimer kan zijn, met name in 
vroege stadia van de ziekte. In hoofdstuk 3 hebben we de ontwikkeling van een nieuwe 
ELISA methode voor het meten van geoxideerd Pin1 beschreven. We hebben dit eiwit 
in hersenweefsel van gezonde controles en van patiënten met de ziekte van Alzheimer 
gemeten en we tonen aan dat de ratio tussen geoxideerd Pin1 en de totale hoeveelheid 
Pin1 verhoogd is in ongeveer 20% van de patiënten met Alzheimer type pathologische 
aandoeningen in hun hersenen. De resultaten  wijzen op de mogelijkheid dat, met verder 
optimaliseren van de ELISA, het meten van geoxideerd Pin1 in CSF mogelijk nuttig kan 
zijn voor het vroegtijdig ontdekken van pathologische veranderingen in de hersenen 
van patiënten met Alzheimer-type dementie. Er is nader onderzoek nodig om definitief 
vast te stellen of het meten van geoxideerd Pin1 in CSF potentie heeft om te dienen als 
biomarker voor beginnende Alzheimer dementie. 
In Deel 3 van dit proefschrift hebben we het gebruik onderzocht van een panel biomarkers 
voor het differentiëren tussen de ziekte van Parkinson en multiple systeem atrofie, een 
ziekte die heel erg op de ziekte van Parkinson lijkt maar een versneld ziektebeeld kent. 
Patiënten met multiple systeem atrofie hebben soms symptomen die levensgevaarlijk 
kunnen zijn (bijvoorbeeld nachtelijke stridor) waarvoor een andere medische behandeling 
nodig is dan die voor de ziekte van Parkinson. In de eerste van twee studies (Hoofdstuk 4) 
hebben we de combinatie van twee vastgestelde maar nog niet gevalideerde biomarkers 
(neurofilament light chain eiwit en tau eiwit) samen met een meer recentelijk ontdekte 
potentiële biomarker (FLT3L eiwit) onderzocht. Ons doel was te ontdekken welke van 
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deze biomarkers, of combinatie van biomarkers, de beste discriminatie geeft tussen de 
ziekte van Parkinson en multiple systeem atrofie. Onze resultaten laten zien dat het FLT3L 
eiwit en het tau eiwit hiervoor niet als zelfstandige biomarkers gebruikt kunnen worden, 
maar het neurofilament light chain eiwit wel. Bij het gebruik van alleen neurofilament 
light chain konden we in onze patiëntengroepen met een sensitiviteit van ongeveer 74% 
multiple systeem atrofie detecteren en konden we met een specificiteit van 92% het 
onderscheid maken tussen multiple systeem atrofie en de ziekte van Parkinson. Bovendien 
was het mogelijk om deze resultaten te valideren in een tweede groep van patiënten (met 
80% sensitiviteit en 97% specificiteit). De combinaties van neurofilament light chain met 
tau en van neurofilament light chain met tau en FLT3L gaf een kleine verbetering in deze 
resultaten, maar de verschillen waren statistisch niet significant. Omdat de concentratie 
van neurofilament light chain niet significant verschillend was tussen gezonde controles 
en mensen met de ziekte van Parkinson dient, vóór de toepassing van deze biomarker(s) 
in de klinische praktijk, het gebruik van neurofilament light chain voor het onderscheiden 
van andere atypische parkinsonismen en multiple systeem atrofie verder onderzocht 
worden. 
In een tweede studie (hoofdstuk 5), hebben we een analyse uitgevoerd van het DJ-1 
eiwit, waarvan bekend is dat deze wordt aangetast in genetische vormen van de ziekte 
van Parkinson, in combinatie met het eiwit tau. We laten zien dat DJ-1, als zelfstandige 
biomarker, met een hoge sensitiviteit (81%), maar een gemiddelde specificiteit (52%), het 
onderscheid kan maken tussen de ziekte van Parkinson en gezonde controles. Bovendien 
hebben we ontdekt dat concentraties van DJ-1 in CSF zijn verhoogd met ongeveer 70% 
bij de patiënten met multiple systeem atrofie in vergelijking met controles. De biomarker 
DJ-1 maakt met hoge accuratesse (sensitiviteit 78% en specificiteit 100%) onderscheid 
tussen deze twee groepen. Omdat ook de concentratie van DJ-1 bij multiple systeem 
atrofie in vergelijking met de ziekte van Parkinson ongeveer 35% hoger ligt is DJ-1, in 
combinatie met tau, ook nuttig voor de discriminatie tussen de ziekte van Parkinson en 
multiple systeem atrofie (sensitiviteit 82% en specificiteit 81%). Deze bevindingen zijn 
tegenstrijdig met eerdere bevindingen van andere onderzoekers, en verder onderzoek is 
dus noodzakelijk om onze resultaten te valideren. Ook de DJ-1 ELISA die in dit onderzoek 
was gebruikt dient nog nader onderzocht te worden omdat deze nog niet volledig is 
gevalideerd voor meting in CSF. 
We hebben een andere benadering gebruikt om fysiologische verschillen tussen de ziekte 
van Parkinson en vasculair parkinsonisme te bestuderen die als mogelijke biomarkers 
kunnen fungeren voor de discriminatie tussen deze ziekten. We hebben hiervoor 
concentraties van drie van de meest voorkomende en belangrijke neurotransmitter 
metabolieten in CSF onderzocht. Veranderingen in neurotransmissie, met name 
gewijzigde concentraties van dopamine, kunnen grote invloed hebben op het initiëren 
van beweging en kunnen grote gevolgen hebben in de (patho)fysiologie van de ziekte 
van Parkinson en daaraan gerelateerde bewegingsstoornissen. Het klinische beeld 
van vasculair parkinsonisme wordt door cerebrovasculaire beschadiging zoals een 
cerebrovasculair accident (CVA of hersenbloeding) of een transiënte ischemische aanval 
(TIA) veroorzaakt. Dit heeft waarschijnlijk een heel ander effect op het neurotransmitter 
metabolisme als gevolg van meer wijdverbreide schade in vergelijking met de ziekte van 
Parkinson, waarin juist degeneratie van een zeer specifieke subset van neuronen wordt 
aangetroffen. Weinig studies hebben de verschillen in neurotransmitter dysfunctie tussen 
Chapter 11
174
deze ziekten vergeleken. Daarom hebben we in hoofdstuk 6 onderzocht of verschillen 
in neurotransmitter metaboliet concentraties in CSF als biomarkers kunnen dienen voor 
het onderscheid tussen de ziekte van Parkinson en vasculair parkinsonisme. Hoewel er 
kleine verschillen in 5-HIAA en HVA (de respectievelijke metabolieten van serotonine 
en dopamine) gevonden werden tussen deze twee patiëntengroepen bleken deze 
verschillen niet significant genoeg te zijn om deze metabolieten verder te onderzoeken 
als potentiële biomarkers. Onze bevindingen geven wel mogelijke verklaringen waarom 
het Parkinson medicijn levodopa – dat als vervanging dient voor het tekort aan dopamine 
– niet goed werkt bij patiënten met vasculair parkinsonisme. Uit onze resultaten blijkt 
namelijk dat de patiënten met vasculair parkinsonisme in onze studie geen gebrek aan 
dopamine hadden. Dit impliceert dat verder onderzoek benodigd is  voor de behandeling 
van patiënten met vasculair parkinsonisme.
In Deel 4 van dit proefschrift hebben we een door ons ontwikkelde methode beschreven 
voor het meten van het eiwit glutamine synthetase in CSF (Hoofdstuk 7). Met gebruik van 
deze methode hebben we vervolgens onderzocht of glutamine synthetase een mogelijke 
biomarker kan zijn voor het onderscheiden van neuromyelitis optica en multiple sclerose 
(Hoofdstuk 8). Omdat glutamine synthetase voornamelijk een astrocytair enzym is en 
neuromyelitis optica een ziekte met veel astrocytaire schade is, hebben we een hypothese 
opgesteld waarin glutamine synthetase in CSF mogelijk toegenomen is bij mensen met 
neuromyelitis optica. Daarnaast hebben we een hypothese opgesteld waarin glutamine 
synthetase meer is toegenomen in CSF van neuromyelitis optica patiënten dan in CSF van 
multiple sclerose patiënten omdat bij multiple sclerose voornamelijk oligodendrocyten 
in plaats van astrocyten aangedaan zijn. Onze verwachting was dat de concentraties 
van glutamine synthetase veel hoger zouden zijn in neuromyelitis optica dan in multiple 
sclerose en dat dit eiwit daarom een mogelijke biomarker zou zijn voor het differentiëren 
tussen deze ziekten. Ons onderzoek liet zien dat glutamine synthetase inderdaad bijna 
twee keer zo hoog was bij onze neuromyelitis optica patiënten dan controles en ook 
22% hoger dan bij multiple sclerose patiënten. Hoewel dit effect groter was bij patiënten 
waarbij auto-antilichamen zijn aangetroffen gericht tegen het eiwit aquaporine 4 (dat een 
rol speelt in het transport van water in astrocyten) lieten de resultaten tevens zien dat 
glutamine synthetase ook ongeveer 68% hoger was bij patiënten met multiple sclerose 
in vergelijking met controles. Uit deze resultaten blijkt dat het verschil in concentraties 
van glutamine synthetase tussen neuromyelitits optica en multiple sclerose niet groot 
genoeg is om glutamine synthetase als biomarker te gebruiken.
Over het algemeen ondersteunen onze studies het gebruik van CSF biomarkers voor de 
differentiële diagnose van neurodegeneratieve ziekten en deze bevindingen worden 
bediscussieerd in Hoofdstuk 9. 
Tot slot: Zoals ook voor vele eerder beschreven potentiële biomarkers dient er meer 
onderzoek gedaan te worden met biologisch materiaal van patiënten met pathologisch 
bewezen ziekte om te bewijzen dat deze eiwitten als goede biomarkers kunnen dienen en 
wat deze biomarkers uiteindelijk kunnen toevoegen in de klinische praktijk. 
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“And what is the use of a book," thought Alice, "without pictures or 
conversation?”
“One of the deep secrets of life is that all that is really worth the doing is 
what we do for others.” 
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“Alice had got so much into the way of expecting nothing but out-of-
the-way things to happen, that it seemed quite dull and stupid for life to 
go on in the common way.” 
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